National Institute for Health and Care Excellence

Draft

Obstructive sleep apnoea/ hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

Evidence review N: Adherence

NICE guideline Intervention evidence review March 2021

> Draft for consultation Developed by the National Guideline Centre



Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their careful or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <u>Welsh Government</u>, <u>Scottish Government</u>, and <u>Northern Ireland Executive</u>. All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2021. All rights reserved. Subject to Notice of rights.

Contents

1	Adh	erence.		5
	1.1		v question: What support improves adherence to CPAP or other entions?	5
	1.2		uction	
	1.3		table	
	1.4		Il evidence	-
		1.4.1	Included studies	
		1.4.2	Excluded studies	8
		1.4.3	Summary of clinical studies included in the evidence review	9
		1.4.4	Quality assessment of clinical studies included in the evidence review	68
	1.5	Econo	mic evidence	78
		1.5.1	Included studies	78
		1.5.2	Excluded studies	78
		1.5.3	Health economic modelling	78
		1.5.4	Health economic evidence statements	78
	1.6	The co	ommittee's discussion of the evidence	78
		1.6.1	Interpreting the evidence	78
		1.6.2	Cost effectiveness and resource use	82
Ap	pendi	ices		92
-	-	endix A:		
	Арре	endix B:	Literature search strategies	99
	Appe	endix C:	Clinical evidence selection	110
	Appe	endix D:	Clinical evidence tables	111
	Appe	endix E:	Forest plots	137
	Appe	endix F:	GRADE tables	146
	Арре	endix G:	Health economic evidence selection	156
	Appe	endix H:	Excluded studies	157
	Appe	endix I:	Research recommendations	160

1

1 **1 Adherence**

1.1 Review question: What support improves adherence to 3 CPAP or other interventions?

4 1.2 Introduction

Adherence to interventions such as CPAP/non-invasive ventilation/oral devices/positional 5 6 modifiers for obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity 7 hypoventilation syndrome (OHS) or COPD-OSAHS overlap syndrome is essential in order for these interventions to be effective. Optimal adherence to CPAP therapy is conventionally 8 9 considered to be four or more hours per night or use for an average of more than 4 hours per night for 70% or more nights. There is some evidence suggesting that increased CPAP use 10 of more than 5 hours a night in OSAHS benefits other aspects of health such as control of 11 blood pressure and cardiovascular risk. However, it is recognised that use of CPAP for four 12 hours per night or more is an arbitrary figure not based on good quality evidence and that 13 14 people can gain some benefit from a shorter period of use. People should be encouraged to maximise their CPAP use to achieve optimal control of their symptoms, underlying 15 conditions, sleep quality and quality of life. Adherence to other devices is thought to be 16 17 equally important to gain any benefit.

An evidence review was conducted to assess interventions designed to inform participants
 about improving adherence of CPAP/ non-invasive ventilation, positional modifiers and oral
 devices, to support them in using these interventions and to modify their behaviour in
 improving their use.

22 1.3 PICO table

23 For full details see the review protocol in appendix A.

24

Table 1: PICO characteristics of review question

Population	People (16 and older) with OSAHS, OHS or COPD-OSAHS overlap syndrome.					
	Population will be stratified by:					
	 population: OSAHS, OHS, COPD-OSAHS overlap syndrome 					
	 severity: mild, moderate, severe (based on AHI/ODI) 					
	devices: positive airway pressure devices, position modifiers, oral devices					
	 types of interventions (educational, behavioural, supportive) 					
Interventions	Short term or sustained behavioural intervention aimed at encouraging uptake, acclimation, improvement or maintenance of adherence to long term OSAHS, OHS, COPD-OSAHS overlap syndrome treatment.					
	Examples may include					
	educational interventions					
	supportive interventions					
	interactive interactions					
	group-based interventions					
	 mindfulness-based interventions 					
	cognitive interventions					
	behavioural interventions					
	motivational strategies					
	combination of multiple interventions.					

© NICE 2021. All rights reserved. Subject to Notice of rights.

Comparisons	 any of the above vs no intervention Background level of information and support at the study centre (that must also be provided to intervention group)
Outcomes	Critical
	 generic or disease specific validated quality of life measures (continuous) mortality (dichotomous)
	 proportion adherent >4hrs/night for CPAP/non-invasive ventilation (dichotomous)
	adherence in hours/night for CPAP and oral devices (continuous)
	 self-reported adherence (continuous)
	Important
	mood or anxiety
	withdrawals
	 treatment related withdrawals (dichotomous)
	 sleepiness scores (continuous, e.g. Epworth)
	 apnoea-Hypopnoea index or respiratory disturbance index (continuous)
	 oxygen desaturation index (continuous)
	 CO₂ control (continuous)
	 minor adverse effects of treatment (rates or dichotomous)
	driving outcomes (continuous)
	neurocognitive outcomes (continuous)
	• impact on co-existing conditions:
	 HbA1c for diabetes (continuous) cardiovascular events for cardiovascular disease (dichotomous)
	$_{\circ}$ systolic blood pressure for hypertension (continuous)
Study design	• RCTs
	 systematic review of RCTs
	 parallel or crossover to be included

1 1.4 Clinical evidence

- 2 1.4.1 Included studies
- 3 **OSAHS**

4 **CPAP**

5

6

7

8

9

10

Total of 46 studies reviewing educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea were included in the review. This included one Cochrane review⁵ with 41 studies and 5 additional studies identified in re-runs^{12, 34, 43, 57, 61} these are summarised in Table 2 below. Evidence from these studies is summarised in the clinical evidence summary below (Table 3).

- 11 Studies were categorised into the following comparisons:
- Behavioural vs. Control interventions employing psychotherapeutic techniques deriving from behavioural, cognitive or cognitive-behavioural models of health behaviour change (e.g., specific models within this broad genre include motivational enhancement therapy [Miller], Transtheoretical/Stages of Change Model [Prochaska and DiClemente], CBT [Beck]). By definition, behavioural interventions under any of these related models involves at least a minimal degree of direct participant

engagement or interaction (as opposed to purely educational, in which information is merely imparted to participants, even if the educational content or style of presentation was based on a cognitive/behavioural model). The objectives of such interventions included enhancing motivation for change, self-efficacy, outcome expectations and/or decisional balance in favour of CPAP. There were a broad range of interventions included in this category such as myofunctional therapy, progressive muscle relaxation training, audiotaped music along with softly spoken directions on relaxation techniques and habit-promoting instructions for using CPAP nightly, motivational interviewing, one to one sessions with a clinical psychologist, motivational enhancement which is devised on the principles of motivational interviewing, motivational enhancement therapy and telephone-linked communications.

- **Educational vs. Control** interventions imparting information about CPAP treatment or about OSAHS more generally, delivered through video format, face-to-face didactic sessions, group educational sessions, written materials, or any combination of these. Interventions that did not involve a component of active engagement from the participants other than reading written materials or observing a presentation or demonstration, even if the content derived from a behavioural change model, were classified as educational.
- **Supportive vs. Control** interventions in which participants were provided with additional clinical follow-up (e.g., additional office or home-based visits or phone check-ins by clinical staff) or with telemonitoring equipment that facilitated self-monitoring of CPAP usage or that facilitated monitoring by clinical staff to prompt as needed clinical follow-up (e.g., a phone call made to participants when CPAP usage fell below a predetermined threshold) for the purpose of addressing barriers or difficulties with CPAP usage in a timely manner (e.g. telemedicine systems, digitised phone calls or audio messages, and/or home visits)
 - Mixed vs. Control interventions that combined elements of the three previously listed intervention-types (e.g. educational video and material provided + telemedicine follow-up)

In cases where studies used a mixed combination of intervention-types (behavioural,
 educational or supportive), but had multiple active intervention arms that had distinct
 elements of one type of intervention (e.g. intervention 1 supportive vs. intervention 2
 educational vs. control), the active interventions groups were separated and included in the
 appropriate comparison subcategory for meta-analysis.

- 36 Studies had people with moderate and severe OSAHS; however, the majority of the studies 37 were in people with severe sleep apnoea.
- 38 No evidence was identified for the critical outcome mortality.

39 Oral devices

40 No studies identified educational, supportive and behavioural interventions to improve usage
 41 of oral devices in adults with obstructive sleep apnoea, OHS and COPD-OSAHS overlap
 42 syndrome.

43 **Positional modifiers**

44 No studies identified educational, supportive and behavioural interventions to improve usage
 45 of positional modifiers in adults with obstructive sleep apnoea, obstructive sleep
 46 apnoea/OHS and COPD-OSAHS overlap syndrome.

47

12

3

4 5

6 7

8 9

10

11 12

13

14

15

16 17

18

19

20

21 22

23

24

25

26

27

28

29 30

1 <u>OHS</u>

No evidence identified for improving adherence of CPAP and non-invasive ventilation (NIV)
 in OHS.

4 COPD-OSAHS overlap syndrome

- 5 No evidence identified for improving adherence of CPAP and non-invasive ventilation (NIV) 6 in COPD-OSAHS overlap syndrome.
- See also the study selection flow chart in appendix C, study evidence tables in appendix D,
 forest plots in appendix E and GRADE tables in appendix F.

9 1.4.2 Excluded studies

- 10 See the excluded studies list in appendix H.
- 11
- 12

$^{∋}$ 1 \leq 1.4.3 Summary of clinical studies included in the evidence review

Table 2: Summary of studies included in the evidence review for CPAP

Study	Intervention and comparison	Population	Outcomes	Comments
Askland 2020 ⁵ Systematic review 41 studies Inclusion study designs: Randomised, parallel-controlled trials of any duration.	For inclusion in the review, intervention and control groups must have either 1) received the same make of CPAP machine and pressure delivery mode (i.e. fixed, auto-titrating, bi-level, etc.) or 2) receive CPAP machines in a randomly distributed manner, such that machine make remained independent of group assignment. Intervention group Any short-term or sustained behavioural intervention aimed at encouraging uptake, acclimation, improvement or maintenance of CPAP adherence among people with a diagnosis of OSA. Examples of modalities that may fall under 'behavioural interventions' include educational, supportive, interactive, group-based, mindfulness-based, cognitive, behavioural, motivational or approaches utilising a combination of these strategies. Control group	Participants were adults of either sex with a diagnosis of obstructive sleep apnoea (OSA) diagnosed using a recognised sleep diagnostic tool giving an Oxygen Desaturation Index (ODI) of ≥5 per hours or an Apnoea Hypopnea Index (AHI) ≥5 per hour. Trials that explicitly recruited patients with central sleep apnoea were not eligible for inclusion.	 Primary outcomes CPAP machine usage (hours/night) as measured by: microprocessor and monitor that measure pressure at the mask for every minute of each 24- hour day counter output that records the cumulative time that power is turned on for a CPAP machine (this does not provide information on actual time of day and duration of CPAP used during each 24-hour period) subjective participant reports of the duration of CPAP use Secondary outcomes 	We have used the data analysed by the Cochrane review team in this review. Majority of the studies for each comparison was in people with severe OSAHS (based on mean AHI) hence they have been categorised as severe OSAHS. When moderate OSAHS studies were included in this stratum, we have downgraded the evidence for indirectness.

All righte ro

D 2

Cubion

to Ninting of rights

0

Study	Intervention and comparison	Population	Outcomes	Comments
	Participants in the control group may receive instruction that would be used by the study centre in question, provided that the equivalent 'background' level of instruction was also offered and/or delivered to the intervention group.		 proportion of participants adherent (≥4 hours/night) symptom scores such as the Epworth Sleepiness Scale (ESS); disease-specific quality of life scores such as Functional Outcomes of Sleep Questionnaire (FOSQ) or Calgary Sleep apnoea Quality of Life Index (SAQLI) scores; and Withdrawals from the study. oxygen desaturation index (ODI), apnoea hypopnoea index (AHI) 	
Aloia 2001 ⁴ RCT Country: USA	Participants were randomised into experimental intervention (n=6) or control (n=6). Intervention: After their CPAP– PSG night, subjects returned to the clinic for a follow-up with the sleep medicine physician. All subjects were then administered the first of two one-to-one sessions. The second session was scheduled after subjects had used CPAP	N = 12 existing patients at investigator sleep centre with OSA. Participants had received prior treatment with CPAP Inclusion criteria: > 55 years of age, RDI (AHI): > 10, Mini Mental Status Examination: > 25 Exclusion criteria: other ICSD, other treatment for apnoea, claustrophobia	 Machine usage (hours/night) at 1 week, 4 weeks, 3 months. N of adherent participants (>= 6 hours per night of usage) 	Included in Cochrane review Behavioural vs control Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	for one full week (typically 1 week after the first session). Each session for both the experimental and control groups lasted approximately 45 minutes and was conducted by a clinical psychologist. Subjects in the experimental condition were administered an intervention designed to educate them on their individual OSAHS severity and the efficacy of CPAP based on PSG. The specific content of the two experimental sessions were: SESSION 1 Review subject's sleep data Review symptoms noticeable to the subject (e.g., anergia, EDS) Review symptoms not apparent (e.g., hypertension, cardiac problems) Review results of performance on cognitive tests Rate the importance of treatment Review PSG with CPAP and specify how this might address the above problems Discuss the advantages and disadvantages of treatment Develop goals for therapy SESSION 2	Baseline Characteristics: Mean age: 63.4, AHI: 43.5, Desaturation: 77.05 ± 9.47. Baseline characteristics not reported: gender, BMI, ESS.		

Study	Intervention and comparison	Population	Outcomes	Comments
	 Examine compliance data for the first week Discuss noticeable changes with treatment Discuss changes not apparent (e.g., hypertension, cardiac problems) Troubleshoot discomfort Discuss realistic expectations of treatment Review treatment goals Control: Two sessions: general discussion of sleep architecture and opinions on sleep clinic Study duration: 12 weeks 			
Aloia 2013 ³ RCT Country: USA	 Participants were randomised in a 1:1:1 ratio into one of three groups standard care (SC, n=74), education (ED, n=80) and motivational enhancement therapy (MET, n=73) balancing for age, sex, education, apnoea severity, and Epworth Sleepiness Scale score. People in the MET and ED groups each received two, 45- min, face-to-face individual counselling sessions by a trained nurse 1 week (7 ± 2 days) and 2 weeks (14 ± 2 days) after initiating PAP treatment. Intervention sessions were delivered after 1 	N= 227 with OSA. Inclusion Criteria: Age 25-85 years, moderate to severe OSA (AHI > 15) by full in- laboratory overnight polysomnography, naïve to PAP therapy. Exclusion criteria: Diagnosis by split-night PSG; evidence of severe neurological condition or unstable psychiatric illness; sleep disorder other than OSA (including primary central sleep apnoea), CHF, ESRD. Baseline Characteristics: 34% female. Mean age 50.2 (±11.1). Mean AHI 46.7.	 CPAP usage (hours/night) at 1, 2, 3, 6, 12 months. Withdrawals Adherence was measured nightly during the course of the year-long study. Participant average adherence from the beginning of the experiment up to 1, 2, 3, 6 and 12 months were used in analyses, i.e., cumulative mean responses were used). Decisional balance measure consists of both pro items, which assess the benefits of engaging in a particular behaviour, and con items, 	Trialists included two intervention arms, one educational and one behavioural. MET vs. Control included in Behavioural meta- analysis. ED vs. control included in Educational meta-analysis. Included in Cochrane review Behavioural vs control Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	 week of PAP use. One additional booster phone call was made to each participant in the MET and ED groups at week 3 of PAP use. MET: motivational enhancement therapy (MET) MET intervention focused on helping patients resolve their ambivalence regarding consistent use of PAP. The nurse counsellor strived to maintain an atmosphere of collaboration and partnership, rather than education. The counselling sessions were tailored to the individual' s readiness to change; less directive approaches were used for those who were ambivalent about using PAP (e.g., asking permission from the patient to discuss aspects of their life that were important to them and how they might be related to sleep), whereas direct problem solving was used for those who were more ready to use and maintain use of the device. Key components of the intervention included: (1) assessing readiness and confidence to change, each on a scale of 1 to 10, and 	Mean ESS 12.1. Mean BMI 35.3 kg/m ² .	which assess the costs to the patient of engaging in PAP adherence. A five-point Likert scale was used to rate each item, with 1 being "not important at all" and 5 being "extremely important." The self-efficacy scale was constructed using assess the extent to which patients believed that they could do the required tasks. Decisional balance and self- efficacy measurements were taken concurrent with the 3-, 6-, and 12-mo PAP adherence measurements	

Study	Intervention and comparison	Population	Outcomes	Comments	
	exploring the reasons for				
	choosing that value;				
	(2) discussing what the patient				
	already knows about the effects of sleep apnoea and PAP on				
	health, eliciting permission to				
	provide feedback about such				
	health effects, providing the				
	information, and eliciting the				
	patient's interpretation of the				
	information ("elicit-provide-				
	elicit" process);				
	(3) perceived benefits of PAP in				
	order to enhance outcome expectations;				
	(4) goal setting, consistent with				
	both MI style and with social				
	cognitive theory (setting				
	specific, attainable, and				
	realistic goals for use, if				
	motivated);				
	(5) identification of rewards for				
	hard work on adherence to PAP; and				
	(6) discussion of important				
	values and goals and the ways				
	in which PAP adherence				
	facilitates and hinders these				
	goals.				
	ED: Education regarding				
	pathophysiology of apnoea, its medical and behavioural				
	consequences, and the				
	benefits of treatment;				

Study	Intervention and comparison	Population	Outcomes	Comments
	presented in standardized formats, with no tailoring to participant readiness. SC: Provided to all participants, consisted of standard clinical care delivered by the authors' sleep disorders centre. Study Duration: 12 months			
Bakker 2016 ⁸ Open-label, parallel-arm, RCT Country: USA	Eligible participants entered a run-in phase before randomisation, consisting of 14 days wearing a nasal CPAP mask during sleep (without a CPAP device). Participants who reported using the mask during the majority of the run-in and who were willing to continue using the mask were eligible for randomization. Randomization took place in a 1:1:1:1 ratio with a block size of 4, based on three stratification factors: diagnostic study (full night or split night with titration), site, CVD status (established or risk factors) to one of four study arms (two control conditions, two treatment conditions): conservative medical therapy (n=44), sham CPAP (n=42), active CPAP (n=42), or active CPAP +ME (n=41). Analyses in the Bakker et al, 2016 report compared the active CPAP and CPAP + ME arms only.	N=83 participants with OSA Inclusion criteria: AHI 4%, \geq 10 or AHI 3%, \geq 15; 45 to 75 years with established CVD or cardio metabolic disease (established coronary artery disease (\geq 70% stenosis in at least one major coronary artery), prior myocardial infarction, coronary artery revascularization procedure, ischemic stroke, or diabetes) OR 55 to 75 years with at least three CVD risk factors (male sex, BMI of 30 kg/m ² or more, hypertension, dyslipidaemia, and \geq 10 pack-years of smoking). Exclusion criteria: cardiovascular event < 4 months before enrolment, prior CPAP, ESS > 14 of 24, drowsy driving within 2 years, commercial driving, or an uncontrolled medical condition (including central sleep apnoea, heart failure, uncontrolled hypertension,	CPAP usage (hours/night) at 6, 12 months	Included in Cochrane review Moderate OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	Intervention (Active CPAP + ME): Motivational enhancement (ME): ME is a behavioural intervention devised on the principles of motivational interviewing. The premise of the therapy is to honour the natural ambivalence that accompanies any change to behaviour and to approach the patient in a thoughtful and empathetic manner that elicits critical thought to maximize behaviour change. The overall goal of each ME session was to resolve the subjects' ambivalence toward establishing consistent CPAP usage patterns and increase the subjects' confidence toward using CPAP regularly. The psychologist delivering the intervention aimed to maintain a collaborative—rather than educational—style of interaction with each subject. Each session involved a discussion regarding the subject's readiness to begin CPAP, the subject's understanding of the health risks associated with untreated OSA, and the extent to which the subject believed that	severe hypoxemia, anaemia, and renal insufficiency). Baseline Characteristics: 33% female. Mean age 63.8 (NR). Mean AHI 22.8. Mean ESS NR. Mean BMI 31.1 kg/m².		

Study	Intervention and comparison	Population	Outcomes	Comments
	consistent CPAP use could resolve these risks. Each subject was encouraged to set concrete goals regarding their future CPAP use and identify rewards that they would provide themselves when those goals were achieved. ME was delivered during 1- hour in-person sessions at baseline and week 1, which included an educational video, and during phone calls of 10 to 30 minutes with the same psychologist at weeks 3, 4, 8, 12, 20, and 32. In-person sessions were audio recorded, to allow independent assessment of fidelity to the intervention framework. Control (Active CPAP): For the Bakker et al, 2016 report and the present Review, CPAP only arm served as the control. Study Duration: 12 months.			
Berry 2020 ¹² Randomised parallel-group trial. Country: USA	(n=124) Intervention 1: Cloud- based sleep coach (CBSC) Participants randomised to SC+CBSC follow-up received all elements of standard care and, in addition, interaction/communication from the CBSC service. The participants were informed that they would receive a telephone call from the CBSC system in 3	 (n=250) (Standard care, n= 126, standard care + cloud- based sleep coaches (CBSC), n= 124). Inclusion criteria: Age 21 to 75 years (men and women) Diagnostic apnoea- hypopnea index ≥ 15 events/h (diagnostic polysomnography [PSG], diagnostic portion of split 	 AHI ESS Number of days used >4 hours at 3 months Follow-up 3 months 	Severe OSAHS based on mean AHI

Study Intervention and comparison	Population	Outcomes	Comments
to 4 days to discuss their experience with therapy. Further contact from the CBSC could be expected if their adherence goals were not reached. All participants received calls on day 3 to 4 ar on day 32 after PAP initiation. The participants were also provided with information on, and encouraged to use, the mobile application (PAPapp), allowing them to view their current adherence. (n=126) Intervention 2: standard care Participants attending PAP setup classes were educated about use of their PAP device, including cleaning, ramp option and humidification. All patients were encouraged to use therapy nightly for as long as they can, preferably for the entire time they sleep. Each participant was fitted with a mask based on physician order, participant preference, and the ability to obtain a good mask seal. The type of PAP device (auto-adjusting CPAP) on pressure settings were determined by physician order Participants practiced putting	 automatically adjusting continuous positive airway pressure or bilevel positive airway pressure Residence in area covered by wireless network. Age: CBSC 54.9 ± 11.5 years; control: 55.2 ± 13.4 years AHI: CBSC 36.6 ± 20.6 events/h; control 36.7 ± 21.1 events/h Gender male %: CBSC 88.7%; control 89.7% Sleepiness: ESS: CBSC 11.2 ± 6.0; control 10.8 ± 6.1 		

Study	Intervention and comparison	Population	Outcomes	Comments
	on their masks and turning on			
	the PAP device. All devices			
	contained wireless modems			
	with information accessed via a			
	cloud-based programme.			
	Device data were uploaded into			
	the database via wireless			
	modems programmed to call in			
	automatically. Device data			
	were associated with the			
	individual participant based			
	upon the serial number of the			
	device and modem entered by			
	the staff. All PAP devices had			
	the ability to deliver heated			
	humidification. At the PAP			
	setup class, participants			
	received information about the			
	PAPapp (written information			
	also supplied with each PAP			
	unit).			
	Participants were provided with			
	telephone numbers for PAP			
	supply replacement and for			
	PAP treatment issues. They			
	were also encouraged to use			
	the secure messaging service			
	"My Healthy Vet" to facilitate			
	communication with the sleep			
	providers. Participants had a 6-			
	week inspection of adherence			
	and efficacy data if ordered by			
	the physician reading the sleep			
	study. Pressure settings could			
	be changed remotely based on			
	physician order. A participant			
	could be scheduled for an			

Study	Intervention and comparison	Population	Outcomes	Comments
	individual mask fitting CPAP RT appointment if discomfort or leak issues were significant. A 3-month (90 to 120 days) sleep clinic visit with a sleep provider (physician or physician extender) was scheduled.			
Bartlett 2013 ⁹ Randomised parallel-group trial. Country: Australia	Prior to recruitment, a randomization sequence by group using random permuted blocks with a 1:1 allocation ratio to control arm, Social Interaction (SI, n=97) or intervention arm, Social Cognitive Therapy (SCT, n=109). SCT: Intervention was based on social cognitive theory factors, including perceived self-efficacy, outcome expectations, and social support. Participants were encouraged to list goals, given slide presentations to discourage unhelpful thoughts of CPAP side effects, taught relaxation strategies, and given additional booklets containing information about sleep OSA/CPAP, and general health. SI: a basic social intervention was given to ensure that equal time was spent with all study participants; SI group was shown a 15-minute video that	N=206 participants with moderate-severe OSA referred to CPAP therapy. Inclusion criteria: None reported other than moderate-severe OSA. Exclusion criteria: Unable to understand fluent English, any previous use of CPAP. Baseline Characteristics: 32% female. Mean age 48.1 (±13.2). Mean AHI 34.9. Mean ESS 11.9. Mean BMI 30.4 kg/m ² .	 CPAP usage (hours/night) at 6 months. N of adherent participants (usage ≥ 4 h per night) Sleepiness (ESS) QoL (FOSQ) CPAP usage was assessed at 7 nights, then 1, 3, and 6 months. 	Included in Cochrane review Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	followed a patient's journey from their baseline diagnostic sleep study to being diagnosed with OSA and undergoing a CPAP titration study. Study Duration: 6 months			
Basoglu 2011 ¹⁰ Randomised, parallel-group study Country: Turkey	Participants were randomised into video education intervention (n=66) or control (n=67). Intervention: 10-Minute videotape on OSA, its consequences and CPAP therapy. In addition, routine information on diagnosis and treatment of OSA given by physician Control: Standard information on OSA and CPAP therapy given by the same physician Study duration: 24 weeks	N = 133 newly diagnosed moderate-to-severe OSAS patients Inclusion criteria: newly diagnosed, moderate to severe OSA, CPAP naive Exclusion criteria: use of sedatives, drug abuse, cardiac co-morbidities, COPD, other sleep disorders Baseline Characteristics, by group: <i>Intervention group:</i> Age: 53.7, Male sex: 82%, AHI 61, ESS: 10.3, BMI: 33.2. <i>Control group:</i> Age: 54.4, Male sex: 70%, AHI: 57.4, ESS: 12.4, BMI: 33 kg/m ²	 Number of adherent participants (CPAP use for at least four hours/night for at least 70% of nights at 1, 3, 6 months Sleepiness (ESS) 	Included in Cochrane review Unpublished information on study design and outcomes obtained from study authors Severe OSAHS based on mean AHI
Bouloukaki 2014 ¹³ Randomised, parallel-group study. Country: Greece	Eligible patients (n=3100) were randomly assigned in a 1:1 ratio to receive either the standard intervention (n=1550), of usual follow-up care, or the intensive intervention (n=1550), with augmented follow-up care based on additional appointments at the CPAP	N=3100 patients with newly diagnosed sleep apnoea randomised to either the standard group (usual follow- up care) or the intensive group (additional visits, telephone calls, and education). Inclusion criteria: newly diagnosed with OSAHS by	 CPAP usage (hours/night) at 1 month, 2 years Number of adherent participants (>= 4 hours/night for >= 70% of nights) Sleepiness (ESS) QoL (SF-36) 	Included in Cochrane review Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	clinic, telephone calls and education. Intensive Intervention: Patients received the same features as standard group, with the addition of follow-up visits involving patients' partners or family. All patients attended a 15-minute video education session cover OSAHS related topics, including the syndrome itself, treatment options, and the benefits of adherence to therapy. This was followed by a 10-15-minute lecture used to reinforce key concepts. During the first week of CPAP set-up, patients were contacted by the nurse, on the second and seventh day, via telephone in order to discuss any concerns they might have regarding air pressure, mask fitting, leaks and other issues as they arose. During the first month of treatment, patients were instructed to keep a sleep diary, and were reviewed by a sleep specialist on the 15 th and 30 th day of treatment. Standard Care: patients were reviewed in the outpatient sleep clinic at 1 month, at 3-month intervals during the first years, and every 6 months afterwards. During these appointments, a clinical assessment was made,	PSG, moderate-to-severe OSAHS, no history of previous CPAP therapy, and above-elementary school education. Exclusion criteria: refusal to participate, refusal of CPAP therapy, central sleep apnoea syndromes, obesity hypoventilation syndrome, restrictive pulmonary and restrictive chest wall diseases, severe congestive heart failure, a history of life- threatening arrhythmias, severe cardiomyopathy, long-term oxygen therapy, family or personal history of mental illness, drug or alcohol abuse, severe cognitive impairment, concurrent oncological diseases, and a history of narcolepsy or restless legs syndrome. Baseline Characteristics: 25% female. Mean age 55.6 (±10.2). Mean AHI 52. Mean ESS 12.1. Mean BMI 37.8 kg/m ² .	• Withdrawals	

Study	Intervention and comparison	Population	Outcomes	Comments
	and patients were further encouraged to use the device. If there were doubts about compliance, the referring physician made personal contact with the patient in order to resolve barriers to adequate compliance. Study Duration: 2 years			
Chen 2015 ¹⁶ Randomised, parallel-group study. Country: China	85 participants were randomised to nurse-led intensive vs standard support, of which 5 refused to participate (group allocation of refusals not reported), resulting in n=40 receiving intervention and n=40 receiving control condition. Intervention: Hospital health education, consisting of pre- treatment 30-minute educational video that explained the pathogen, mechanism, risks, benefit, and treatment methods for SAHS; personalized guidance from a nurse; and a SASH Health education Manual. In addition, several patient self- management interventions were delivered including: 15- minute interview with nurse for troubleshooting within 5 days of receiving CPAP treatment, nurse home visits after CPAP treatment was initiated, healthy	N=85 participants with new SAHS diagnosis. Inclusion criteria: AHI >15, daytime sleepiness, two major symptoms of the syndrome, lived within 100 miles from Zhejiang. Exclusion criteria: previously received CPAP therapy, suffering with chronic obstructive pulmonary disease, asthma, or neurological problems. Baseline Characteristics: 38.3% female. Mean age 50.4 (NR). Mean AHI 54.5. Mean ESS 13. Mean BMI 32.5 kg/m ² .	 CPAP usage (hours/night) at 1, 3, 6, 12 months. Sleepiness (ESS) QoL (SF-36) 	Included in Cochrane review Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	lifestyle (diet, exercise) guidance, and a psychological intervention, informing patients of the importance of maintaining a good mental state for disease rehabilitation, and teaching the patients methods and techniques on how to respond to anxiety and depression. Finally, each subject in the intervention arm received a ~30-minute consultation with sleep physician within 1 month of CPAP initiation. Control: ~30-minute consultation with sleep physician at 1, 3, 6 and 12 months. Study Duration: 12 months.			
Chervin 1997 ¹⁷ Randomised parallel-group trial Country: USA	No information provided as to the group allocation of all randomised subjects. Allocation Ns only available for the 33 participants who completed the study: Intervention group 1 (n=12), Intervention group 2 (n=14), control (n=7). Intervention 1: Telephone call each week during trial (max trial time of two months) Intervention 2: Two printed documents Control: No additional support Study duration: 8 weeks	N = 40 subjects with OSA (about to start or already receiving CPAP) recruited from clinic. Baseline Characteristics: Mean age 51.7. Mean AHI 49.4. ESS 10.9 ± 5.1. Lowest 02 Sat 75.6% (± 14.4). MSLT 6 (± 3.9)	 Machine usage (hours/night) at 1 to 2 months Dropouts/Lost-to- follow-up 	Included in Cochrane review Two of 33 used Bi-PAP. Both CPAP-naive users and those who had been on CPAP before trial were studied. Reading done at enrolment and at between 1 to 2 months after enrolment Difference in AHI between active and control groups at baseline. Trialists included two intervention arms, one educational and one supportive. Intervention 1 (telephone support) vs. Control included in Supportive meta- analysis. Intervention 2

Study	Intervention and comparison	Population	Outcomes	Comments
D. 1. 004520				(educational documents) vs. control included in Educational meta-analysis. Severe OSAHS based on mean AHI
Dantas 2015 ²⁰ Randomised parallel-group trial. Country: Portugal	Motivational interviewing: a single group session is delivered 1 month after beginning APAP therapy to promote adherence among patients newly diagnosed with OSAS. This standardised group educative session was conducted by a pulmonologist, a psychologist, and a respiratory physiotherapist and includes information about OSAS and APAP treatment goals and function mode. Two questions were used to gauge the patient's conviction and confidence: "How important to you is the use of the device in your treatment?" and "How confident are you that you can use the device?" The degree of conviction and confidence permitted to establish the stage of change in each patient and to define specific strategies to be applied in an individual 10-min-long interview. During the	N=41 patients diagnosed with OSAS, meeting the criteria for APAP therapy, were randomly allocated to one of two groups: Intervention Group (IG) brief educational intervention (n=20) using motivational strategies or control group 1 (CG1, n=21). ('Control Group 2' (CG2) comprised a convenience sample selected from the sleep lab's initial consultations but were not part of the randomization procedures.). Inclusion criteria: >18 years old, AHI >= 15, diagnosis that indicates ventilator (CPAP) therapy, willingness to participate in the study. Exclusion criteria: chronic obstructive pulmonary disease, neuromuscular disease, heart disease, neurological disease, and patients taking psychotropic drugs. Baseline Characteristics: 23% female. Mean age 56.5	 CPAP Usage (hours/night) at 1 and 2 months. % Days of APAP use (>4 h per night on 70 % of the nights during a period of 30 consecutive days) Sleepiness (ESS) AHI 	Moderate and severe OSAHS

Study	Intervention and comparison	Population	Outcomes	Comments
	intervention, the patient's beliefs, expectations, and feelings were assessed. The authors postulated that according to Prochaska and co- workers that a pre- contemplation stage corresponded to a score of 0 to 3 in the conviction and confidence scales. At this stage, patients were informed about the disease, the possible benefits of the treatment, and the risks of noncompliance with the treatment. To be considered in the contemplation stage, patients had to rate their conviction between 2 and 5 and their confidence between 5 and 8. At this stage, the intervention focused on emphasizing intrinsic motivation and reaffirming the patient's autonomy regarding whether or not to adhere to the treatment. When patients rated their conviction between 6 and 8 and their confidence between 7 and 10, they were considered in the preparation stage. In this stage, they were assisted with developing concrete plans and clarifying objectives. At the end of the intervention, a new interview was scheduled, and written information was	(±10). Mean AHI NR. Mean ESS 9.9. Mean BMI 32.9 kg/m².		

Study	Intervention and comparison	Population	Outcomes	Comments
	delivered about OSAS disease and treatment. control: Participants received only standardized information about APAP (the device and interface) during the 10-min interview, regardless of their confidence and conviction scores. "Control Group 2" (CG2) is a convenience sample submitted to standard procedures, which was not part of the randomization procedures. CG2 is excluded from Review. Study Duration: 2 months			
DeMolles 2004 ²⁴ Randomised parallel-group study. Methods of randomisation not reported Country: USA	Participants were randomised to Telephone-linked communications technology (TLC, n=15) versus usual care (UC, n=15). UC: Described as usual medical care, patient education and demonstration of equipment use. TLC: UC plus computerised digitised human speech programme. TLC asks questions designed to elicit information from participant regarding adherence, education and reinforcement. Study duration: 8 weeks	N = 30 patients being started on CPAP for OSAS. Inclusion criteria: Starting nasal CPAP therapy; > 18 years; English-speaking; AHI > 15 Exclusion criteria: Prior CPAP use. Baseline Characteristics: Mean age 46. Mean BMI 38 kg/m ² . Mean AHI 40. Functional Outcomes of Sleep Questionnaire: TLC: 15.3, Control: 13.8	 CPAP usage (hours/night) at 2 months QoL (FOSQ) 	Included in Cochrane review Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
Diaferia 2017 ²⁶ Randomised parallel-group study. Country: Brazil	Participants were randomised to 2 of 4 study groups were considered: CPAP only (n=27) or CPAP + myofunctional therapy (MT, n=22). [Full study had 2 additional arms: placebo myofunctional therapy (n=24) and myofunctional therapy (n=27) in addition to those noted above for this review.] *CPAP only: standard care, including attending a PSG to determine optimal pressure of CPAP Myofunctional therapy +CPAP: Myofunctional therapy consisted of muscular endurance exercises aimed at toning the oropharynx muscle groups; optimizing muscle tension mobility; and adjusting the position of the soft tissues and the suitability of the chewing, sucking, swallowing, and breathing orofacial functions, according to previously standardised protocols. The therapies were performed at home for 3 months with three daily exercise sessions of 20 min each. Study Duration: Patients underwent evaluations before	For this Review, only the N=49 (male) participants with OSAS Inclusion criteria: Men aged 25-65 years, BMI of less than 35 kg/m ^{2,} confirmed OSAS diagnosis (via polysomnographic criteria). Exclusion criteria: Female gender (excluded "since hormonal decline in the menopausal phase could lead to loss of muscle mass, causing a bias in the study"), other sleep disorders, previous treatment for OSAS, serious or decompensated clinical or psychiatric medical illnesses, such as congestive heart failure, cardiomyopathy, chronic obstructive pulmonary disease, chronic active hepatitis, liver cirrhosis with severe symptoms, myasthenia gravis, demyelinating disease, motor neuron disease, depression, schizophrenia, obsessive compulsive disorder, disorder anxiety, bipolar disorder, eating disorder, attention deficit disorder, and hyperactivity; patients who used alcohol, stimulants or	 CPAP usage (hours/night) at 1 week, 1 and 3 months N of adherent participants (usage ≥ 4 h per night on 70% of nights) Sleepiness (ESS) 	Included in Cochrane review Only CPAP and CPAP + Myofunctional therapy groups included in Review/meta-analysi

Study	Intervention and comparison	Population	Outcomes	Comments
	and after 3 months of treatment, and after 3 weeks wash-out period.	sedatives; and patients with grade III or IV palatine tonsils, grade II or III septal deviation, or evident micrognathia. Baseline Characteristics: 0% female. Mean age 46.9 (±9.9). Mean AHI NR. Mean ESS 12. Mean BMI 28.3 kg/m ² .		
Falcone 2014 ²⁹ Randomised, parallel-group study. Country: Italy	Participants were randomised into educational support (ES, n=103) or standard support group (SS, n=103). SS: Sleep medicine physician provided each subject a full explanation (~10 minutes) of the need for and benefits of CPAP. Prior to CPAP titration the subjects received education regarding CPAP operation, mask placement, and a 20-min period of auto-CPAP exposure. ES: In addition to standard support, each educational support group subject viewed 2 consecutive PSGs on the computer screen: the first recorded during a standard diagnostic overnight polysomnography, and the second during a full-night polysomnography with nasal CPAP. The subject's attention was drawn only to the flow and	N=206 newly diagnosed patients with OSA Inclusion criteria: newly diagnosed OSA, AHI ≥15 events/h, with or without daytime symptoms. Exclusion criteria: COPD, any global respiratory failure, central sleep apnoea syndrome, previous diagnosis of congestive heart failure or cardiomyopathy, any chronic neurological disorder, any severe mental or psychological impairment. Baseline Characteristics: 25% female. Mean age 61.3. Mean AHI 54. Mean ESS 11.2. Mean BMI 32.1 kg/m ² .	 CPAP usage (hours/night) at 1, 3, 12 months. Sleepiness (ESS) 	Included in Cochrane review Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	oxyhaemoglobin saturation curves. Study Duration: 12 months			
Fox 2012 ³⁰ Randomised parallel-group study Country: Canada	Participants were randomised to telemedicine intervention (TM, n=39) or standard care (SC, n=36). TM: Physiological data (PAP adherence, applied PAP, mask leak, residual respiratory events) were downloaded using modem attached to the PAP device and sent across the telephone line each morning. Downloaded information was reviewed every weekday except holidays by the research coordinator, who contacted the participant if poor compliance or other problems with treatment (e.g. mask leak) were detected. Participants were advised over the phone or visited the PAP coordinator. Standard care identical to control group SC: 20-Minute orientation to PAP session and mask fitting. Participants contacted after two days to check adherence and to troubleshoot problems, followed up at four to six weeks and at three months; each time, physiological data downloaded from machines and any problems with treatment	N = 75 adults with moderate- severe OSA by PSG. Inclusion criteria: adult (≥ 19 years), moderate to severe OSA (AHI ≥ 15) Exclusion criteria: active cardiopulmonary or psychiatric disease, previously treated for OSA, no access to telephone line in bedroom, not able to return for follow-up Baseline Characteristics: 20.1% female. Mean age 53.5 (±11.2). Mean AHI 41.6. ESS 9.8. BMI 32.4 kg/m ² .	 Machine usage (minutes per day) Adherence on nights PAP used % days PAP used Decrease in ESS AHI on treatment 	Included in Cochrane review Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	addressed. In addition, data downloaded at eight weeks Study duration: 12 weeks			
Hanger, 2018 ³⁴ Randomised, parallel-group study. Country: USA	 (n=23) Intervention 1: Telemedicine care group (TM). In addition to standard care, participants randomised to the TM group received the intervention, which entailed an initial call to all participants after one week of PAP therapy. CPAP usage data was monitored weekly via a web- based database. Use of CPAP of less than 4 hours per night, on less than 70% of nights (or more than 2 days), in the preceding week of monitoring, was considered non-adherent and triggered a phone call from the research coordinator to provide support and troubleshooting as needed. Participants were seen back in clinic after 6 weeks, per standard care. Data monitoring, as outlined above, continued for the first 3 months of CPAP usage. The study period culminated with a phone call, by the author, to all participants from both study arms, at the end of 3 months, to discuss any questions or concerns and to survey satisfaction of their follow-up care. 	(n=56) (standard care, n=23); telemedicine (n=33). Inclusion criteria: Adults, at least 18 years of age, newly diagnosed with moderate to severe OSA on HSAT or PSG; provision of CPAP device by DME with wireless data transmission capability and English speaking. Age (mean SD): medicine 60.0±14.2; control: 51.4±13.8 AHI: telemedicine38.0±21.1; control 37.27±18.8 Gender: female%: telemedicine 42; control 42.1 Sleepiness: ESS: telemedicine 8.8±4.9; control 11.3±5.5	 AHI at 3 months ESS at 3 months Number of days used >4 hours at 3 months 	Severe OSAHS based on mean AHI.

Study	Intervention and comparison	Population	Outcomes	Comments
	(n=23) Intervention 2: Standard			
	care			
	Participants in the standard			
	care (SC) group received the			
	standard follow-up regimen			
	currently used by the Sleep			
	Center. Following diagnosis of			
	moderate or severe OSA and			
	the participant was prescribed			
	CPAP therapy. Patients			
	obtained equipment; they were			
	fitted with a mask and given			
	instructions on set up, use and			
	care of the PAP machine.			
	Devices were equipped with wireless data transmission			
	technology. Patients were			
	advised to call for any			
	equipment concerns and the			
	Sleep Center with any other			
	concerns or questions related			
	to PAP use; they were seen			
	back in clinic after 6 weeks to			
	discuss adherence and			
	efficacy, review device data,			
	and to address any issues or			
	questions they may have. If			
	patients were doing well, they			
	were seen back yearly for			
	monitoring, with more frequent			
	follow-up if needed.			

Study	Intervention and comparison	Population	Outcomes	Comments
Hoet 2017 ³⁶ Randomised, parallel-group study. Country: Belgium	Participants were randomised to usual care (UC, n=23) or telemonitoring (TM, n=23) group. TM: In addition to usual care, telemonitoring device was attached to CPAP machines. Via this device, sleep laboratory technical staff analysed participant data and contacted patients in the case of air leaks, residual AHI >10/h, or CPAP use less than 3 hours in three consecutive days UC: Group educational session 1 month after CPAP initiation, and a visit to the pneumologist scheduled and 1.5 and 3 months after CPAP initiation. Study Duration: 3 months	N=46 patients with a recent diagnosis of moderate to severe OSAS Inclusion Criteria: At least 18 years old, recently diagnosed with OSAS (AHI ≥20/h). Exclusion criteria: previous exposure to CPAP therapy, mixed/predominantly central sleep apnoea, language barriers, cognitive or psychiatric disorders making it difficult to comprehend information regarding CPAP therapy and provide informed consent, significant comorbidities such as severe chronic obstructive pulmonary disease or hypoventilation syndromes. Baseline Characteristics: 63% female. Mean age 56.6 (±13.5). Mean AHI 49.5. Mean ESS 11. Mean BMI 31.5 kg/m ² .	 CPAP usage (hours/night) at 3 months. 	Included in Cochrane review Severe OSAHS based on mean AHI
Hoy 1999 ³⁷ Randomised, parallel study. Method of randomisation not reported. ITT Country: UK (Scotland)	Participants were randomised into usual care (UC, n=40) or Telemonitoring (TM, n=40). TM: Full explanation of need for and benefits of CPAP by sleep physician, 20-minute video education programme, given mask to try for 20 minutes, titration of CPAP pressure overnight with following day	N = 80 patients with SAHS. Inclusion criteria: AHI ≥ 15, plus daytime sleepiness or two other major symptoms of the syndrome; resident within 50 miles of Edinburgh Exclusion criteria: prior use of CPAP; coexisting COPD, asthma or neurological problems	 Machine usage (hours/night) at 6, 12 months Quality of life Symptom score (in- house questionnaire) Epworth Sleepiness Scale score 	Included in Cochrane review Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	 discharge, nurses telephoned on days two and 21, reviewed in hospital at one, three and six months. Initial education at home with partner, two extra nights in hospital, sleep nurses' home visits to participant and partner at seven, 14 and 28 days and four months after starting CPAP UC Full explanation of need for and benefits of CPAP by sleep physician, 20-minute video education programme, given mask to try for 20 minutes, titration of CPAP pressure overnight with following day discharge, nurses telephoned on days two and 21, reviewed in hospital at one, three and six months Study Duration: 6 months 	Baseline Characteristics: 2.5% female. Mean age 51 (±11). Mean AHI 58. Mean ESS 13. Mean BMI 33 kg/m².		
Hui 2000 ³⁸ Randomised, parallel-group study Country: China (Hong Kong)	Participants were randomised to basic CPAP support (BS, n=54) or augmented support (AS, n=54) AS: 10-Minute CPAP education programme by respiratory nurse, brochure on OSA and CPAP treatment in Chinese, short trial CPAP therapy with comfortable mask for 30 minutes, CPAP titration on second night of study by AutoSet, nursing support following day, follow-up by	N = 108 patients with newly- diagnosed OSA. Inclusion criteria: diagnosis of OSA (AHI > 10 and subjective daytime sleepiness) Exclusion criteria: none reported. Baseline Characteristics: 10% female. Mean age 45 (±11). Mean AHI 48. Mean ESS 12.8. Mean BMI 30 kg/m ² .	 Machine usage (objective and participant reported) At least four hours of CPAP use/night for at least 70% of nights/week) Quality of life ESS SAQLI 	Included in Cochrane review Severe OSAHS based on mean AHI

OSAHS: DRAFT FOR CONSULTATION Adherence

Study	Intervention and comparison	Population	Outcomes	Comments
	 nursing staff and physician at 1 and 3 months. Locally produced 15-minute videotape, additional nurse led 15-minute educational session, review by physicians at weeks one and two, respiratory nurse telephone call on days one and two, weeks one, two, four, eight and 12 BS: 10-Minute CPAP education programme by respiratory nurse, brochure on OSA and CPAP treatment in Chinese, short trial CPAP therapy with comfortable mask for 30 minutes, CPAP titration on second night of study by AutoSet, nursing support following day, follow-up by nursing staff and physician at 1 and 3 months. Study duration: 12 weeks 			
Hwang 2017 ³⁹ Cluster- randomised parallel-group study Country: USA	Classes (and all participants in each class) were randomised (1:1:1:1) to one of four arms: 1) web-based OSA education (Tel-Ed, n=380), 2) telemonitoring and automated feedback (Tel-TM, n=375), 3) Tel-Ed + Tel-TM (Tel-Both, n=346), and 4) usual care (UC, n=354) using a four-arm, randomised, factorial design. Usual Care: All patients attended a 1-hour, small-group	N=1455 patients with suspected OSA were randomised to four study arms, by class-based (cluster) randomised design. This study used the existing home-based testing triage structure at the trialists institution. As they report, "Most patients are referred by primary care physicians, and a sleep medicine physician triages appropriate	 CPAP usage (hours/night) at 90 days Sleepiness (ESS) Residual AHI Number of adherent participants (Medicare definition, usage ≥ 4 h per night) QoL (FOSQ) 	Included in Cochrane review Trialists included three intervention arms. One arm was educational (Tel-Ed), one was Supportive (Tel-TM) and the third was Mixed (Tel-Both). These were compared to control in respective meta-analyses (i.e., Educational, Supportive, Mixed). Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	education class with HSAT setup. After the trial, those willing to continue CPAP were prescribed therapy and scheduled for a 3-month follow- up appointment. Tel-Ed: Education about the pathophysiology of OSA, health-related risks, impact on daytime vigilance, introduction to CPAP therapy. For patients eventually determined to have OSA, a link to a second education program was emailed. This focused on how to use CPAP, potential benefits, methods of acclimating, and equipment care instructions. Education sessions were interactive and self-paced. Tel-TM: Intervention based on automatic processing of device data. During the 3-month study period, if CPAP usage thresholds were met, a message was automatically sent to the patient providing encouragement to improve use or positively reinforcing successful adherence. Tel-both: Patients received Tel- Ed and Tel-TM Study Duration: 90 days	patients to home sleep apnoea testing (HSAT) after review of the referral information and electronic health record chart. HSAT classes (up to 13 people) are led by a sleep trained respiratory therapist and sleep technologist and provide interactive OSA education and individualized HSAT setup. After a one- night test, each patient returns for an individual appointment with a respiratory therapist to review the results. Those with OSA are recommended to undergo a 1-week CPAP trial followed by an individual return appointment with a respiratory therapist to review CPAP data and patient experience. Patients willing to commit to CPAP therapy is immediately dispensed a device; otherwise CPAP troubleshooting or alternative treatments are discussed." This trial enrolled Consecutive patients referred to the Kaiser Permanente Fontana Sleep Disorders Centre (Fontana, CA) for evaluation of suspected OSA and triaged		

Study	Intervention and comparison	Population	Outcomes	Comments
		to HSAT between November 2014 and August 2015.To conform to the sleep centre's usual care procedures, groups of patients were randomised, with all participants in each HSAT class following the same treatment arm. Inclusion criteria: At least 18 years of age, no previous sleep testing or trial of OSA therapy, eligible for HSAT. Exclusion criteria: At risk of other sleep disorders (e.g., severe insomnia), significant cardiopulmonary disease (e.g., heart failure, chronic respiratory failure), or English not preferred language. Baseline Characteristics: 51% female. Mean age 49.1 (±12.5). Mean AHI 22.7. Mean ESS 9.1. Mean BMI 34 kg/m ² .		
Kotzian 2019 ⁴³ RCT Austria	 (n=70) Intervention 1: tele medical monitoring system to improve CPAP adherence. All patients referred to PAP therapy received a 30 min introductory lesson with nasal or oro-nasal mask fitting, device handling and information about PAP therapy. Patients were provided with an 	Subacute adult (19-70 years of age) stroke survivors (>1 months to <1 year post stroke) with a completed stroke confirmed by a neurologist based on the history of a sudden onset of a neurological deficit lasting longer than 24 h, the presence of a neurological	 Days PAP used >4 h- new outcome AHI Mean adherence all days (min per day)- new outcome 	Follow-up 12 months Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	AirSendse 10 Autoset CPAP including humidifier and were set to auto-titrate at pressures between 6 and 13 cm H20. The PAP coordinator at the homecare provider reviewed the downloaded information every morning except on weekends and holidays and contacted the patients if the 90 th percentile of pressure was >16 com H20 or mask leakage of the 95 th percentile was >24l/min or use was <4h or the AHI was >10 events/h for three consecutive days. (n=181) Intervention 2: Standard PAP treatment. No tele medical monitoring system	deficit upon physical examination, and a brain lesion compatible with the neurological deficit in computerised tomography or MRI of the brain were included. For evaluation of OSA, eligible patients underwent in hospital sleep studies. Therapy relevant OSA was defined as showing an AHI >15 per hour of sleep, indicating moderate sleep apnoea. Age: telemonitoring: 62.9 (5.3 years); control: 61.8 (5.3) years Gender: male: telemonitoring 64.7%: control: 75% BMI: telemonitoring: 30.9 kg/m ² (4.8): control: 29kg/m ² (3.1) AHI: telemonitoring: 37 (14.1): control: 37 (12.8)		
Lai 2014 ⁴⁶ , Lai 2017 ⁴⁴ Randomised, parallel-group study Country: China (Hong Kong)	Participants were randomised to usual care (UC, n=51) or UC + brief motivational enhancement program (ME, n=49). UC: Usual Care: Usual care was provided by nurses in the Sleep Disorders Center who provided a 15-min talk to	N=100 patients with newly diagnosed OSA. Inclusion Criteria: At least 18 years old, newly diagnosed OSA, AHI >= 5, receiving in- laboratory auto-CPAP titration for the first time, no prior OSA or CPAP education classes.	 CPAP usage (hours/night) at 1 and 3 months. Number of adherent participants (usage ≥ 4 h per night for at least 70% of nights) Sleepiness (ESS) 	Included in Cochrane review Moderate OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	 introduce the basic operation of the CPAP device and titration procedure. Subjects tried the CPAP device for approximately 30 min for acclimatization before the start of the overnight titration procedure. The next morning after CPAP titration, the subject met the medical officer-in-charge, who provided an explanation of OSA, explained the subject's particular test results, and prescribed treatment. Nurses gave further advice (about 15 min) on the importance of CPAP therapy and care of accessories before the subjects were given their devices and discharged from the Sleep Disorder Center. ME: Brief Motivational Enhancement Education: The aim of brief motivational enhance those factors that may influence behavioural skills and bring about behavioural change. The brief motivational enhancement education programme, which was designed to enhance the subject's programme, which was designed to enhance in the 	Exclusion criteria: central sleep apnoea, periodic leg movement disorders, COPD, pregnancy, psychiatric illness on treatment, cognitive impairment, illiteracy, unstable health conditions, unable to attend the education session before discharge from Sleep Disorders Centre, scheduled for OSA follow-up in other hospitals, or participating in another clinical trial. Baseline Characteristics: 17% female. Mean age 51.98 (±10). Mean AHI=29.42. Mean ESS=9.25. Mean BMI=28.96 kg/m ² .	 QoL (FOSQ, CSAQLI, SF-36) ESS Follow-up 3 months and 1 year 	

Study	Intervention and comparison	Population	Outcomes	Comments
	ability to apply CPAP treatment			
	(self-efficacy), and association			
	of their behaviour to the desired			
	outcome (adherence) or			
	outcome expectancy, included			
	a session in the morning after			
	CPAP titration and a telephone call on day 2 of CPAP use,			
	providing early follow-up.			
	The subject was shown a 25-			
	min video together with an			
	information booklet providing			
	the knowledge on OSA and			
	CPAP. The video included the			
	real-life experience of a current			
	CPAP user. Then, a 20-min			
	patient centred face-to-face			
	brief motivational interview was			
	conducted and aimed to			
	facilitate the subject's intrinsic			
	motivation toward CPAP			
	therapy.			
	Several tools and strategies			
	were applied, which were as			
	follows:			
	(1) using importance and			
	confidence rulers with higher-			
	lower exercise			
	to explore the barriers and			
	facilitators of using CPAP			
	(2) using a decision matrix to			
	discuss the positive and			
	negative aspects			
	of using or not using CPAP,			
	and (3) looking forward to the			

Study	Intervention and comparison	Population	Outcomes	Comments
	expected outcomes or benefits of using CPAP. The interview was conducted by one of the investigators who was both a nurse and polysomnographic technologist who had received prior training to conduct motivational interviews by a clinical psychologist (member of Motivational Interviewing Network of Trainers). Thereafter, a 10-min phone call was made to the subjects by the same interviewer on day 2 of CPAP use. Checklists for interview and phone follow-up were used to ensure treatment fidelity. Duration: 3 months.			
Lewis 2006 ⁴⁷ Prospective, single-blinded interventional study Country: UK	Participants were randomised to standard support (SS, n=36) or intensive support (IS, n=36) group. IS: 20-Minute educational video about SAHS. Telephone interview by research assistant between days two and five after CPAP issued to identify early problems and advise. Extra appointment to see sleep physician within seven to 14 days after being issued CPAP. Further appointment with sleep	N = 72 patients with newly diagnosed SAHS immediately prior to CPAP titration. Inclusion criteria: diagnosis of OSA (based on home sleep study) and subjective daytime sleepiness Exclusion criteria: not reported Baseline Characteristics: 13.8% female. Mean age 51.4 (±8.6). Mean AHI 42.5. Mean ESS 15.7. Mean BMI 36.5 kg/m ² .	Machine usageSide effectsSatisfactions	Included in Cochrane review Only 20/36 participants in the intervention group watched the educational video tape. Eight of the 17 defaulters returned machines at different times of the year and had negligible hours of use. Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	physician at 1, 6, and 12 months SS: Participants provided telephone number for support within office hours. Sleep physician reviewed participants at 1, 6, and 12 months Study duration: 52 weeks			
Mendelson 2014 ⁵³ Randomised, parallel-group study. Randomization was stratified by recruitment centre in blocks of 6 participants. Country: France	Participants were randomised to telemedicine (n=54) or standard care (n=53). Standard Care: Evaluated at baseline, fitted with a nasal mask and given an auto titrating machine. Patients were contacted after 2 days to ask about adherence and to troubleshoot. After 4 weeks of treatment, patients met with their sleep specialist and data downloaded from machines. After 4 months of treatment, patients consulted their sleep specialist and were re- evaluated. Telemedicine: In addition to standard care, TM participants were equipped with a smartphone for uploading BP measurements, CPAP adherence, sleepiness, and quality of life data. They received daily pictograms containing health-related messages. Study Duration: 4 months.	N=107 patients with OSA and a high cardiovascular risk (cardiovascular SCORE > 5% or secondary prevention). Inclusion Criteria: Age between 18 and 85 years, diagnosed with OSA on diagnostic sleep study (AHI > 15), BMI of less than 40 kg/m ² , cardiovascular risk SCORE > 5%, or being in secondary prevention with a past history of cardiovascular disease. Exclusion criteria: Central sleep apnoea syndrome cardiovascular score < 5%, cardiac failure, history of hypercapnic chronic respiratory failure, incapacitated patients, pregnancy or taking part in another clinical trial. Baseline Characteristics: 16.8% female. Mean age 63 (±9). Mean AHI=39. Mean	 Home self-measured blood pressure (BP) CPAP usage (hours/night) Sleepiness (ESS) QoL (SF-36) All outcomes were measured at 4 months only. 	Included in Cochrane review Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
		ESS=7.9. Mean BMI=29.9 kg/m².		
Meurice 2007 ⁵⁴ Randomised parallel-group trial. Country: France	Participants were randomised to Intervention Group 1 (n=27), Group 2 (n=27), , Group 3 (n=27) or Group 4 (n=26), defined as follows: Intervention Group 1: RP + RH Intervention Group 2: RP + SH Intervention Group 3: SP + RH Intervention Group 4: SP + SH (Control) Reinforced education by Homecare Network (RH): Home visit by technician at installation and further visits for explanation at one week, one month and two and three months of treatment for repetition of education and problem solving Reinforced education by prescriber (RP): Written material on CPAP use; explanation of OSA and CPAP with side effects; emphasis on importance of compliance with CPAP and detailed demonstration Standard education by the homecare network (SH): Homecare visit to supply the CPAP machine fit the mask and explain the technique of using the apparatus. CPAP	N=112 participants with severe OSA and no prior treatment for OSA. Inclusion Criteria: PSG- confirmed OSA (AHI > 30), no prior OSA treatment, treated with constant pressure. Exclusion criteria: None reported. Baseline Characteristics: Mean age 58 (±11). Mean AHI=58(±25). Authors reported mean ESS and BMI by intervention arm and reported no significant differences. Gender distribution not reported.	 CPAP usage (hours/night) at 3 months (6 and 12 months data also presented but outside study protocol time period). Sleepiness (ESS) Quality of life (SF- 36) 	Included in Cochrane review Intervention groups 1, 2 and 3 combined for comparison to Control group (4) in Meta- Analysis, as recommended in Cochrane Handbook section 16.5.4. Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	 mechanism and method of using the machine and mask were explained. Participant was encouraged to ask questions and could phone at any time to resolve problems Standard education by the prescriber (SP): Standard oral explanation of OSA and CPAP, brief demonstration of machine use plus manufacturer's literature. Participant was encouraged to ask questions and clarify misunderstandings. Study duration: 3 months, per protocol. Follow-up to 52 weeks (intervention administered at outset of study). Data extracted at three months. Authors report 'During the remaining 9 months following the initial study design, there was no specific follow-up protocol and patients benefited from the standard homecare surveillance recommended in the ANTADIR network, with a review every 3 months'. 			
Munafo 2016 ⁵⁶ Randomised, parallel-group study. Country: USA	Participants were randomised to standard of care (SOC, n=64) alone, or SOC + web- based automated telehealth messaging program (TH, n=58). SOC: Patients were dispensed a CPAP device on Day 0, then	N=122 newly diagnosed patients with OSA. Inclusion criteria: Age 18–80 years, CPAP-naïve, confirmed OSA (AHI 5–70) diagnosis based on polysomnography (PSG) or home sleep test, access to	 CPAP usage (hours/night) at 90 days Number of adherent participants (Medicare: use for >= 4 h/night on 70 % of nights during a 30 	Included in Cochrane review Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	 contacted via phone on Days 1, 7, 14, 30, and 90. CPAP usage and efficacy data were tracked via the wireless modem attached to CPAP machine. Modem data were accessed via online platform. Frequent phone calls and return clinic visits were provided, as necessary. TH: CPAP device dispensed on Day 0, along with a pamphlet about U-Sleep, a web-based application to monitor adherence and message patients and providers via automated series of text messages/emails were triggered by pre-set conditions. Study Duration: 3 months 	and be able to utilize communication technology (text messaging, e-mail). Exclusion criteria: prominent central apnoea (>20 %), claustrophobia, current use of mandibular repositioning device, other OSA therapy. Baseline Characteristics: 31% female. Mean age 51.2 (±11.2). Mean AHI=30.4. Mean ESS=10.5. Mean BMI=33.2 kg/m ² .	consecutive-day period anytime during first 90 days of initial usage) • Sleepiness (ESS) • Residual AHI All outcomes measured at 90 days.	
Murase 2020 ⁵⁷ RCT Japan	 (n=161) Intervention 1: Telemedicine group Physician checked adherence data utilising the telemonitoring system. Follow-every 3 months. (3 months n= 166; 1 month, n=156) Intervention 2: No telemedicine Follow-up 1 month and 3 months 	N=508 The criteria for patient inclusion were >18 years old; fulfilled the requirements for CPAP treatment under Japanese governmental health insurance (AHI>20/h by PSG or respiratory event index >40/h by portable monitoring device at OSA diagnosis; CPAP implemented more than 3 months previously; residual AHI under CPAP use<20/h; having clinic visits every month or every 2 months for	CPAP use min/night	Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
		follow-up of CPAP therapy; recent CPAP adherence data available. Age: telemedicine group: 60 (11); control: 60 (13) years AHI: telemedicine: 40.6; control 40.6		
		Gender: male%: telemedicine 87%; control 86.1% BMI: telemedicine: 27.4 kg/m ² (3.8); control: 27 kg/m ² (5.4) Sleepiness: ESS: telemedicine 5.7 (4.0); 4.9		
NUL- 004061	(07) later weather 4	(2.3)		
Nilius 2019 ⁶¹ RCT Germany	(n=37) Intervention 1: telemedicine Therapy was uniformly initiated in all eligible patients that is after a positive PSG. Patients were visited by sleep lab staff, and a training session and mask adjustment followed before the initial therapy PSG. The device used was usually an APAP device set to a pressure 4-18 cm H20. The online data for the telemedicine group was	(n=80)Patients who had suffered an ischaemic stroke within last 3 months; a moderate to severe baseline OSA with an AHI>15, that had been confirmed in the sleep laboratory; physical capability to operate a PAP device and mask; age<75;CPAP naïve; no COPD; and regular PAP usage (<3h/night) during the inpatient phase.	 Usage hours/night- added to outcome ESS- end point added to outcome SF-12 physical SF-12 mental Systolic blood pressure Diastolic blood pressure 	Severe OSAHS based on mean AHI
	anonymously transferred to the password protected web server each morning. The data was evaluated for relevant therapy	Age: telemedicine 55.4 (10.4) years; control: 58.6 (9.3) years Gender: all females		

Study	Intervention and comparison	Population	Outcomes	Comments
	details each week starting 7 days after the individual discharge date of each patient. (n=38) Intervention 2: No intervention – Standard care All patients went home with a PAP device and the sleep lab informed the homecare provider about the therapy settings and equipment. The patients were advised to visit their primary care physician or lung specialist if they experienced any problem. Follow-up 6 months	BMI: telemedicine 31.7 kg/m ² (5.4); control 30.1 kg/m ² (6.6); Sleepiness ESS: telemedicine 2.4 (3.7); 3.9 (4.9); AHI: 41.2 (19); control: 37.6 (18.4)		
Olsen 2012 ⁶² Randomised parallel-group study Country: Australia	Participants were randomised to motivational interviewing intervention (MINT, n=53) or control (n=53) group. MINT: Motivational interview nurse therapy (MINT) Three sessions of CPAP- specific Motivational Interview Nurse Therapy (MINT) one month apart. Each session lasted approximately 30 minutes. Participants were followed up at two to four weeks by physician and at two months by a nurse. A questionnaire and a machine meter data on adherence were obtained at one, three and 12 months.	N = 100 with OSA diagnosed by PSG. Inclusion criteria: OSA confirmed by polysomnography, age ≥ 18, naive to CPAP Exclusion criteria: need for bi-level ventilation, failed to complete CPAP titration, severe depression Baseline Characteristics: 31% female (41.5% intervention, 28.3% control). Mean age 56.6 (±11.0). Mean RDI 34.3. Mean ESS 21.9. Mean BMI 34.5 kg/m ² .	 CPAP acceptance and adherence FOSQ ESS 	Included in Cochrane review Severe OSAHS based on mean RDI

Study	Intervention and comparison	Population	Outcomes	Comments
	The manual was initially informed by the Motivational Enhancement therapy manual developed by Miller and colleagues but with significant modification to increase the relevance to OSA population. As well as receiving general feedback about OSA severity, patients were provided feedback on their own responses to a satisfaction with life scale and apperception of functional severity questionnaire completed at baseline. Sessions 1 and 2 were approximately 30 min in duration (maximum 45 mins), and the booster session was approximately 20 min in length (maximum 30 min). Participants were encouraged to bring along a significant other to the two initial MINT sessions.			
	Nurse training Three nurses with 2-16 years specific sleep medicine training delivered the intervention. The nurses underwent a full day training session with a registered psychologist trained in clinical, health, sleep and neuropsychology. The nurse			

Study	Intervention and comparison	Population	Outcomes	Comments
	 training session was a structured protocol based on the manual used for this intervention. The training day was Video recorded. Control: Standard one-on-one 45-minute education session conducted on the day of CPAP titration. Participants were followed up at two to four weeks by physician and at two months by a nurse Study duration: 52 weeks 			
Parthasarathy 2012 ⁶⁴ Randomised parallel-group open-label Country: USA	Participants were randomised to usual care (UC, n=17) or peer buddy system (PBS, n=22) group. PBS: Trained peers with OSA and good CPAP adherence record were paired with newly diagnosed participants over three months. During two face- to-face sessions and eight telephone-based conversations, trained peers shared their experiences on coping strategies with CPAP, knowledge of perceived vulnerabilities of untreated OSA, motivated participants and promoted methods for improving efficacy of CPAP UC: CPAP initiation and education class, participants were asked to send CPAP	N = 39 veterans with OSA prescribed CPAP. Inclusion criteria: age 21-85, new diagnosis of OSA, AHI > 5, full night or split night polysomnography, no sedative medications used Exclusion criteria: central or complex sleep apnoea, requirement of oxygen or Bi- PAP, unstable medical co- morbidities, irregular lifestyle pattern, excess alcohol use Baseline Characteristics: 0% female. Mean age 52 (±14). Mean AHI 37. Mean ESS 10.8. Mean BMI 34 kg/m ² .	 CPAP adherence Functional Outcomes of Sleep Questionnaire (FOSQ) 	Included in Cochrane review Additional information on study methods and mean CPAP adherence obtained from the study author. These data were available from a pilot study. Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	adherence 'smart cards' and were followed up at one and three months Study duration: 90 days			
Pengo 2018 ⁶⁵ Randomised, parallel-group study. Country: UK	Participants were randomised to receive, in addition to CPAP therapy, either positively (n=36) or negatively framed (n=37) messages, or standard care (n=39) alone. All patients received 2 weeks of APAP, followed by 4 weeks of fixed CPAP. Standard care: Included explanation of importance of treating OSA, APAP introduction by expert sleep technicians, standard instructions on use of devices, review for troubleshooting, and compliance assessment at 2- weeks post treatment initiation. Positive: Positively framed messages in addition to CPAP. Patients were phoned weekly and read the framed health messages (up to a total of 6 phone calls per patient). Negative: Negatively frames messages (up to a total of 6 phone calls per patient). Study Duration: 6 weeks	N=112 patients who had positive home-based pulse oximeter screen for OSA. Inclusion Criteria: Following at-home screening using nocturnal pulse oximetry, patients who had 4% ODI ≥5 and typical symptoms of sleep apnoea (ESS>10 points), or a 4% ODI > 15 were invited for CPAP treatment. Exclusion Criteria: Mental or physical disability precluding compliance with study protocol, unable to participate in trial follow-up. Baseline Characteristics: 25% female. Mean age 49.1 (±12.1). Mean ODI=24.8. Mean ESS=11.3. Mean BMI=36.5 kg/m ² .	 CPAP usage (hours/night) at 6 weeks. % Days CPAP used for > 4 hours Sleepiness (ESS) All outcomes reported at 2 and 6 weeks. 	Included in Cochrane review Intervention arms (positively- and negatively balanced messages) combined for comparison to Control arm in Meta-Analysis, as recommended in Cochrane Handbook section 16.5.4. Moderate OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
Pepin 2019 ⁶⁶ Randomised, multi- centre parallel- group study. Country: France	Participants were randomised to usual care (UC, n=149) or multimodal telemonitoring (TM, n=157) for 6 months. TM: CPAP-related factors (adherence, leaks, and residual events), BP and physical activity recorded by connected devices. Symptoms and quality of life were recorded via electronic questionnaires completed by patients. Patients received demonstration home telemonitoring use and an explanation of why monitoring these physiological variables was relevant for their care. Automatic algorithms were constructed for the prompt adjustment of CPAP treatment. UC: Received standard care usually received from their assigned sleep centres. Study Duration: 6 months	N=306 patients with newly- diagnosed OSA. Inclusion Criteria: 18 to 75 years, severe OSA (AHI > 30) on the basis of respiratory polygraphy or PSG, at least one cardiovascular disease or exhibit an elevated cardiovascular risk (Systematic Coronary Risk Evaluation risk > 5% at 10 years or in secondary prevention). Exclusion Criteria: Central sleep apnoea, heart failure with a left ventricular ejection fraction < 40%. Baseline Characteristics: 26% female. Median age 61.3 (IQR: 54.1-66.1). Median AHI=46. Median ESS=9. Median BMI=32.0 kg/m ² .	 Systolic blood pressure [Author's primary outcome] CPAP usage (hours/night) at 6 months. Sleepiness (ESS) QoL (SF-12) All outcomes were reported for 6-month endpoint only. 	Included in Cochrane review Severe OSAHS based on mean AHI
Richards 2007 ⁶⁹ Randomised, parallel-group trial Country: Australia	Participants were randomised to treatment as usual (TAU, n=50) or Intervention (n=50) group. Intervention: Cognitive- behavioural therapy. Two one- hour group sessions; slide presentation on sleep, OSA and treatment. CPAP machine on display and relaxation techniques in the	N = 100 participants with newly-diagnosed OSA referred for CPAP titration. Inclusion criteria: Newly diagnosed with OSA referred for CPAP titration Exclusion criteria: Inability to understand fluent English, previous use of CPAP. Baseline Characteristics: 4% female. Mean age 56. Mean	Machine usage	Included in Cochrane review Severe OSAHS based on mean RDI.

Study	Intervention and comparison	Population	Outcomes	Comments
	event of anxiety caused by wearing CPAP mask Participants also benefited from video presentation with emphasis on perseverance with treatment and educational pamphlet made available TAU: One standardised group education session; explanation of CPAP titration process; familiarisation with equipment used and procedure to be followed on the titration night. Explanation of side effects, all participants strongly encouraged to contact staff to obtain relevant help and support. Participants assessed and fitted with comfortable mask to be worn during titration Study duration: 28 days	RDI 26.5. Mean ESS 10.5. Mean BMI 30.3 kg/m ² .		
Roecklein 2010 ⁷¹ Randomised parallel-group study Country: USA	Participants were randomised to standard education (SE, n=16) or personalized feedback (PF, n=14) group. PF: Written personalised feedback report, including detailed information on severity of the disease, self-reported daytime sleepiness, individually estimated risk of adverse health outcome and risk of motor vehicle accident, all compared with normative data. Feedback addressed barriers to using CPAP, ambivalence	N = 30 patients diagnosed with OSA by PSG, naive to CPAP and reporting intent to use CPAP. Inclusion criteria: age 18 to 65, CPAP naive, reported intent to use CPAP (other sleep, psychiatric or health problems were not exclusion criteria) Exclusion criteria: None reported. Baseline Characteristics: 70% female. Mean age 46.3 (±11.2). Mean AHI 44.4.	 Objective CPAP usage (total hours, average hours/night, number of sessions) Self-reported CPAP usage 	Included in Cochrane review Participants were not provided machines but obtained them 'naturalistically', most commonly through insurance. Most participants were low-income African Americans. Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	about treatment and difficulties of behaviour change and promoted self-efficacy and personal responsibility for choosing to use CPAP SE (control): Written information from the American Academy of Sleep Medicine on OSA, Snoring and PAP therapy for OSA Study duration: 3 months	Mean ESS 11.6. Mean BMI 42.1 kg/m ² .		
Sarac 2017 ⁷² Randomised, parallel-group study. Country: Turkey	Participants were randomised to receive standard support (SS, n=63) or educational support (ES, n=52). SS: General explanation (~10- 15 min) of OSA and PAP. ES: SS + additional education (~ 20 min) by a sleep medicine physician , including: viewing his/her own polysomnography chart on morning post PAP- titration, comparing the PSG from diagnostic and CPAP titration studies with explanations that emphasized obstructive events and oxygen desaturations, and the disappearance of those signs on PAP treatment. Study Duration: Approximately 6 months	N=115 patients with OSA. Inclusion criteria (not explicit): ≥18 years old), newly diagnosed OSA (AHI ≥5), free from upper airway obstructions. Exclusion criteria (not explicit): Not interested in PAP or in study participation, living outside Istanbul, unable to come to follow-up. Baseline Characteristics: 24.5% female. Mean age 51 (±9.3). Mean AHI=41.4. Mean ESS=10.0. Mean BMI=32.5 kg/m ² .	 CPAP usage (hours/night) at 5 time points, participants invited to return at 15, 30, 60, 90- and 180-days post-randomisation (actual time of measurements varied by participant) Number of adherent participants (usage ≥ 4 h per night on at least 70% of nights) at short-term (first) and long-term (last) follow-up Sleepiness (ESS) 	Included in Cochrane review 58 out of 63 patients in the SS group, and 49 out of 52 patients in the ES group completed the five follow-up appointments during the study period. The median time from randomization to first follow-up was 20 days for both groups with an IQR 17–27 days for the SS group, and 16–26 days for the ES group (p=0.89). The median time to last follow-up was 187 days (IQR 170-202 days) in the SS group, and 184 days (IQR 173–198 days) in the ES group (p=0.16). Severe OSAHS based on mean AHI
Sawyer 2017 ⁷³	Participants were randomised to receive usual care (UC, n=57) or a multi-phased and	N=118 adults with newly diagnosed OSA Any adult patient referred for a	 CPAP usage (hours/night) at 1 	Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
Randomised, parallel-group study. Country: USA	 tailored intervention (TI, n=61) targeting social cognitive perceptions of OSA–PAP treatment. TI: Intervention addressed cognitive perceptions of the diagnosis and treatment, outcome expectancies with PAP treatment, and PAP treatment self-efficacy, all domains of SCT. Intervention delivered in four phases: pre- diagnosis, post diagnosis (i.e., post diagnostic polysomnogram), immediately post-PAP titration polysomnogram, and with week 1 of home PAP treatment. Intervention delivery guided by a protocol and script templates for specific exposure phases to minimize a potential interventionist effect. UC: Followed current practice standards for the diagnosis and treatment of OSA in adults (Epstein et al., 2009; Kushida et al., 2006). Included sleep centre–provided informational brochures about OSA, diagnostic testing, and PAP prescription. In addition, access by telephone to sleep centre staff for problems, questions, or concerns was provided during daytime and evening. 	diagnostic PSG was invited to participate in the study. Inclusion Criteria: newly diagnosed with OSA (AHI > 10), PAP-naive, ≥18 years of age, able to read and speak English. Exclusion criteria: previous diagnosis or treatment of OSA; medical record documented new psychiatric diagnosis within previous six months of study enrolment; requirement of supplemental oxygen or bi- level PAP identified on PAP titration PSG suggesting diagnosis other than OSA; diagnosis of another sleep disorder in addition to OSA based on polysomnogram (i.e., periodic limb movement disorder [≥10 limb movements/hr of sleep with arousal], central sleep apnoea [≥5/hr central apnoea's], insomnia, sleep hypoventilation syndrome, or narcolepsy). Baseline Characteristics (per-protocol): 30% female. Mean age 51.3 (±11.1). Mean AHI=36. Mean ESS=19.6. Mean BMI=38.0 kg/m ² .	 week, 1 month and 3 months. Number of adherent participants (usage ≥ 4 h per night) at 1 week, 1 month and 3 months. 	

Study	Intervention and comparison	Population	Outcomes	Comments
	Study Duration: 3 months			
Scala 2012 ⁷⁴ Randomised, parallel-group study. *** FULL INFORMATION PENDING TRANSLATED FULL TEXT *** Country: Italy	Participants were randomised to standard care (SC, N=15) or an educational intervention (EDU, N=13). EDU: 3 interactive sessions, video with discussion, focus group and role play, respectively 1, 2 and 3 months after receiving the CPAP device. Study Duration: 6 months	N=28 patients with newly- diagnosed OSAS. Inclusion Criteria: Newly- diagnosed, OSAS. Exclusion criteria: Not reported. Baseline Characteristics: 75.3% female. Mean age 57 (±11.2). Mean AHI NR. Mean ESS 12.6. Mean BMI NR.	 CPAP usage (hours/night) at 6 months (12-month results pending at time of report) Sleepiness (ESS) QoL (SF-36) Outcomes measured at 6 months. 	Included in Cochrane review
Sedkaoui 2015 ⁷⁷ Randomised, parallel-group study. Country: France	 Participants were randomised to standard support (SS, n=190) or coached support (CS, n=189). SS: Received information from their physician about modalities and usefulness of CPAP treatment. Technician performed CPAP set-up at participant's home, re-explained the device's function, and checked for mask fit and adaptation. Follow-up performed at 1 month and 4 months to assess CPAP parameters. CS: In addition to SS, participants in CS received standardized support completed through 5 sessions (day 3, 10, 30, 60, and 90) via telephone-base counselling. Session 1 objective was to 	N=379 with newly diagnosed SAHS Inclusion Criteria: OSAHS, prescribed CPAP, AHI ≥ 30 or AHI < 30 and > 10 arousals/hour, French fluency. Exclusion criteria: Age <18 years, under guardianship, previous CPAP use, psychiatric illness, participating in another clinical trial Baseline Characteristics: 72.0% female. Mean age 63. Mean AHI 42.2. Mean ESS 11.6. Mean BMI 40 kg/m ² .	 CPAP usage (hours/night) at 4 months Number of adherent participants (usage ≥ 3 h per night) at 4 months 	Included in Cochrane review Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	assess patient's knowledge about the disease, device and health consequences; to emphasises importance of good adherence; to encourage CPAP use throughout sleep every day. Objectives of the other educational sessions were to identify disadvantages or obstacles CPAP treatment and then focus on the benefits linked to use of CPAP. A particular effort was made to discuss misconceptions about sleep apnoea and barriers to use, concerns fears and beliefs, as well as the perceptions of their partners and family, in order to increase patients' positive expectations regarding CPAP benefits. Study Duration: 4 months			
Shapiro 2017 ⁷⁸ Randomised parallel-group trial Country: USA	Participants were randomised to standard care (SC, n=33) or CPAP-SAVER Intervention (CI, n=33). SC: Basic OSA and CPAP teaching and follow-up provided by respiratory therapist/CPAP education employed by home medical supplier. CI: Standard care plus airway model, video education sheet, report card components, support calls.	N=46 newly-diagnosed with OSA and prescribed CPAP for the first time. Inclusion criteria: >= 18 years; newly-diagnosed by PSG; commencing CPAP for first time; able to read/speak/understand/write English; CPAP with smart card technology Exclusion criteria: requires BiPAP, significant craniofacial abnormalities, Downs syndrome, cognitive	CPAP usage (hours/night) at 1 month	Included in Cochrane review Moderate OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
		delay, hypertonia, neuromuscular degenerative disorder, taking anti-anxiety medication, pregnant. Baseline Characteristics: 45.5% female, Mean age 51.8 (13.1). Mean AHI 26.2. Mean ESS NR. Mean BMI 35.7kg/m ² .		
Smith 2006 ⁸² Randomised parallel-group trial Country: USA	Participants were randomised to control (n=9) or intervention (n=10) group. Intervention: Two-way telehealth sessions mediated by video link-up through phone line. Research nurse emphasised nightly, bedtime routine for CPAP. After standardised protocols, nurse visually assessed participant, guided correct CPAP routine and determined whether the CPAP mask fits properly. Nurse described consequences of non-adherence and managing barriers to CPAP use. Benefits of nightly CPAP use for general health were emphasised Control: Two-way telehealth sessions mediated by video link-up through phone line. Protocols drawn up to mimic content delivered to intervention group. Instead of CPAP-related information,	N = 19 with newly-diagnosed OSA, non-adherent with CPAP for 3 months Inclusion criteria: New OSA diagnosis, first CPAP prescription, received initial education on CPAP use and supplemental audiotaped/videotaped reinforcement at two and four weeks, non-adherent with CPAP for 3 months Exclusion criteria (unclear if a priori): positive screen for drug or alcohol abuse, depression requiring hospitalization Baseline Characteristics: % female NR. Mean age 63 (±8). Mean AHI NR. Mean ESS NR. Mean BMI NR.	 Number of adherent participants (usage ≥ 4 hrs/night on ≥ 9 of 14 nights) at 12 weeks 	Included in Cochrane review Non-adherence in the study defined as less than four hours of CPAP use per night for fewer than nine of 14 consecutive nights' use TJL emailed for details of randomisation and outcome data 12/09/2008. Carol Smith responded 15/09/2008. For updated review, further email communication was required to verify that updated inclusion criteria were met, confirmation received from Carol Smith, 27mar2019.

OSAHS: DRAFT FOR CONSULTATION Adherence

Study	Intervention and comparison	Population	Outcomes	Comments
	participants given content on vitamin intake Study duration: 12 weeks			
Smith 2009 ⁸¹ Randomised parallel-group trial Country: USA	Participants were randomised to control (n=42) or CPAP Habit Intervention (Intervention, n=55) group. All participants received usual education on OSA and demonstration of CPAP equipment Intervention: The Habit- Promoting Experimental Audio Intervention: CPAP Every Day —The CPAP intervention packet called, "Get in the Habit of CPAP Every Day," included audiotaped music along with softly-spoken directions for using CPAP nightly. The sleep inducing audio music entitled, "Building a Routine for Sleep Time." The audio music guided patients in preparing the CPAP machine at bedtime and in creating a relaxing environment in congruence with music and lyrics. The 20-minute audio provides instructions for putting on the CPAP mask comfortably, correctly connecting air hoses and relaxing despite the ventilation equipment positive air pressure and noise. The audio first instructs the patient to practice breathing in deeply and then	N = 97 patients with newly- diagnosed OSA. Mean age: 63.4, Male sex: 55%, Mean AHI: Intervention group: 52.3, Control group: 47.3 Inclusion criteria: new diagnosis of OSA, age ≥ 18, AHI ≥ 20 Exclusion criteria (unclear if a priori): positive screen for drug or alcohol abuse, depression requiring hospitalization Baseline Characteristics: 45% female. Mean age 63. Mean AHI 50.1. Mean ESS NR. Mean BMI NR.	 Number of participants adhering to CPAP (≥ 4 hours/day and ≥ 9 of 14 nights) at 1, 3 and 6 months 	Included in Cochrane review Severe OSAHS based on mean AHI

Study Intervention and comparison	Population	Outcomes	Comments
StudyIntervention and comparisonexhaling slowly for relaxation. Next, the patient is guided to relax his or her muscles slowly from toes to head, using repeated reminders for slow, deep breathing and spoken images of long restful sleep (e.g., "feel the gentle air pressure slowly filling your lungs") to sensitize patients to CPAP benefits. The gradually decreasing music tempo induces relaxation by slowly reducing the rhythms to a typical resting heart rate cadence.The intervention packet had informational handout sheets, CPAP use reminder placards and a 4-week diary for recording audio use and writing about their experiences with CPAP. Handouts in the packet list the health consequences of not using CPAP, such as the high risk of stroke and heart attack, falling asleep while driving, poor functioning on work activities due to sleepiness, or missing out on social activities due to fatigue or tiredness and an audio disc,	Population	Outcomes	Comments

Study	Intervention and comparison	Population	Outcomes	Comments
	Materials also provided information about benefits of adherence (increased alertness, energy for activities, less irritability). Thus, the intervention integrated CPAP benefit and non-use risk information, music relaxation and habit-promoting instructions as a guide to routine nightly use of CPAP]. Control: Audiotaped music along with spoken information about vitamins. Information packet was the same in format and length as the intervention group, but content was on vitamins Study duration: 6 months			
Soares-Pires 2013 ⁸³ Randomised, parallel-group study. Country: Portugal	Education group: Participants were assigned to a single group education session one month after beginning APAP therapy. Sessions were conducted by a pulmonologist, a psychologist, and a respiratory physiotherapist. Sessions included information regarding OSAHS, its symptoms and risks, APAP treatment, the importance of good adherence, and different machine interfaces. Patients were invited to share their experience on the use of APAP, and each patient's	N=202 patients with OSAHS. Inclusion criteria: AHI ≥15 or ≥5 events per hour plus symptoms that included unintentional sleep episodes while awake, daytime sleepiness, unrefreshing sleep, fatigue, insomnia, gasping or choking, or loud snoring and/or apnoea described by the patient's bed partner. Exclusion criteria: lung disease, obesity hypoventilation syndrome, restrictive ventilatory syndromes, long-term	 CPAP usage (hours/night) at 6 months. Number of adherent participants (usage > 4 h/night for ≥ 70% days 	Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	adherence reports were analysed and discussed. Patients; concerns, fears, and beliefs were also addressed. Standard Care: The sleep physician provided a brief explanation of the disease to patients of both groups, as well as informed patients of the need for APAP treatment, its benefits and function mode. None of the patients had previously received any form of PAP therapy. Approximately 3– 5 days after the prescription, technicians from the PAP systems delivery companies performed a home visit to drop the APAP device. In this visit, an explanation on how to turn on and off the machine and on the placement of the interface was provided to all patients. Study Duration: 6 months	oxygen therapy, Cheyne– Stokes breathing pattern, central apnoea, cognitive disability. Baseline Characteristics: 29.5% female. Median age 58.5. Median AHI 38. Median ESS 12. Median BMI 32 kg/m ² .		
Sparrow 2010 ⁸⁴ Randomised parallel-group trial Country: USA	Participants were randomised to control (n=126) or interactive voice response system, TLC- CPAP (TLC-CPAP, n=124) group. TLC-CPAP: (telephone-linked communications for CPAP (TLC-CPAP), (n=124) The TLC-CPAP was designed around the concepts of motivational interviewing, a	N = 250 patients undergoing initial set-up of fixed- pressure CPAP or BiPAP. Inclusion criteria: Age 18 to 80 years, AHI > 10 Exclusion criteria: Not reported Baseline Characteristics: 18% female. Median age 55. Median AHI 38.3. Median	 Machine usage (data downloaded from memory cards or by direct interrogation of CPAP devices) at 6and 12 months. Number of adherent participants (usage > 4 h per night) 	Included in Cochrane review Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	 patient-centred approach to increase motivation to engage in a health behaviour by addressing the themes of perceived importance of using CPAP and confidence to adhere to CPAP. The TLC-CPAP system was automated and adapted from the intervention described by Aloia et al as Motivational Enhancement for CPAP. TLC-CPAP uses digitised human speech to speak to the patients and the patients communicate via the touch-tone keypad of their telephones. The TLC-CPAP content includes assessment of the patient's perceptions about and experiences with OSAS and CPAP therapy and the patient's reported CPAP use (hours per night and nights per week) during the week preceding each call; assessment of the patient's goals with regard to OSAS therapy; and feedback and counselling to enhance motivation to use CPAP and address barriers and poor self-efficacy. Participants were required to make weekly calls to TLC-CPAP during the first month beginning 3 days after starting CPAP therapy and the reafter monthly for the 12- 	ESS 10.5. Median BMI 35.1 kg/m².		

Study	Intervention and comparison	Population	Outcomes	Comments
	month duration of the study. The computer system called the participants if they did not make a call at the expected times (some grace time was allowed). Control: Attention placebo control' group received general education on a variety of health topics via a telephone-linked communication (TLC) system. Participants were required to make calls on the same schedule as the intervention group Study duration: 12 months			
Stepnowsky 2007 ⁸⁶ Randomised parallel-group trial Country: USA	Participants were randomised to usual care (UC, n=24) or telemonitoring (TM, n=21) group. TM: Review of compliance and efficacy data. Monitored information garnered as objective compliance data and subjective reports of usage. Follow-up tailored to how CPAP used by participants. Details on how many total hours the PAP unit was used each night at therapeutic pressure. Efficacy data consisted of the amount of mask leakage (L/s) and the AHI (total number of	N = 45 patients newly- diagnosed with OSA. Inclusion criteria: AHI ≥ 15, no prior CPAP treatment, stable sleep environment Exclusion criteria: allergies/sensitivity to mask or mask material, previous use of any other PAP device (e.g. bi-level PAP, auto- adjusting PAP), current use of prescribed supplemental oxygen or significant comorbid medical conditions that could interfere with daily use of CPAP Baseline Characteristics: 2% female. Mean age 59 (±14.3). Mean AHI 39. Mean	 CPAP usage (hours/night) % nights with CPAP use > 4 hours Sleepiness (ESS) QoL (FOSQ) AHI All outcomes reported at 2 months. 	Included in Cochrane review Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	apnoea/apnoea's and hypopnoeas per hour of sleep) UC: Telephone call from staff one week after CPAP initiation and office follow-up visit at one month. Participants encouraged to call clinic any time with problems or concerns Study duration: 2 months	ESS 12.6. Mean BMI 32.8 kg/m².		
Stepnowsky 2013 ⁸⁵ Randomised parallel-group trial Country: USA	Participants were randomised to telemonitoring (TM, n=126) usual care (UC, n=115) group. TM: Main goals of MyCPAP intervention were to (a) allow both the patient and provider access to tele monitored adherence and efficacy data on a daily basis, (b) act on that data collaboratively to guide CPAP management and troubleshoot problems early and effectively, and (c) emphasize ways for the patient to express their preferences and needs UC: Diagnostic sleep study, CPAP instruction and setup by trained health care provider, and follow-up at predetermined times (1-week, 1 month) by CPAP clinic staff. Beyond these pre-determined clinic contacts, patients were encouraged to call whenever they had a problem or concern.	N=241 patients with a recent OSA diagnosis and prescription for CPAP therapy. Inclusion criteria: Diagnosis of OSA (apnoea-hypopnea index ≥ 15), CPAP therapy prescription, and age ≥ 18 years. Exclusion criteria: residence in a geographical area outside of San Diego County, fatal comorbidity (life expectancy less than 6 months as indicated by physician); or significant documented substance/chemical abuse. Baseline Characteristics: % female NR (may be all male veterans). Mean age 52.1 (±13.3). Mean AHI 36.5. Mean ESS 10.6. Mean BMI 32.5 kg/m ² .	 CPAP usage (hours/night) Sleepiness (ESS) QoL (SAQLI) Outcomes were reported at 2 and 4 months. 	Included in Cochrane review Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	Study Duration: 4 months			
Turino 2017 ⁹² Prospective randomised controlled trial. Country: Spain	 Participants were randomised to standard management (SM, n=48) or a telemonitoring programme (TM, n=52) TM: Each CPAP device equipped with mobile 2G technology capable of sending daily information on CPAP adherence, CPAP pressures, mask leak and residual respiratory events to the web database. Automatic alarms for the provider were generated in case of mask leak >30 L/min for >30% of the night or usage of <4 h/night on two consecutive nights. In case of alarm, the pulmonary specialist medical officer of the CPAP provider contacted the patient, providing case-by-case problem solving. SM: Patients were fitted with a mask and given a CPAP device and a leaflet explaining how to use it. A short instruction session on CPAP device use was provided to patients and partners in the sleep unit by a trained nurse. This included a practical demonstration of how to put on the mask, and the correct management and cleaning of the tubes, masks and humidifier. Information on 	N=100 newly diagnosed OSA patients Inclusion criteria: >18 years, newly diagnosed OSA requiring treatment with CPAP (AHI >15). Exclusion criteria: Impaired lung function (COPD- OSAHS overlap syndrome, obesity hypoventilation and restrictive disorders), severe heart failure, psychiatric disorders, periodic leg movements, pregnancy, other dyssomnias or parasomnias, history of previous CPAP treatment. Baseline Characteristics: 23% female. Mean age 55 (NR). Mean AHI 52. Mean ESS NR. Mean BMI 35 kg/m ² .	 Machine usage (hours/night) at 1 month, 3 months QoL (EQ-5D) Blood pressure 	Included in Cochrane review Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
Wang 2012 ⁹⁵ Randomised parallel-group	how to turn the CPAP device on and off was provided by the homecare provider at the time of machine delivery. All patients were visited after 1 month of treatment by the nurse at the sleep unit. Participants were randomised to one of four arms: PMR+EDU (n=38), EDU (n=38), PMR	N=152 participants with a new OSA diagnosis. Inclusion criteria: new OSA	 CPAP usage (hours/night) at 4, 8 and 12weeks 	Included in Cochrane review Trialists included three
study. Country: China	(n=38), Control (n=38). Education (EDU only): Three nights of CPAP titration in the first week, four-hour group education session on OSA and CPAP in the first week, participants were given a brochure describing benefits of CPAP and CD containing a 20- minute video demonstrating how to optimise CPAP treatment, 24-hour consultation telephone line to the sleep nurses was available Progressive Muscle Relaxation Training (PMR only): One night of CPAP titration in the hospital, 12 × 40-minute group Progressive Muscle Relaxation (PMR) practice sessions over 12 weeks, one per week. Self- practice of PMR before each CPAP treatment. Brochure and CD with a guide for PMR practice at home.	diagnosis, AHI ≥ 10, above elementary school education, 'conscious mind and able to communicate clearly' Exclusion criteria: personal or family history of mental illness, drug or alcohol abuse, severe cognitive impairment, 'concurrent oncologic or psychiatric diseases' Baseline Characteristics: 6.8% female. Mean age NR. Mean AHI 43.1. Mean ESS=14.1. Mean BMI NR. Authors did not report mean age for full sample or by intervention arm (reported only distribution Ns per (4) age groups for each arm). Also did not report average BMI for full sample or by intervention arm (reported only distribution Ns per (4) BMI groups for each arm).	 Number of adherent participants (≥ 4 hours/night and at least 9 of 14 nights ventilator use) at 4, 8 and 12 weeks of intervention Sleepiness (ESS) QoL 	intervention arms. One arm was Educational (EDU), one was Behavioural (PMR) and the third was Mixed (EDU+PRM). These were compared to control in respective meta-analyses (i.e., Educational, Behavioural, Mixed). Severe OSAHS based on mean AHI

Study	Intervention and comparison	Population	Outcomes	Comments
	EDU + PMR: Three nights of CPAP titration in the hospital. Combination of interventions as in Education and PMR group (see above) Control: One night of CPAP titration in the hospital in the first week Study duration: 12 weeks			

See appendix D for full evidence tables.

1 **J1.4.4** Quality assessment of clinical studies included in the evidence review

	No of			Anticipated absolute effects		
Outcomes	Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% Cl)	Risk with Control	Risk difference with Behavioural therapy + CPAP versus control + CPAP (95% CI)	
CPAP Device Usage (hours/night) Higher is better	577 (8 studies)	 ⊕⊖⊖⊖ VERY LOW^{1,2,4} due to risk of bias, imprecision, indirectness 		The mean CPAP device usage (hours/night) in the control groups was 3.32	The mean CPAP device usage (hours/night) in the intervention groups was 1.31 higher (0.95 to 1.66 higher)	
N deemed adherent (≥ four	549	$\oplus \Theta \Theta \Theta$	RR 1.33	Moderate		
hours/night) Higher is better	(6 studies)	VERY LOW ^{1,2,4} due to risk of bias, imprecision, indirectness	(1.1 to 1.61)	408 per 1000	135 more per 1000 (from 41 more to 249 more)	
Withdrawal	(10 studies) V di in	 ⊕⊖⊖⊖ VERY LOW^{1,2,4} due to risk of bias, imprecision, indirectness 	RR 0.7 (0.51 to 0.98)	Moderate		
				81 per 1000	24 fewer per 1000 (from 2 fewer to 40 fewer)	
Epworth Sleepiness Scale (Endpoint scores) Lower is better	371 (6 studies)	⊕⊖⊖⊖ VERY LOW ^{1,3,4} due to risk of bias, inconsistency, indirectness		The mean ESS in the control groups was 9.0	The mean epworth sleepiness scale in the intervention groups was 2.22 lower* (3.68 to 0.75 lower)	
AHI on treatment – Endpoint Lower is better	89 (2 studies)	 ⊕⊖⊖ VERY LOW^{1,2,4} due to risk of bias, imprecision, indirectness 		The mean AHI in the control group was 4	The mean ahi on treatment in the intervention groups was 0.95 lower (2.25 lower to 0.35 higher)	
Quality of Life - Comparison of Values at Endpoint - QoL: FOSQ – Endpoint Higher is better	200 (2 studies)	⊕⊕⊖⊖ LOW ^{1,4}		The mean quality of life - comparison of values at endpoint -	The mean quality of life - comparison of values at endpoint - QOL: FOSQ - endpoint in the intervention groups	

 Table 3: Clinical evidence summary: Behavioural therapy + CPAP versus control + CPAP- Severe OSAHS

	No of			Anticipated absolut	e effects
Outcomes	Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Risk with Control	Risk difference with Behavioural therapy + CPAP versus control + CPAP (95% CI)
		due to risk of bias, indirectness		QOL: FOSQ - endpoint in the control groups was 10.6	was 0 higher (0.15 lower to 0.16 higher)
Quality of Life - Comparison of Values at Endpoint - QoL: SF-36 (PH) – Endpoint Scale from 0-100 Higher is better	28 (1 study)	⊕⊕⊖⊖ LOW ^{1,4} due to risk of bias, indirectness		The mean quality of life - comparison of values at endpoint - QOL: sf-36 (ph) - endpoint in the control groups was 78.1	The mean quality of life - comparison of values at endpoint - QOL: sf-36 (ph) - endpoint in the intervention groups was 1.1 lower (11.46 lower to 9.26 higher)
Mortality (critical outcome)	-	-	-	-	Not reported

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by one increment if the confidence interval crossed one MID and downgraded by two increments if the confidence interval crossed both MIDs. MID for machine usage (adherence)- 1 hour; Established MIDs for SF-36 physical/mental- 2/3; FOSQ- 2; ESS -2.5; SAQLI - 2. GRADE default MID (0.5XSD) used for all continuous other outcomes.

3 Downgraded by 1 or 2 increments for heterogeneity, unexplained by subgroup analysis. Random effect analysis used. 4 Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively

*Not sleepy in both groups

)SAHS:

DRAFT FOR CONSULTATION

	No of			Anticipated absolu	te effects
Outcomes	Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Risk with Control	Risk difference with Educational interventions + CPAP versus usual care + CPAP (95% CI)
CPAP Device Usage (hours/night) Higher is better	1128 (10 studies)	 ⊕⊖⊖ VERY LOW^{1,2,3,4} due to risk of bias, inconsistency, imprecision, indirectness 		The mean CPAP device usage (hours/night) in the control group was 3.5	The mean CPAP device usage (hours/night) in the intervention groups was 0.88 higher (0.4 to 1.36 higher)
N deemed adherent (≥ four	/night) (7 studies) VERY LOW ^{1,3,4} due to risk of bias, imprecision,	$\oplus \oplus \ominus \ominus$	VERY LOW ^{1,3,4} (1.15 to 5. due to risk of bias, 1.48) imprecision,	Moderate	
hours/night) Higher is better		due to risk of bias,		547 per 1000	170 more per 1000 (from 82 more to 263 more)
Withdrawal	1745	$\oplus \oplus \ominus \ominus$	RR 0.73	Moderate	
	(9 studies)	LOW ^{1,4} due to risk of bias, indirectness	(0.52 to 1.02)	150 per 1000	41 fewer per 1000 (from 72 fewer to 3 more)
Epworth Sleepiness Scale - Comparison of Values at Endpoint- Scale from 0-24 Higher is worse	355 (3 studies)	$\bigoplus \bigcirc \bigcirc$ VERY LOW ^{1,3,4} due to risk of bias, imprecision, indirectness		The mean ESS in the control group was 6.41	The mean epworth sleepiness scale scores in the intervention groups was 0.08 lower * (0.92 lower to 0.76 higher)
Mortality (critical outcome)	-	-	-	-	Not reported

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by 1 or 2 increments for heterogeneity, unexplained by subgroup analysis. Random effect analysis used.

3 Downgraded by one increment if the confidence interval crossed one MID and downgraded by two increments if the confidence interval crossed both MIDs. MID for machine usage (adherence)- 1 hour; Established MIDs for SF-36 physical/mental- 2/3; FOSQ- 2; ESS -2.5; SAQLI - 2. GRADE default MID (0.5XSD) used for all other continuous outcomes.

4Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively *Not sleepy in both groups

1)

NICE 2021 All righte recon

202

Cubion

of righte

20 Notion

Table 5: Clinical evidence summary: Increased practical support and encouragement during follow-up + CPAP versus usual care + CPAP - Severe OSAHS

				Anticipated absolute effects		
Outcomes	No of Participant s (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% Cl)	Risk with Control	Risk difference with Increased practical support and encouragement during follow-up + CPAP versus usual care + CPAP (95% CI)	
CPAP Device Usage (hours/night) Higher is better	1501 (14 studies)	 ⊕⊖⊖⊖ VERY LOW^{1,2,3} due to risk of bias, inconsistency, imprecision 		The mean CPAP device usage (hours/night) in the control group was 3.6	The mean CPAP device usage (hours/night) in the intervention groups was 0.83 higher (0.45 to 1.22 higher)	
Days PAP used >4 hours at 12 months Higher is better	23 (1 study)	⊕⊕⊝⊝ LOW² due to imprecision		The mean days pap used >4 hours in the control group was 282 days	The mean days pap used >4 hours at 12 months in the intervention groups was 11 lower (75.76 lower to 53.76 higher)	
Days PAP used >4 hours at 3 months Higher is better	294 (2 studies) 3 months	⊕⊕⊕⊕ HIGH		The mean days pap used >4 hours in the control group was 65.8 days	The mean days pap used >4 hours at 3 months in the intervention groups was 8.06 higher (1.80 to 14.33 higher)	
Mean adherence all days (min per day) at 12 months Higher is better	23 (1 study)	 ⊕⊕⊕⊖ MODERATE² due to imprecision 		The mean adherence all days (min per day) at 12 months in the control group was 307	The mean adherence all days (min per day) at 12 months in the intervention groups was 45 higher (20.99 lower to 110.99 higher)	
CPAP use min/night Higher is better	327 (1 study)	⊕⊕⊕⊕ HIGH		The mean CPAP use min/night in the	The mean CPAP use min/night in the intervention groups was	

				Anticipated absolute effects		
Outcomes	No of Participant s (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Risk with Control	Risk difference with Increased practical support and encouragement during follow-up + CPAP versus usual care + CPAP (95% CI)	
				control groups was 307	20 higher (1.51 lower to 41.51 higher)	
N deemed adherent (≥ four hours/night)	376	$\oplus \Theta \Theta \Theta$	RR 1.19	Moderate		
	(2 studies) VERY LOW ^{1,2,4} due to risk of bias, imprecision, indirectness	due to risk of bias,	(1.03 to 1.37)	635 per 1000	121 more per 1000 (from 19 more to 235 more)	
Withdrawals	1702	⊕⊖⊖⊖ VERY LOW ^{1,2,4} due to risk of bias, imprecision, indirectness	RR 1.22 (0.97 to 1.52)	Moderate		
	· · · ·			118 per 1000	26 more per 1000 (from 4 fewer to 61 more)	
Epworth Sleepiness Scale - Comparison Endpoint or Change from Baseline Values - ESS: Endpoint Scores Scale from 0-24 Lower is better	1527 (15 studies)	$\oplus \oplus \ominus \ominus$ LOW ^{1,3} due to risk of bias, inconsistency		The mean epworth sleepiness scale - in the control groups was 3.16	The mean epworth sleepiness scale - comparison endpoint or change from baseline values - ESS: endpoint scores in the intervention groups was 0.28 lower (0.73 lower to 0.16 higher)	
Quality of Life: Comparison of Values at Endpoint - QoL: FOSQ – Endpoint Scale from 5-20 Higher is better	109 (3 studies)	$\oplus \oplus \ominus \ominus$ LOW ^{1,4} due to risk of bias, indirectness		The mean quality of life: FOSQ - in the control groups was 16.1	The mean quality of life: comparison of values at endpoint - QOL: FOSQ - endpoint in the intervention groups was 0.55 higher (0.81 lower to 1.9 higher)	
Quality of Life: Comparison of Values at Endpoint - QoL: SAQLI – Endpoint Higher is better	240 (1 study)	$\oplus \oplus \bigcirc$ LOW ^{1,4} due to risk of bias, indirectness		The mean quality of life: SAQLI in the control groups was 4.6	The mean quality of life: comparison of values at endpoint - QOL: SAQLI - endpoint in the intervention groups was	

				Anticipated absolut	e effects
Outcomes	No of Participant s (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% Cl)	Risk with Control	Risk difference with Increased practical support and encouragement during follow-up + CPAP versus usual care + CPAP (95% CI)
					0.5 higher (0.09 lower to 1.09 higher)
Quality of Life: Comparison of Values at Endpoint - QoL: SF-36 (PH) – Endpoint Scale from 0-100 Higher is better	334 (3 studies)	$\bigoplus \ominus \ominus \ominus$ VERY LOW ^{1,2,4} due to risk of bias, indirectness, imprecision		The mean quality of life: sf-36 (ph) - in the control groups was 46	The mean quality of life: comparison of values at endpoint - QOL: sf-36 (ph) - endpoint in the intervention groups was 1.09 higher (0.34 lower to 2.52 higher)
Quality of Life: Comparison of Change from Baseline Values - QoL: FOSQ - Change from Baseline Higher is better	39 (1 study)	$\bigoplus \bigcirc \bigcirc$ VERY LOW ^{1,2,4} due to risk of bias, indirectness, imprecision		The mean quality of life: FOSQ - in the control groups was 1.1	The mean quality of life: comparison of change from baseline values - QOL: FOSQ - change from baseline in the intervention groups was 0.8 higher (1.25 lower to 2.85 higher)
Quality of Life: Comparison of Change from Baseline Values - QoL: SF-36 (PH) - Change from Baseline Higher is better	82 (1 study)	$\bigoplus \ominus \ominus \ominus$ VERY LOW ^{1,2,4} due to risk of bias, indirectness, imprecision		The mean quality of life: sf-36 (ph) - in the control groups was 2.9	The mean quality of life: comparison of change from baseline values - QOL: sf-36 (ph) - change from baseline in the intervention groups was 0.3 higher (3.1 lower to 3.7 higher)
Quality of Life: Comparison of Change from Baseline Values - QoL: FOSQ-10 - Change from Baseline Higher is better	173 (1 study)	$\bigoplus \bigcirc \bigcirc$ VERY LOW ^{1,2,4} due to risk of bias, indirectness, imprecision		The mean quality of life: fosq-10 - in the control groups was -14.2	The mean quality of life: comparison of change from baseline values - QOL: fosq-10 - change from baseline in the intervention groups was

				Anticipated absolut	e effects
Outcomes	No of Participant s (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Risk with Control	Risk difference with Increased practical support and encouragement during follow-up + CPAP versus usual care + CPAP (95% CI)
					3.3 higher (0.1 to 6.5 higher)
diastolic blood pressure	55 (1 study)	 ⊕⊕⊕⊖ MODERATE² due imprecision 		The mean diastolic blood pressure in the control groups was 82.8	The mean diastolic blood pressure in the intervention groups was 4.4 lower (9.82 lower to 1.02 higher)
systolic blood pressure	55 (1 study)	$\oplus \oplus \oplus \ominus$ MODERATE, ² due imprecision		The mean systolic blood pressure in the control groups was 138.8	The mean systolic blood pressure in the intervention groups was 9.3 lower (17.57 to 1.03 lower)
AHI on treatment - Comparison of Values at Endpoint Lower is better	411 (5 studies)	$\bigoplus \ominus \ominus \ominus$ VERY LOW ^{1,2,3} due to risk of bias, inconsistency, imprecision		The mean ahi on treatment performed in control group was 4.2	The mean ahi on treatment performed in the intervention groups was 0.80 higher (0.66 lower to 2.25 higher)
Mortality (critical outcome)					Not reported

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by one increment if the confidence interval crossed one MID and downgraded by two increments if the confidence interval crossed both MIDs. MID for machine usage (adherence)- 1 hour; Established MIDs for SF-36 physical/mental- 2/3; FOSQ- 2; ESS -2.5; SAQLI – 2. GRADE default MID (0.5XSD) used for all other continuous outcomes.

3 Downgraded by 1 or 2 increments for heterogeneity, unexplained by subgroup analysis. Random effect analysis used.

4Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively

				Anticipated absolu	nticipated absolute effects	
Outcomes	No of Participant s (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% Cl)	Risk with Control	Risk difference with Increased practical support and encouragement during follow-up + CPAP versus usual care + CPAP (95% CI)	
*Not sleepy in both groups		(010122)				

Table 5: Clinical evidence summary: Mixed (SUP/EDU/BEH) Intervention + CPAP versus Usual Care + CPAP - Severe OSAHS

	No of			Anticipated absolute effects	
Outcomes	Participant s (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Risk with Control	Risk difference with Mixed (SUP/EDU/BEH) Intervention + CPAP versus Usual Care + CPAP (95% CI)
CPAP Device Usage (hours/night) Higher is better	4451 (10 studies)	 ⊕⊖⊖ VERY LOW^{1,2,3,4} due to risk of bias, inconsistency, imprecision, indirectness 		The mean CPAP device usage (hours/night) in the control group was 4.8	The mean CPAP device usage (hours/night) in the intervention groups was 0.82 higher (0.2 to 1.43 higher)
N deemed adherent (≥ four hours/night)	4015	$\oplus \Theta \Theta \Theta$	RR 1.14	Moderate	
Higher is better	(9 studies)	VERY LOW ^{1,3,2,4} due to risk of bias, inconsistency, imprecision indirectness	(1.04 to 1.26)	656 per 1000	92 more per 1000 (from 26 more to 171 more)
Withdrawal	4956	0000	RR 0.64	Moderate	
(11 studie:	(11 studies)		(0.32 to 1.28)	136 per 1000	49 fewer per 1000 (from 92 fewer to 38 more)

	No of			Anticipated absolut	e effects
Outcomes	Participant s (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% Cl)	Risk with Control	Risk difference with Mixed (SUP/EDU/BEH) Intervention + CPAP versus Usual Care + CPAP (95% CI)
Quality of Life: Comparison of Change from Baseline Values - QoL: FOSQ-10 - Change from Baseline Higher is better	176 (1 study)	 ⊕⊖⊖⊖ VERY LOW^{1,3,4} due to risk of bias, indirectness, imprecision 		The mean quality of life: fosq-10 - in the control groups was -14.2	The mean quality of life: comparison of change from baseline values - QOL: FOSQ-10 - change from baseline in the intervention groups was 2.9 higher (0.52 lower to 6.32 higher)
Quality of Life: Comparison of Change from Baseline Values - QoL: SF-36 (PH) - Change from Baseline Higher is better	2836 (1 study)	 ⊕⊖⊖⊖ LOW^{1,4} due to risk of bias, indirectness 		The mean quality of life: sf-36 (ph) - in the control groups was 5.9	The mean quality of life: comparison of change from baseline values - QOL: sf-36 (ph) - change from baseline in the intervention groups was 5.7 higher (4.98 to 6.42 higher)
Quality of Life: Comparison of Values at Endpoint - QoL: FOSQ – Endpoint Scale from 5-20 Higher is better	177 (1 study)	$\bigoplus \bigcirc \bigcirc$ LOW ^{1,4} due to risk of bias, indirectness		The mean quality of life: FOSQ - in the control groups was 16.7	The mean quality of life: comparison of values at endpoint - QOL: FOSQ - endpoint in the intervention groups was 0.3 higher (0.56 lower to 1.16 higher)
Quality of Life: Comparison of Values at Endpoint - QoL: SF-36 (PH) – Endpoint Scale from 0-100 Higher is better	3014 (3 studies)	⊕⊖⊖⊖ LOW ^{1,4} due to risk of bias, indirectness		The mean quality of life: sf-36 (ph) - in the control groups was 56.9	The mean quality of life: comparison of values at endpoint - QOL: sf-36 (ph) - endpoint in the intervention groups was 4.85 higher (2.49 to 7.21 higher)

	No of	of		Anticipated absolute effects	
Outcomes	Participant s (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Risk with Control	Risk difference with Mixed (SUP/EDU/BEH) Intervention + CPAP versus Usual Care + CPAP (95% CI)
Epworth Sleepiness Scale Score Scale from 0-24 Lower is better	6388 (8 studies)	 ⊕⊖⊖⊖ VERY LOW^{1,3,4} due to risk of bias, imprecision, indirectness 		The mean ESS in the control group was 8.4	The mean epworth sleepiness scale score in the intervention groups was 1.32 lower * (2.48 to 0.16 lower)
Nortality (critical outcome)	-	-	-	-	Not reported
1 Downgraded by 1 increment if the majorit at very high risk of bias 2 Downgraded by 1 or 2 increments for het	•	C C		°	

3 Downgraded by one increment if the confidence interval crossed one MID and downgraded by two increments if the confidence interval crossed both MIDs. MID for machine usage (adherence)- 1 hour; Established MIDs for SF-36 physical/mental- 2/3; FOSQ- 2; ESS -2.5; SAQLI – 2... GRADE default MID (0.5XSD) used for all other continuous outcomes.

4 Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively *Not sleepy in both groups.

See appendix F for full GRADE tables.

1 1.5 Economic evidence

- 2 1.5.1 Included studies
- 3 No health economic studies were included.

4 1.5.2 Excluded studies

- 5 No relevant health economic studies were excluded due to assessment of limited 6 applicability or methodological limitations.
- 7 See also the health economic study selection flow chart in appendix G.

8 1.5.3 Health economic modelling

9 Original modelling was not prioritised for this question.

10 **1.5.4** Health economic evidence statements

11 No relevant economic evaluations were identified.

12 1.6 The committee's discussion of the evidence

13 **1.6.1 Interpreting the evidence**

14 **1.6.1.1** The outcomes that matter most

15 The committee considered the outcomes of proportion adherent >4hrs/night for CPAP/noninvasive ventilation, adherence in hours/night for CPAP and oral devices, self-reported 16 adherence, quality of life and mortality as critical outcomes for decision making. Other 17 18 important outcomes included, sleepiness scores (e.g. Epworth), apnoea-Hypopnoea index (AHI) or respiratory disturbance index, oxygen desaturation index, mood or anxiety, 19 withdrawals, treatment related withdrawals, CO₂ control, minor adverse effects of treatment, 20 21 driving outcomes, neurocognitive outcomes and impact on co-existing conditions:HbA1c for diabetes, cardiovascular events for cardiovascular disease and systolic blood pressure for 22 23 hypertension.

No evidence was identified for the outcomes of mortality, mood or anxiety, neurocognitive
 outcomes and impact on co-existing conditions: HbA1c for diabetes, cardiovascular events
 for cardiovascular disease and systolic blood pressure for hypertension for the OSAHS
 population.

28 **1.6.1.2** The quality of the evidence

29 OSAHS

30 **CPAP**

The quality of the evidence for interventions to improve usage of CPAP in adults with OSAHS varied from moderate to very low quality; majority of the evidence was downgraded due to risk of bias, inconsistency, indirectness and imprecision. Risk of bias was most commonly due to selection bias. Studies were downgraded for indirectness if they included mixed severity OSAHS. The committee also acknowledged that some uncertainty existed across the effect sizes seen within the evidence, with some confidence intervals crossing the

- 1 MID thresholds or line of no effect. The committee took into account the quality of the 2 evidence, including the uncertainty in their interpretation of the evidence.
- 3 The committee considered the clinical importance for AHI on a case by case basis, taking 4 into consideration the baseline AHI and the improvement in severity of sleep apnoea.

5 There was evidence from 46 studies evaluating educational, supportive and behavioural 6 interventions to improve use of continuous positive airway pressure in adults with obstructive 7 sleep apnoea. Interventions in the review were classified as: educational interventions, 8 behavioural interventions, supportive interventions and mixed interventions. There was a 9 huge variation in the specific type of interventions used in all the categories.

- Educational interventions included imparting information about CPAP treatment or about
 OSAHS more generally, delivered through video format, face-to-face didactic sessions,
 group educational sessions, written materials, or any combination of these.
- 13There were a broad range of behavioural interventions, with a huge variation in the type14(motivational interviewing, oropharyngeal exercises, audio tape with CPAP information and15relaxation techniques), delivery (by psychologists, nurses/nurse counsellors) and timing of16interventions (after the first session of CPAP/1 week after CPAP/1 month after CPAP).
- Supportive interventions included where participants were provided with additional clinical
 follow-up (e.g. additional office or home-based visits, video or phone check-ins by clinical
 staff) or with telemonitoring equipment that facilitated self-monitoring of CPAP usage or that
 facilitated monitoring by clinical staff to prompt 'as needed' clinical follow-up.
- 21 Mixed interventions combined elements of the three previously listed intervention-types.
- Most of the studies included people who are new to CPAP, and there was very little evidence
 available on people who have difficulty using CPAP. Studies included people with moderate
 and severe OSAHS.
- The committee recognised the lack of evidence in people with mild sleep apnoea and in people who have difficulty using CPAP.

27 **Positional modifiers**

There was no evidence for educational, supportive and behavioural interventions to improve usage of positional modifiers in adults with OSAHS.

30 Oral devices

- There was no evidence for educational, supportive and behavioural interventions to improve usage of oral devices in adults with OSAHS.
- 33 OHS
- No evidence was identified for improving adherence of CPAP and non-invasive ventilation
 (NIV) in OHS.

36 COPD-OSAHS overlap syndrome

37 No evidence was identified for improving adherence of CPAP and non-invasive ventilation
 38 (NIV) in COPD-OSAHS overlap syndrome.

39 1.6.1.3 Benefits and harms

- 40 **OSAHS**
- 41 **CPAP**

1 Behavioural therapy + CPAP versus control + CPAP

2

3

4 5

6

7

9

10

11 12

13

14

The evidence suggested that there was clinically important benefit with behavioural therapy + CPAP compared to control + CPAP for the outcomes CPAP device usage (hours/night) and number of participants deemed adherent (≥ four hours/night), although there was some uncertainty around the effect estimates. The evidence suggested that there was no clinically important difference between behavioural therapy + CPAP and control + CPAP for the outcomes of withdrawal, Epworth Sleepiness Scale, AHI on treatment, and quality of life.

8 Educational interventions + CPAP versus usual care + CPAP

The evidence suggested that there was clinically important benefit with educational interventions + CPAP compared to usual care + CPAP for the outcomes CPAP device usage (hours/night) and number of participants deemed adherent (≥ four hours/night), although there was some uncertainty around the effect estimates. The evidence suggested that there was no clinically important difference between educational interventions + CPAP and usual care + CPAP for the outcomes of withdrawal and Epworth Sleepiness Scale.

15Increased practical support and encouragement during follow-up + CPAP versus16usual care + CPAP

17 The evidence suggested that there was clinically important benefit with supportive 18 interventions + CPAP compared to control + CPAP for the outcomes CPAP device usage (hours/night), number of participants deemed adherent (\geq four hours/night), mean 19 adherence all days (min per day), days CPAP used > 4 hours at 3 months and systolic and 20 diastolic blood pressure, although there was some uncertainty around the effect estimates. 21 22 The evidence suggested that there was no clinically important difference between supportive 23 interventions + CPAP and control + CPAP for the outcomes of days CPAP used > 4 hours at 24 12 months, CPAP use (min/night), withdrawal, Epworth Sleepiness Scale, AHI on treatment. 25 The evidence for quality was life was inconsistent, with no difference between supportive 26 interventions + CPAP and control + CPAP for quality of life scales SF-36, SAQLI, FOSQ and benefit for increased practical support for quality life FOSQ-10. 27

28 Mixed (educational/supportive/behavioural) intervention + CPAP versus usual care + 29 CPAP

30 The evidence suggested that there was clinically important benefit with mixed interventions + CPAP compared to control + CPAP for the outcomes CPAP device usage (hours/night) and 31 32 number of participants deemed adherent (\geq four hours/night), although there was some 33 uncertainty around the effect estimates. The evidence suggested that there was no clinically important difference between mixed interventions + CPAP and control + CPAP for the 34 35 outcomes of withdrawal, Epworth Sleepiness Scale, and AHI on treatment. The evidence for quality was life was inconsistent, with no difference between mixed interventions + CPAP 36 and control + CPAP for quality of life scale FOSQ and benefit for mixed interventions for 37 quality life FOSQ-10 and SF-36 (physical health). 38

39Interventions to improve adherence of interventions for OSAHS- committee's40consideration of the evidence

41 The overall evidence suggested that all types of interventions (educational, behavioural, supportive and mixed) increased CPAP usage to varying degrees in CPAP-naive participants 42 43 with moderate to severe OSAHS. However, it was unclear from the evidence whether any of these interventions also led to meaningful improvement of daytime symptoms or quality of 44 45 life. There was no evidence of harm associated with these interventions. Although there was 46 uncertainty around the effect estimates for some of the outcomes, the committee agreed that 47 the direction of effect on the whole was positive and the evidence base was large enough to 48 justify a recommendation. The evidence did not show which category of interventions is best suited for individual patients. Also, optimum duration/intensity and long-term effectiveness of 49 these interventions were not clear from the evidence. However, the committee did not make 50

2

3

4

5

6

7 8

9

10

11 12

13 14 a research recommendation on this as they did not consider it to be a priority for research recommendation.

In current practice some form of educational interventions is offered, however the content and delivery of these interventions is not consistent across all centers.

Based on the evidence and their knowledge of current practice, the committee agreed that educational or supportive interventions or a combination of these, provided by specialist staff, would help to improve adherence to CPAP. Educational interventions include providing information about OSAHS, its treatment and outcomes, which can be delivered using a variety of different sessions and formats, whereas supportive interventions involve additional clinical follow-up (for example, extra clinic visits, teleconsultations, video consultations or use of telemonitoring) to provide support. Due to the lack of standardised content of behavioural interventions, delivery of interventions (psychologists or nurses or nurse counsellors) and the difficulty in identifying the effective components within these interventions, the committee agreed not to make a make recommendation for any specific behavioural intervention.

- 15 The committee discussed that though CPAP therapy is considered as the first line treatment of moderate and severe OSAHS and for symptomatic mild OSAHS if other management 16 such as weight loss has not been effective (see discussion of evidence for CPAP in evidence 17 reports E and F), the uptake and adherence can be low which limits its clinical effectiveness 18 in patients with OSAHS. The committee from their experience stated that adhering to regular 19 20 use of CPAP treatment has multiple benefits including improving the quality of sleep, reducing sleepiness during waking hours, preventing vehicle accidents, improving blood 21 22 pressure control and reducing the risk of cardiovascular events. Therefore, they agreed that 23 educational/supportive interventions to improve adherence of CPAP should be offered to all patients at initiation of therapy and as required at follow-up. 24
- Optimal adherence to CPAP therapy is conventionally considered to be 4 hours or more per 25 night or use for an average of more than 4 hours per night for 70% or more nights. Early 26 27 adherence studies focused on control of sleepiness but there is evidence that increased CPAP use of more than 5 hours a night in OSAHS benefits other aspects of health such as 28 29 control of blood pressure and cardiovascular risk. However, it is recognised that people can 30 gain some benefit from a shorter period of use and individual response is variable. People 31 should be encouraged to maximise their CPAP use to achieve optimal control of their 32 symptoms, underlying conditions, sleep quality and quality of life.
- Although evidence was available only for moderate and severe OSAHS, the committee
 agreed that the recommendations would be applicable to all severities, including people with
 mild OSAHS.
- The committee stated that the choice of these interventions should be tailored to match
 individual patient needs. The committee agreed it is more helpful to focus on the content of
 the intervention rather than the specific type of intervention.
- The committee highlighted the importance of timing of the delivery of CPAP education and
 support; they agreed that the initial contact and information session is a critical component in
 CPAP uptake and adherence.
- The committee agreed that the recommendations reflect best practice, but current provision
 varies across NHS settings. Therefore, the recommendations will involve a change of
 practice for some providers.
- 45 The committee also discussed the importance of staff being appropriately trained to offer 46 these interventions. They discussed that a low ratio of patients to staff should be maintained 47 to allow individualised input but agreed that staffing issues are outside the remit of this 48 guideline.

There was no evidence available for improving adherence for oral devices and positional modifiers in OSAHS; however, the committee agreed that the educational/supportive interventions for improving adherence for CPAP could be generalised for oral devices and positional modifiers as well.

5 There was no evidence for improving adherence in people who have difficulty using CPAP. 6 The committee hence made a research recommendation for people who continue to find 7 CPAP difficult to use despite having received some education from trained sleep 8 professionals, access to support in the early adaptation period and/or clinical review to 9 optimise aspects such as machine pressure, mask fit and humidification (Appendix I).

10 OHS

1

2 3

4

11 The committee agreed that the interventions to improve use of CPAP/non-invasive ventilation 12 could be offered in people with OHS as the evidence for OSAHS population could be 13 extrapolated to this population. The committee noted that the recommendations reflect best 14 practice but are currently implemented to varying degrees across NHS settings and will 15 involve a change of practice for some providers.

16 COPD-OSAHS overlap syndrome

17 The committee agreed that the interventions to improve use of CPAP/ non-invasive 18 ventilation could be offered in people with COPD-OSAHS overlap syndrome as the evidence 19 for OSAHS population could be extrapolated to this population. The committee noted that the 20 recommendations reflect best practice but are currently implemented to varying degrees 21 across NHS settings and will involve a change of practice for some providers.

22 **1.6.2** Cost effectiveness and resource use

23 There were no economic evaluations identified for this review question.

24 There was clinically important benefit for educational, supportive, behavioural and a mixture 25 of these strategies for improving device usage (hours per night). There was also some 26 evidence of better blood pressure control. The evidence for improvement in quality of life was 27 mixed but from their experience, the committee explained that quality of life gains associated with using CPAP and other interventions could only be achieved and sustained if the device 28 was used regularly. Poor adherence could lead to interventions no longer being cost-29 effective. The committee therefore agreed that providing education and support was 30 31 reasonable because they can improve adherence and contribute to the cost-effectiveness of 32 the intervention.

33 The provision of education and support is current practice for people who are newly provided 34 with CPAP. This has traditionally been provided in the form of sleep specialist (usually nurse 35 or physiologist)-led outpatient appointments but is now most likely to be conducted remotely. People receive their first outpatient appointment for CPAP when collecting the device. During 36 37 this appointment people requiring CPAP receive advice and are educated on how to use 38 their new device e.g. cleaning, plus are fitted with an appropriate mask and taught how to 39 ensure the mask is on properly to avoid leaks. They have reminders of the importance of 40 using the device regularly. This appointment when initiating people with CPAP is deemed to 41 be important by the committee because they explained early encouragement and successful adherence is an important factor on whether people will be compliant over a longer time 42 horizon. The provision of information is then typically provided again during a follow-up sleep 43 specialist outpatient appointment 1 month after initiation with CPAP and then per annum 44 thereafter. It is important to note that provision of education and advice are incorporated into 45 46 these appointments, but they are not exclusively for providing education and support. For example, during the same appointment sleep specialist would explore whether people with 47 OSAHS have adequate control of their symptoms and whether further assistance is required 48

1 to improve symptoms (e.g. changing mask types, increasing machine pressure) and 2 download data on adherence from the CPAP machine.

The provision of education and support is consistent with the minimum level of care all people should expect as explained in the Patient experiences guideline (CG138). It was therefore agreed provision of education and support should also be extended to people receiving positional modifiers or oral devices for OSAHS and CPAP or non-invasive ventilation for (COPD-OSAHS overlap syndrome and OHS). As these recommendations are consistent with what occurs in current practice, a significant resource impact is not expected due to these recommendations.

10 The committee noted that providing intensive behavioural interventions as described in some 11 of the clinical studies would be quite costly. Due to the lack of cost effectiveness evidence 12 and a concern that behavioural interventions could be interpreted in different ways (which 13 would increase variation in practice) the committee opted to not make a recommendation for 14 this intervention. Finally, in those people who have difficulty with using the device, the 15 committee decided to make a research recommendation to explore a range of strategies 16 (including behavioural strategies) that could be utilised to improve adherence.

17

3

4 5

6 7

8

9

References

- 1. Aardoom JJ, Loheide-Niesmann L, Ossebaard HC, Riper H. Effectiveness of eHealth interventions in improving treatment adherence for adults with obstructive sleep apnea: Meta-analytic review. Journal of Medical Internet Research. 2020; 22(2):e16972
- Aloia M, Harrington J, Cartwright A, Goelz K, Edinger JD, Lee-Chiong T. Personalized video to improve adherence to PAP therapy. Sleep. 2013; 36(Suppl):A407-A408
 - 3. Aloia MS, Arnedt JT, Strand M, Millman RP, Borrelli B. Motivational enhancement to improve adherence to positive airway pressure in patients with obstructive sleep apnea: A randomized controlled trial. Sleep. 2013; 36(11):1655-1662
 - 4. Aloia MS, Di Dio L, Ilniczky N, Perlis ML, Greenblatt DW, Giles DE. Improving compliance with nasal CPAP and vigilance in older adults with OAHS. Sleep & Breathing. 2001; 5(1):13-21
- Askland K, Wright L, Wozniak DR, Emmanuel T, Caston J, Smith I. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. Cochrane Database of Systematic Reviews 2020, Issue 4. Art. No.: CD007736. DOI: 10.1002/14651858.CD007736.pub3.
 - 6. Bague-Cruz A, Esteller E. Pneumotoning (oropharyngeal and pulmonary exercises, electrical stimulation and manual therapy) to improve the continuous positive airway pressure's compliance in patients with obstructive sleep apnea-hipopnea. A pilot study. European Respiratory Journal. 2014; 44(Suppl 58):4678
 - 7. Bague A. Pneumotoning (oropharyngeal and pulmonary exercises, electrical stimulation and manual therapy) to improve the CPAP compliance in patients with obstructive sleep apnea-hypopnea. A pilot study. Somnologie. 2015; 19(Suppl 1):38
 - 8. Bakker JP, Wang R, Weng J, Aloia MS, Toth C, Morrical MG et al. Motivational enhancement for increasing adherence to CPAP: A randomized controlled trial. Chest. 2016; 150(2):337-345
 - 9. Bartlett D, Wong K, Richards D, Moy E, Espie CA, Cistulli PA et al. Increasing adherence to obstructive sleep apnea treatment with a group social cognitive therapy treatment intervention: A randomized trial. Sleep. 2013; 36(11):1647-1654
 - Basoglu OK, Midilli M, Midilli R, Bilgen C. Adherence to continuous positive airway pressure therapy in obstructive sleep apnea syndrome: Effect of visual education. Sleep & Breathing. 2012; 16(4):1193-1200
 - 11. Berger M, Barthelemy J, Hupin D, Labeix P, Donnat M, Iddir H et al. A supervised community physical activity program as an effective treatment in moderate obstructive sleep apnea: A randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2018; 197:A4395
 - 12. Berry RB, Beck E, Jasko JG. Effect of cloud-based sleep coaches on positive airway pressure adherence. Journal of Clinical Sleep Medicine. 2020; 16(4):553-562
- 42
 43
 43
 44
 45
 45
 43
 44
 45
 44
 45
 45
 45
 45
 46
 47
 47
 48
 49
 49
 49
 40
 40
 41
 41
 42
 44
 45
 45
 46
 47
 47
 48
 49
 49
 49
 49
 49
 40
 40
 41
 41
 41
 42
 44
 45
 45
 46
 47
 47
 48
 49
 49
 49
 49
 40
 40
 41
 41
 41
 41
 41
 42
 41
 42
 42
 43
 44
 44
 45
 45
 46
 47
 47
 47
 47
 48
 49
 49
 49
 49
 40
 40
 41
 41
 41
 42
 44
 44
 45
 45
 46
 47
 47
 47
 47
 47
 48
 49
 49
 49
 49
 49
 49
 49
 49
 40
 40
 40
 41
 41
 41
 42
 44
 44
 45
 46
 47
 47
 47
 47
 48
 48
 49
 49
 49
 49
 49
 49
 49
 49
 49
 40
 40
 41
 41
 42
 44
 44
 45
 46
 47
 47
 47
 47
 48
 48
 49
 49
 49
 49
 49
 49
 49
 49
 49
 40
 40
 41
 41
 41
 42
 44
 44
 44
 44
 44
 44
 44
 45
 <

3

4

5

6 7

8

9

10 11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31 32

33

34 35

36

37

38

39 40

- 14. Cartwright A, Depew A, Burleson A, Vannoni V, Simmons B, Goelz K et al. Use of a personalized video to enhance PAP adherence: Preliminary report from a randomized clinical trial. Sleep. 2017; 40(Suppl 1):A190
 - 15. Chen C, Wang J, Pang L, Wang Y, Ma G, Liao W. Telemonitor care helps CPAP compliance in patients with obstructive sleep apnea: a systemic review and metaanalysis of randomized controlled trials. Therapeutic Advances in Chronic Disease. 2020; https://dx.doi.org/10.1177/2040622320901625
- Chen X, Chen W, Hu W, Huang K, Huang J, Zhou Y. Nurse-led intensive interventions improve adherence to continuous positive airway pressure therapy and quality of life in obstructive sleep apnea patients. Patient Prefer Adherence. 2015; 9:1707-1713
 - 17. Chervin RD, Theut S, Bassetti C, Aldrich MS. Compliance with nasal CPAP can be improved by simple interventions. Sleep. 1997; 20(4):284-289
- 18. Cotton J, Zarrouf FA. Weekly text messaging to improve CPAP compliance: A randomized prospective trial. Sleep. 2012; 35:A165
- 19. Cunali PA, Almeida FR, Santos CD, Valdrichi NY, Nascimento LS, Dal-Fabbro C et al. Mandibular exercises improve mandibular advancement device therapy for obstructive sleep apnea. Sleep & Breathing. 2011; 15(4):717-727
 - 20. Dantas AP, Winck JC, Figueiredo-Braga M. Adherence to APAP in obstructive sleep apnea syndrome: Effectiveness of a motivational intervention. Sleep & Breathing. 2015; 19(1):327-334
 - 21. Dawson JD, Yu L, Aksan NS, Tippin J, Rizzo M, Anderson SW. Feedback from naturalistic driving improves treatment compliance in drivers with obstructive sleep apnea. Proceedings of the International Driving Symposium on Human Factors in Driver Assessment, Training, and Vehicle Design. 2015; 2015:30-35
 - 22. De Vries GE, Hoekema A, Claessen J, Stellingsma C, Stegenga B, Kerstjens H et al. Long-term objective compliance with a mandibular advancement device and continuous positive airway pressure in moderate obstructive sleep apnea. European Respiratory Journal. 2018; 52(Suppl 62):OA5373
 - 23. De Vries GE, Hoekema A, Wijkstra PJ. Objective compliance with oral appliance therapy versus CPAP in moderate obstructive sleep apnea. European Respiratory Journal. 2017; 50(Suppl 61):PA4725
 - DeMolles DA, Sparrow D, Gottlieb DJ, Friedman R. A pilot trial of a telecommunications system in sleep apnea management. Medical Care. 2004; 42(8):764-769
- 25. Deng T, Wang Y, Sun M, Chen B. Stage-matched intervention for adherence to CPAP in patients with obstructive sleep apnea: A randomized controlled trial. Sleep & Breathing. 2013; 17(2):791-801
 - 26. Diaferia G, Santos-Silva R, Truksinas E, Haddad FLM, Santos R, Bommarito S et al. Myofunctional therapy improves adherence to continuous positive airway pressure treatment. Sleep & Breathing. 2017; 21(2):387-395
- 42 27. Epstein L, Graham L, Turner A, Iarkin E, Garshick E, Ayas N. Comparison of two
 43 methods for achieving CPAP compliance. American Journal of Respiratory and
 44 Critical Care Medicine. 2000; 161:A358

- Escourrou P, Durand-Zaleski I, Charrier N, Agostini H, Alfandary D, Orvoen-Frija E et al. Respiradom: A telemedicine system for the follow-up of patients with Sleep Apnea Syndrome. Journal of Sleep Research. 2012; 21(Suppl 1):50
- 29. Falcone VA, Damiani MF, Quaranta VN, Capozzolo A, Resta O. Polysomnograph chart view by patients: A new educational strategy to improve CPAP adherence in sleep apnea therapy. Respiratory Care. 2014; 59(2):193-198
- 30. Fox N, Hirsch-Allen AJ, Goodfellow E, Wenner J, Fleetham J, Ryan CF et al. The impact of a telemedicine monitoring system on positive airway pressure adherence in patients with obstructive sleep apnea: A randomized controlled trial. Sleep. 2012; 35(4):477-481
 - 31. Garbuio SA, Dal-Fabbro C, Veloso FB, Zamin LK, Bittencourt LR. Compliance to the continuous positive airway pressure and oral appliances in the same sample of obstructive sleep apnea syndrome patients. Sleep. 2008; 31(Suppl):A183
 - Gauthier L, Laberge L, Beaudry M, Laforte M, Rompre PH, Heinzer R et al. Follow-up study of two mandibular advancement appliances: Preliminary results. Sleep & Breathing. 2010; 14(3):278-279
- 33. Guralnick AS, Balachandran JS, Szutenbach S, Adley K, Emami L, Mohammadi M et al. Educational video to improve CPAP use in patients with obstructive sleep apnoea at risk for poor adherence: A randomised controlled trial. Thorax. 2017; 72(12):1132-
 - 34. Hanger KL. Use of telemedicine to improve CPAP non-adherence in patients with obstructive sleep apnea, a pilot study. 2018; Doctor of Nursing Practice (DNP) Final Clinical Projects. 22
 - 35. Harris DL, Nielsen DB, Densley A, Caldwell M, Muhlestein J, Bradshaw D. CPAP compliance > 4 hours per night in the CPAP utilization development from directed learning, education and supervision (CUDDLES) study. Sleep. 2014; 37:A119-A120
- 36. Hoet F, Libert W, Sanida C, Van den Broecke S, Bruyneel AV, Bruyneel M. Telemonitoring in continuous positive airway pressure-treated patients improves delay to first intervention and early compliance: A randomized trial. Sleep Medicine. 2017; 39:77-83
- 37. Hoy CJ, Vennelle M, Kingshott RN, Engleman HM, Douglas NJ. Can intensive support improve continuous positive airway pressure use in patients with the sleep apnea/hypopnea syndrome? American Journal of Respiratory and Critical Care Medicine. 1999; 159(4 Pt 1):1096-1100
 - 38. Hui DS, Chan JK, Choy DK, Ko FW, Li TS, Leung RC et al. Effects of augmented continuous positive airway pressure education and support on compliance and outcome in a Chinese population. Chest. 2000; 117(5):1410-1416
- 39. Hwang D, Chang JW, Benjafield AV, Crocker ME, Kelly C, Becker KA et al. Effect of telemedicine education and telemonitoring on continuous positive airway pressure adherence. The Tele-OSA randomized trial. American Journal of Respiratory and Critical Care Medicine. 2018; 197(1):117-126
- 4240.Isetta V, Leon C, Embid C, Duran-Cantolla J, Campos-Rodriguez F, Galdeano M et43al. Telemedicine-based strategy in the management of sleep apnea: A multicenter44randomized controlled trial. American Journal of Respiratory and Critical Care45Medicine. 2014; 189:A6358

41. Isetta V, Negrin MA, Monasterio C, Masa JF, Feu N, Alvarez A et al. A bayesian cost-1 2 effectiveness analysis of a telemedicine-based strategy for the management of sleep 3 apnoea: A multicentre randomised controlled trial. Thorax. 2015; 70(11):1054-1061 4 42. Kataria LV, Sundahl CA, Skalina LM, Shah M, Pfeiffer MH, Balish MS et al. Annie: 5 The veterans health administration's personalized text message application promotes compliance with positive airway pressure. Sleep. 2017; 40(Suppl 1):A196 6 7 Kotzian ST, Saletu MT, Schwarzinger A, Haider S, Spatt J, Kranz G et al. Proactive 43. 8 telemedicine monitoring of sleep apnea treatment improves adherence in people with stroke- a randomized controlled trial (HOPES study). Sleep Medicine. 2019; 64:48-55 9 44. Lai A, Fong D, Lam J, Ip M. Long-term efficacy of an education programme in 10 improving adherence with continuous positive airway pressure treatment for 11 12 obstructive sleep apnoea. Hong Kong Medical Journal. 2017; 23 Suppl 2(3):24-27 Lai AYK. Education programme on continuous positive airway pressure treatment. 13 45. 14 2014. Available from: https://clinicaltrials.gov/ct2/show/nct01173406 Last accessed: 15 12/07/2019. 16 Lai AYK, Fong DYT, Lam JCM, Weaver TE, Ip MSM. The efficacy of a brief 46. 17 motivational enhancement education program on CPAP adherence in OSA: A 18 randomized controlled trial. Chest. 2014; 146(3):600-610 Lewis KE, Bartle IE, Watkins AJ, Seale L, Ebden P. Simple interventions improve re-19 47. 20 attendance when treating the sleep apnoea syndrome. Sleep Medicine. 2006; 7(3):241-247 21 22 Lopez-Martin S, Sanchez-Munoz G, Gonzalez-Moro JMR, de Miguel-Diez J, 48. 23 Pedraza-Serrano F, de Lucas-Ramos P. CPAP treatment compliance in patients with 24 obstructive sleep apnea syndrome (OSAS) does it improve when the treatment is 25 inhaled under supervision. Proceedings of the American Thoracic Society. 2005; 26 2:C29 27 49. Lugo VM, Garmendia O, Suarez-Giron M, Torres M, Vazquez-Polo FJ, Negrin MA et 28 al. Comprehensive management of obstructive sleep apnea by telemedicine: Clinical 29 improvement and cost-effectiveness of a Virtual Sleep Unit. A randomized controlled trial. PloS One. 2019; 14(10):e0224069 30 31 50. Luyster FS, Aloia MS, Buysse DJ, Dunbar-Jacob J, Martire LM, Sereika SM et al. A 32 couples-oriented intervention for positive airway pressure therapy adherence: A pilot 33 study of obstructive sleep apnea patients and their partners. Behavioral Sleep 34 Medicine. 2018:1-12 35 51. Margues S. Bento AR. Monteiro S. Gralho A. Silva F. Duarte M et al. The impact of a telemedicine monitoring on positive airway pressure in naive obstructive sleep apnea 36 37 patients' outcomes: A randomized controlled trial. Sleep Medicine. 2017; 40(Suppl 38 1):e83 52. 39 Marshall MJ, Scammels C, Lowe S. Does proactive intervention influence compliance on continuous positive airway pressure therapy (CPAP)? . Respiratory Care. 2003; 40 41 48(11):1094 42 53. Mendelson M, Vivodtzev I, Tamisier R, Laplaud D, Dias-Domingos S, Baguet JP et al. 43 CPAP treatment supported by telemedicine does not improve blood pressure in high 44 cardiovascular risk OSA patients: A randomized, controlled trial. Sleep. 2014; 45 37(11):1863-1870

54. Meurice JC, Ingrand P, Portier F, Arnulf I, Rakotonanahari D, Fournier E et al. A 1 2 multicentre trial of education strategies at CPAP induction in the treatment of severe 3 sleep apnoea-hypopnoea syndrome. Sleep Medicine. 2007; 8(1):37-42 4 55. Moore WR, Olson EJ, Vickers Douglas K, Dierkhising RA, Sikkink VK, Heim-Penokie PC et al. Can video based positive airway pressure (PAP) education impact 5 acceptance, self efficacy and adherence to PAP in the management of obstructive 6 sleep apnea? Sleep. 2012; 35(Suppl):A170 7 8 56. Munafo D, Hevener W, Crocker M, Willes L, Sridasome S, Muhsin M. A telehealth program for CPAP adherence reduces labor and yields similar adherence and 9 efficacy when compared to standard of care. Sleep & Breathing. 2016; 20(2):777-785 10 57. Murase K, Tanizawa K, Minami T, Matsumoto T, Tachikawa R, Takahashi N et al. A 11 12 randomized controlled trial of telemedicine for long-term sleep apnea CPAP 13 management Annals of the American Thoracic Society. 2020; 17(3):329-337 14 58. Murphie P, Paton R, Little S. Non-invasive ventialtion (NIV)-Our experience of 15 telemonitoring in a remote and rural Service. European Respiratory Journal. 2016; 48(Suppl 60):PA3710 16 17 59. Nadeem R, Rishi MA, Srinivasan L, Copur AS, Naseem J. Effect of visualization of 18 raw graphic polysomnography data by sleep apnea patients on adherence to CPAP therapy. Respiratory Care. 2013; 58(4):607-613 19 20 60. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [Updated 2018]. London. National Institute for Health and Care Excellence, 21 22 2014. Available from: 23 http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview 24 61. Nilius G, Schroeder M, Domanski U, Tietze A, Schafer T, Franke KJ. Telemedicine 25 improves continuous positive airway pressure adherence in stroke patients with 26 obstructive sleep apnea in a randomized trial. Respiration. 2019; 98(5):410-420 27 62. Olsen S, Smith SS, Oei TP, Douglas J. Motivational interviewing (MINT) improves 28 continuous positive airway pressure (CPAP) acceptance and adherence: A 29 randomized controlled trial. Journal of Consulting and Clinical Psychology. 2012; 30 80(1):151-163 Ong JC, Crawford MR, Dawson SC, Fogg LF, Turner AD, Wyatt JK et al. A 31 63. 32 randomized controlled trial of CBT-I and PAP for obstructive sleep apnea and 33 comorbid insomnia: Main outcomes from the MATRICS study. Sleep. 2020; 34 43(1):zsaa041 Parthasarathy S. Wendel C. Havnes PL. Atwood C. Kuna S. A pilot study of CPAP 35 64. adherence promotion by peer buddies with sleep apnea. Journal of Clinical Sleep 36 37 Medicine. 2013; 9(6):543-550 Pengo MF, Czaban M, Berry MP, Nirmalan P, Brown R, Birdseye A et al. The effect 38 65. 39 of positive and negative message framing on short term continuous positive airway pressure compliance in patients with obstructive sleep apnea. Journal of Thoracic 40 41 Disease. 2018; 10(Suppl 1):S160-S169 42 66. Pepin JL, Jullian-Desayes I, Sapene M, Treptow E, Joyeux-Faure M, Benmerad M et 43 al. Multimodal remote monitoring of high cardiovascular risk patients with osa initiating CPAP: A randomized trial Chest. 2019; 155(4):730-739 44 Pepin JLD, Woehrle H, Liu D, Shao S, Armitstead JP, Cistulli PA et al. Adherence to 45 67. positive airway therapy after switching from CPAP to ASV: A big data analysis. 46 47 Journal of Clinical Sleep Medicine. 2018; 14(1):57-63

68. Quintela MM, Uechi CH, Pacheco Filho F. Evaluation of initial patient adherence to 1 2 use of a trial-appliance for obstructive sleep apnea therapy. Sleep Medicine. 2009; 10:S77 3 4 69. Richards D, Bartlett DJ, Wong K, Malouff J, Grunstein RR. Increased adherence to CPAP with a group cognitive behavioral treatment intervention: A randomized trial. 5 Sleep. 2007; 30(5):635-640 6 7 Rodgers B, Brown LK, Lopez S, Glasser J. Increased engagement and adherence in 70. 8 adults with obstructive sleep apnea. Sleep. 2015; 38:A182 9 71. Roecklein KA, Schumacher JA, Gabriele JM, Fagan C, Baran AS, Richert AC. Personalized feedback to improve CPAP adherence in obstructive sleep apnea. 10 Behavioral Sleep Medicine. 2010; 8(2):105-112 11 72. 12 Sarac S, Afsar GC, Oruc O, Topcuoglu OB, Salturk C, Peker Y. Impact of patient education on compliance with positive airway pressure treatment in obstructive sleep 13 14 apnea. Medical Science Monitor. 2017; 23:1792-1799 15 73. Sawyer AM, King TS, Weaver TE, Sawyer DA, Varrasse M, Franks J et al. A Tailored 16 Intervention for PAP Adherence: The SCIP-PA Trial. Behavioral Sleep Medicine. 17 2019; 17(1):49-69 18 74. Scala D, Starace A, Lembo L, de Falco F, Niola M, Lisi R et al. Therapeutic patient 19 education program for patient with Obstructive Sleep Apnea Syndrome (OSAS): 20 Preliminary results. Bollettino della Società Italiana di Farmacia Ospedaliera. 2012; 21 59(5):195-201 22 75. Schiefelbein J. Internet interventions for older persons with obstructive sleep apnea: 23 Preparedness and problem-solving confidence. Kansas, K.S. University of Kansas. 24 2005 25 76. Schoch OD, Baty F, Boesch M, Benz G, Niedermann J, Brutsche MH. Telemedicine for continuous positive airway pressure in sleep apnea: A randomized, controlled 26 study. Annals of the American Thoracic Society. 2019; 16(12):1550-1557 27 77. 28 Sedkaoui K, Leseux L, Pontier S, Rossin N, Leophonte P, Fraysse JL et al. Efficiency 29 of a phone coaching program on adherence to continuous positive airway pressure in 30 sleep apnea hypopnea syndrome: A randomized trial. BMC Pulmonary Medicine. 2015; 15:102 31 32 78. Shapiro AL. Effect of the CPAP-SAVER intervention on adherence. Clinical Nursing 33 Research. 2019; https://doi.org/10.1177/1054773819865875 34 79. Sheets V, Maerz R, Johnston W, Magalang U, Firestone A. Increasing adherence to 35 mandibular advancement devices for obstructive sleep apnea. Sleep. 2019; 42 (Suppl 36 1):A396-A397 Singhal P, Joshi Y, Singh G, Kulkarni S. Study of factors affecting compliance of 37 80. continuous positive airway pressure (CPAP) in obstructive sleep apnea-hypopnea 38 syndrome (OSAHS). European Respiratory Journal. 2016; 48(Suppl 60):PA2362 39 Smith CE, Dauz E, Clements F, Werkowitch M, Whitman R. Patient education 40 81. 41 combined in a music and habit-forming intervention for adherence to continuous 42 positive airway (CPAP) prescribed for sleep apnea. Patient Education and 43 Counseling. 2009; 74(2):184-190 44 82. Smith CE, Dauz ER, Clements F, Puno FN, Cook D, Doolittle G et al. Telehealth 45 services to improve nonadherence: A placebo-controlled study. Telemedicine and e-46 Health. 2006; 12(3):289-296

3

4

5

6 7

8

9

10

11

12

13

14

15

16

17

18

19 20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36 37

38

39

- 83. Soares Pires F, Drummond M, Marinho A, Sampaio R, Pinto T, Goncalves M et al. Effectiveness of a group education session on adherence with APAP in obstructive sleep apnea--a randomized controlled study. Sleep & Breathing. 2013; 17(3):993-1001 84. Sparrow D, Aloia M, Demolles DA, Gottlieb DJ. A telemedicine intervention to improve adherence to continuous positive airway pressure: A randomised controlled trial. Thorax. 2010; 65(12):1061-1066 85. Stepnowsky C, Edwards C, Zamora T, Barker R, Agha Z. Patient perspective on use of an interactive website for sleep apnea. International Journal of Telemedicine & Applications. 2013; 2013:239382 86. Stepnowsky CJ, Palau JJ, Marler MR, Gifford AL. Pilot randomized trial of the effect of wireless telemonitoring on compliance and treatment efficacy in obstructive sleep apnea. Journal of Medical Internet Research. 2007; 9(2):e14
 - Suarez MC, Garmendia O, Lugo VM, Moraleda A, Farre R, Guerrero G et al. Simple telemedicine intervention to improve CPAP compliance on OSA patients to minimal (>4 h) and optimal (> 5.5 h) use: study design (CPAP-rescue). Sleep Medicine. 2017; 40(Suppl 1):e317
 - 88. Sweetman A, Lack L, Catcheside PG, Antic NA, Smith S, Chai-Coetzer CL et al. Cognitive and behavioral therapy for insomnia increases the use of continuous positive airway pressure therapy in obstructive sleep apnea participants with comorbid insomnia: a randomized clinical trial. Sleep. 2019; 42(12):24
 - Tatousek J, Lacroix J, Visser T, Teuling N. Promoting adherence to CPAP with tailored education and feedback: a randomized controlled clinical trial. Sleep. 2015; 38:A182
 - Taylor Y, Eliasson A, Andrada T, Kristo D, Howard R. The role of telemedicine in CPAP compliance for patients with obstructive sleep apnea syndrome. Sleep & Breathing. 2006; 10(3):132-138
 - 91. Tolson J, Miles JC, Bartlett DJ, Barnes M, Jackson ML. An intensive CPAP program to improve treatment adherence and self-efficacy in patients with obstructive sleep apnea. Sleep. 2016; 39:A150-A151
 - 92. Turino C, de Batlle J, Woehrle H, Mayoral A, Castro-Grattoni AL, Gomez S et al. Management of continuous positive airway pressure treatment compliance using telemonitoring in obstructive sleep apnoea. European Respiratory Journal. 2017; 49(2):1601128
 - 93. Vanderveken OM, Dieltjens M, De Backer WA, Van De Heyning PH, Braem MJ. Comparison of subjective and objective measures of oral appliance compliance during treatment of sleep-disordered breathing. Sleep & Breathing. 2011; 15(2):259-260
 - 94. Vanderveken OM, Dieltjens M, Wouters K, De Backer WA, Van de Heyning PH, Braem MJ. Objective measurement of compliance during oral appliance therapy for sleep-disordered breathing. Thorax. 2013; 68(1):91-96
- 4295.Wang Y, Gao W, Sun M, Chen B. Adherence to CPAP in patients with obstructive43sleep apnea in a Chinese population. Respiratory Care. 2012; 57(2):238-243
- 4496.Wiese HJ, Boethel C, Phillips B, Peters J, Viggiano T. CPAP compliance: Video45education may help! . Chest. 2002; 122:P256

- 97. Yoshioka Y, Yamamoto U, Tsuda H, Handa S, Yoshimura C, Tokunoh T et al. The factors that affect to the better compliance of mandibular advancement device when compared with continuous positive airway pressure in the patients with moderate to severe sleep apnea syndrome. Sleep Medicine. 2017; 40(Suppl 1):e357-e358

Appendices

1

2

3

Appendix A: Review protocols

Table 6: Review protocol: adherence

Field	Content
PROSPERO registration number	Not registered.
Review title	Adherence
Review question	What support improves adherence to CPAP or other interventions?
Objective	To determine what support improves adherence to CPAP or other interventions.
Searches	The following databases will be searched:
	Cochrane Central Register of Controlled Trials (CENTRAL)
	Cochrane Database of Systematic Reviews (CDSR)
	• Embase
	MEDLINE
	• Epistemonikos
	Searches will be restricted by:
	English language studies
	The searches may be re-run 6 weeks before the final committee meeting and further studies retrieved for inclusion if relevant.
	The full search strategies will be published in the final review.
Condition or domain being studied	Obstructive sleep apnoea/hypopnoea syndrome is the most common form of sleep disordered breathing. The guideline will also cover obesity hypoventilation syndrome and COPD-OSAHS overlap syndrome (the coexistence of obstructive sleep apnoea/hypopnoea syndrome and chronic obstructive pulmonary disease).
Population	Inclusion: People (16 and older) with OSAHS, OHS or COPD-OSAHS overlap syndrome
	 Population will be stratified by: Population: OSAHS, OHS, COPD-OSAHS overlap syndrome Severity: Mild, moderate, severe (based on AHI/ODI) Devices: Positive airway pressure devices, position modifiers, oral devices Types of interventions (educational, behavioural, supportive) Severity:
	 Mild OSAHS: AHI >5 but <15

© NICE 2021. All rights reserved. Subject to Notice of rights.

	Moderate OSAHS: AHI >/= 15 but <30
	• Severe OSAHS: AHI >/= 30
	When a mixed severity population is included the severity of the majority of the population will be used by taking the mean AHI of the patients included and the study will be downgraded for indirectness.
	Exclusion:
	Children and young adults (under 16 years old)
Intervention/Exposure/ Test	 Short term or sustained behavioural intervention aimed at encouraging uptake, acclimation, improvement or maintenance of adherence to long term OSAHS, OHS, COPD-OSAHS overlap syndrome treatment Examples may include educational interventions, supportive interventions, interactive interactions, group-based interventions, mindfulness-based interventions, cognitive interventions, behavioural interventions, motivational strategies combination of multiple interventions
Comparator/Reference standard/Confounding factors	 Any of the above vs no intervention Background level of information and support at the study centre (that must also be provided to intervention group)
Types of study to be included	 RCTs Systematic review of RCTs Parallel or crossover to be included
Other exclusion criteria	Non-English language studies. Conference abstracts will be excluded as it is expected there will be sufficient full text published studies available.
Context	-
Primary outcomes (critical outcomes)	 Generic or disease specific validated quality of life measures (continuous) Mortality (dichotomous) Proportion adherent >4hrs/night for CPAP/ non-invasive ventilation (dichotomous) Adherence in hours/night for CPAP and oral devices (continuous) Self-reported adherence (continuous)
Secondary outcomes (important outcomes)	 mood or anxiety withdrawals Treatment related withdrawals (dichotomous) Sleepiness scores (continuous, e.g. Epworth) Apnoea-Hypopnoea index or respiratory disturbance index (continuous) Oxygen desaturation index (continuous) CO₂ control (continuous) Minor adverse effects of treatment (rates or dichotomous) Driving outcomes (continuous)

 \circledcirc NICE 2021. All rights reserved. Subject to Notice of rights.

	Neurocognitive outcomes (continuous)
	Impact on co-existing conditions:
	• HbA1c for diabetes (continuous)
	 Cardiovascular events for cardiovascular disease (dichotomous)
	 Systolic blood pressure for hypertension (continuous)
	Outcomes will be separated into short term (latest follow-up to 6 months) and long term (latest follow-up beyond 6 months)
Data extraction (selection and coding)	EndNote will be used for reference management, sifting, citations and bibliographies. All references identified by the searches and from other sources will be screened for inclusion. 10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer. The full text of potentially eligible studies will be retrieved and will be assessed in line with the criteria outlined above. EviBASE will be used for data extraction.
Risk of bias (quality) assessment	Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual.
	Systematic reviews: Risk of Bias in Systematic Reviews (ROBIS)
	Randomised Controlled Trial: Cochrane RoB (2.0)
	10% of all evidence reviews are quality assured by a senior research fellow. This includes checking:
	 papers were included /excluded appropriately
	 a sample of the data extractions
	 correct methods are used to synthesise data
	 a sample of the risk of bias assessments
	Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.
Strategy for data synthesis	 Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5).
	• GRADEpro will be used to assess the quality of evidence for each outcome, taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each outcome. Publication bias is tested for when there are more than 5 studies for an outcome.
	The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group <u>http://www.gradeworkinggroup.org/</u>
	 Where meta-analysis is not possible, data will be presented, and quality assessed individually per outcome.
	 WinBUGS will be used for network meta-analysis, if possible, given the data identified.

	Heterogeneity between the studies in effect measures will be assessed using the l ² statistic and visually inspected. An l ² value greater than 50% will be considered indicative of substantial heterogeneity. Sensitivity analyses will be conducted based on pre-specified subgroups using stratified meta- analysis to explore the heterogeneity in effect estimates. If this does not explain the heterogeneity, the results will be presented pooled using random-effects.				
Analysis of sub-groups	 Subgroups (to be assessed in the presence of heterogeneity) High risk occupational groups (for example heavy goods vehicle drivers) vs general population Sleepiness – Epworth >9 vs Epworth 9 or less Coexisting conditions – type 2 diabetes vs atrial fibrillation vs hypertension vs none BMI – obese vs non-obese Stage of intervention – treatment naïve vs prior treatment use Age – <65 vs >/=65 Hours per night outcome – minute by minute reporting vs counter output for time on 				
Type and method of review	⊠ Intervention				
		Diagnostic			
		Prognostic			
		Qualitative			
		Epidemiologic			
		Service Delivery			
		Other (please specify)			
Language	English				
Country	England				
Anticipated or actual start date	NA – not registered on PROSPERO				
Anticipated completion date	NA – not registered of	on PROSPERO			
Named contact	5a. Named contact				
	National Guideline Centre				
	5b Named contact e	-mail			
	SleepApnoHypo@nic				
	5e Organisational af				
	National Institute for Health and Care Excellence (NICE) and the National Guideline Centre				
Review team members	From the National G	uideline Centre:			
	Carlos Sharpin, Guid				

	Sharangini Rajesh, Senior systematic reviewer
	Audrius Stonkus, Systematic reviewer
	Emtiyaz Chowdhury (until January 2020), Health economist
	David Wonderling, Head of health economics
	Agnes Cuyas, Information specialist (till December 2019)
	Jill Cobb, Information specialist
Funding sources/sponsor	This systematic review is being completed by the National Guideline Centre which receives funding from NICE.
Conflicts of interest	All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.
Collaborators	Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence- based recommendations in line with section 3 of <u>Developing NICE</u> <u>guidelines: the manual</u> . Members of the guideline committee are available on the NICE website: https://www.nice.org.uk/guidance/indevelopment/gid- ng10098
Other registration details	NA – not registered
Reference/URL for published protocol	NA – not registered
Dissemination plans	NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as:
	 notifying registered stakeholders of publication
	 publicising the guideline through NICE's newsletter and alerts
	 issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE.
Keywords	-
Details of existing review of same topic by same authors	NA
Additional information	-
Details of final publication	www.nice.org.uk

Table 7: Health economic review protocol

1

Review question	All questions – health economic evidence
Objectives	To identify health economic studies relevant to any of the review questions.

© NICE 2021. All rights reserved. Subject to Notice of rights.

Search criteria	 Populations, interventions and comparators must be as specified in the clinical review protocol above.
	• Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).
	 Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) Unpublished reports will not be considered unless submitted as part of a call for evidence.
	Studies must be in English.
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below.
Review strategy	Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.
	Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014). ⁶⁰
	Inclusion and exclusion criteria
	• If a study is rated as both 'Directly applicable' and with 'Minor limitations' then it will
	be included in the guideline. A health economic evidence table will be completed, and it will be included in the health economic evidence profile.
	• If a study is rated as either 'Not applicable' or with 'Very serious limitations' then it will usually be excluded from the guideline. If it is excluded, then a health economic evidence table will not be completed, and it will not be included in the health economic evidence profile.
	 If a study is rated as 'Partially applicable', with 'Potentially serious limitations' or both then there is discretion over whether it should be included.
	Where there is discretion
	The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.
	The health economist will be guided by the following hierarchies. <i>Setting:</i>
	• UK NHS (most applicable).
	 OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
	• OECD countries with predominantly private health insurance systems (for example, Switzerland).
	 Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.
	Health economic study type:
	Cost–utility analysis (most applicable).

- Other type of full economic evaluation (cost-benefit analysis, cost-effectiveness analysis, cost-consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations. Year of analysis:
- The more recent the study, the more applicable it will be.
- Studies published in 2003 or later but that depend on unit costs and resource data entirely or predominantly from before 2003 will be rated as 'Not applicable'.
- Studies published before 2003 will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

• The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

Appendix B: Literature search strategies

1	Sleep Apnoea search strategy 1 adherence
2	This literature search strategy was used for the following review;
3	 What support improves adherence to CPAP or other interventions?
4	The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual 60
5	outlined in Developing NICE guidelines: the manual. ⁶⁰

For more information, please see the Methods Report published as part of the accompanying 6 7 documents for this guideline.

Clinical search literature search strategy B.1 8

9 Searches were constructed using a PICO framework where population (P) terms were 10 combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well 11 described in title, abstract or indexes and therefore difficult to retrieve. Search filters were 12 13 applied to the search where appropriate.

> Search filter used Database **Dates searched** 1946 - 6 July 2020 Medline (OVID) **Exclusions** Randomised controlled trials Systematic review studies Embase (OVID) 1974 - 6 July 2020 **Exclusions** Randomised controlled trials Systematic review studies Cochrane Reviews to 2020 The Cochrane Library (Wiley) None Issue 7 of 12 CENTRAL to 2020 Issue 7 of 12 Inception - 29 November 2018 Epistemonikos (Epistemonikos None Foundation)

Table 8: Database date parameters and filters used

14

Medline (Ovid) search terms

1.	exp Sleep Apnea Syndromes/
2.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
3.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
4.	(OSAHS or OSA or OSAS).ti,ab.
5.	(obes* adj3 hypoventil*).ti,ab.
6.	pickwick*.ti,ab.
7.	or/1-6
8.	limit 7 to English language
9.	letter/
10.	editorial/
11.	news/
12.	exp historical article/
13.	Anecdotes as Topic/
14.	comment/

<Click this field on the first page and insert footer text if required> © NICE 2021. All rights reserved. Subject to Notice of rights.

15.	case report/		
16.	(letter or comment*).ti.		
10.	or/9-16		
17.	randomized controlled trial/ or random*.ti,ab.		
19.			
20.	17 not 18 animals/ not humans/		
_	exp Animals, Laboratory/		
21.			
22.	exp Animal Experimentation/		
23.	exp Models, Animal/		
24.	exp Rodentia/		
25.	(rat or rats or mouse or mice).ti.		
26.	or/19-25		
27.	8 not 26		
28.	Patient compliance/ or patient dropouts/ or treatment refusal/		
29.	(discontinu* or abstention or abstain* or stop* or abandon* or uptak* or acclimat* or mainten* or keep*).ti,ab.		
30.	(adhere* or adhering or nonadhere* or non-adhere* or non-adhering or complian* or complying or non-complian* or noncomplian* or concordance or capacitance).ti,ab.		
31.	or/28-30		
32.	((oral or intraoral or intra-oral) adj3 (device* or prosthes* or appliance* or splint*)).ti,ab.		
33.	(MAD or MADs or MAS or MRS).ti,ab.		
34.	((dental or orthodontic* or orthosis or orthotic) adj3 (device* or prosthes* or appliance* or splint*)).ti,ab.		
35.	 (tongue adj3 (device* or prosthes* or appliance* or splint* or retain* or reposition* or stabiliz* or stabilis* or advancement or advancing or retention or protruding or protrude or protruded or protrusion or forward or mouthpiece*)).ti,ab. 		
36.	(mandib* adj3 (device* or prosthes* or appliance* or splint* or advancement or advancing or protruding or protrude or protruded or protrusion or reposition* or position*)).ti,ab.		
37.	(positive airway* pressure or PAP or CPAP or aPAP or nCPAP or auto- CPAP or biPAP or BPAP or NBiPAP or NBPAP or NIV).ti,ab.		
38.	(positive adj3 pressure adj (therapy or device* or ventilat*)).ti,ab.		
39.	or/32-38		
40.	27 and 31 and 39		
41.	randomized controlled trial.pt.		
42.	controlled clinical trial.pt.		
43.	randomi#ed.ti,ab.		
44.	placebo.ab.		
45.	randomly.ti,ab.		
46.	Clinical Trials as topic.sh.		
47.	trial.ti.		
48.	or/41-47		
49.	Meta-Analysis/		
50.	exp Meta-Analysis as Topic/		
51.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.		
52.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.		
53.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.		

54.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.	
55.	(search* adj4 literature).ab.	
56.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.	
57.	cochrane.jw.	
58.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.	
59.	or/49-58	
60.	40 and (48 or 59)	

Embase (Ovid) search terms

1.	exp Sleep Disordered Breathing/		
2.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.		
3.	(sleep* adj4 disorder* adj4 breath*).ti,ab.		
4.	(OSAHS or OSA or OSAS).ti,ab.		
5.	(obes* adj3 hypoventil*).ti,ab.		
6.	pickwick*.ti,ab.		
7.	or/1-6		
8.	limit 7 to English language		
9.	letter.pt. or letter/		
10.	note.pt.		
11.	editorial.pt.		
12.	case report/ or case study/		
13.	(letter or comment*).ti.		
14.	or/9-13		
15.	randomized controlled trial/ or random*.ti,ab.		
16.	14 not 15		
17.	animal/ not human/		
18.	nonhuman/		
19.	exp Animal Experiment/		
20.	exp Experimental Animal/		
21.	animal model/		
22.	exp Rodent/		
23.	(rat or rats or mouse or mice).ti.		
24.	or/16-23		
25.	8 not 24		
26.	patient compliance/ or patient dropout/ or treatment refusal/		
27.	(discontinu* or abstention or abstain* or stop* or abandon* or uptak* or acclimat* or mainten* or keep*).ti,ab.		
28.	(adhere* or adhering or nonadhere* or non-adhere* or non-adhering or complian* or complying or non-complian* or noncomplian* or concordance or capacitance).ti,ab.		
29.	or/26-28		
30.	((oral or intraoral or intra-oral) adj3 (device* or prosthes* or appliance* or splint*)).ti,ab.		
31.	(MAD or MADs or MAS or MRS).ti,ab.		
32.	((dental or orthodontic* or orthosis or orthotic) adj3 (device* or prosthes* or appliance* or splint*)).ti,ab.		

33.	(tongue adj3 (device* or prosthes* or appliance* or splint* or retain* or reposition* or stabiliz* or stabilis* or advancement or advancing or retention or protruding or protrude or protruded or protrusion or forward or mouthpiece*)).ti,ab.		
34.	(mandib* adj3 (device* or prosthes* or appliance* or splint* or advancement or advancing or protruding or protrude or protruded or protrusion or reposition* or position*)).ti,ab.		
35.	(positive airway* pressure or PAP or CPAP or aPAP or nCPAP or autoCPAP or auto- CPAP or biPAP or BPAP or NBiPAP or NBPAP or NIV).ti,ab.		
36.	(positive adj3 pressure adj (therapy or device* or ventilat*)).ti,ab.		
37.	or/30-36		
38.	25 and 29 and 37		
39.	random*.ti,ab.		
40.	factorial*.ti,ab.		
41.	(crossover* or cross over*).ti,ab.		
42.	((doubl* or singl*) adj blind*).ti,ab.		
43.	(assign* or allocat* or volunteer* or placebo*).ti,ab.		
44.	crossover procedure/		
45.	single blind procedure/		
46.	randomized controlled trial/		
47.	double blind procedure/		
48.	or/39-47		
49.	systematic review/		
50.	meta-analysis/		
51.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.		
52.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.		
53.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.		
54.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.		
55.	(search* adj4 literature).ab.		
56.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.		
57.	cochrane.jw.		
58.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.		
59.	or/49-58		
60.	38 and (48 or 59)		

Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Sleep Apnea Syndromes] explode all trees	
#2.	(sleep* near/4 (apnea* or apnoea* or hypopnea* or hypopnoea*)):ti,ab	
#3.	(sleep* near/4 disorder* near/4 breath*):ti,ab	
#4.	(OSAHS or OSA or OSAS):ti,ab	
#5.	(obes* near/3 hypoventil*):ti,ab	
#6.	pickwick*:ti,ab	
#7.	(OR #1-#6)	
#8.	MeSH descriptor: [Patient Compliance] this term only	
#9.	MeSH descriptor: [Patient Dropouts] this term only	
#10.	MeSH descriptor: [Treatment Refusal] this term only	

#11.	(discontinu* or abstention or abstain* or stop* or abandon* or uptak* or acclimat* or mainten* or keep*):ti,ab		
#12.	(adhere* or adhering or nonadhere* or non-adhere* or non-adhering or complian* or complying or non-complian* or noncomplian* or concordance or capacitance):ti,ab		
#13.	(OR #8-#12)		
#14.	((oral or intraoral or intra-oral) near/3 (device* or prosthes* or appliance* or splint*)):ti,ab		
#15.	(MAD or MADs or MAS or MRS):ti,ab		
#16.	((dental or orthodontic* or orthosis or orthotic) near/3 (device* or prosthes* or appliance* or splint*)):ti,ab		
#17.	(tongue near/3 (device* or prosthes* or appliance* or splint* or retain* or reposition* or stabiliz* or stabilis* or advancement or advancing or retention or protruding or protrude or protruded or protrusion or forward or mouthpiece*)):ti,ab		
#18.	(mandib* near/3 (device* or prosthes* or appliance* or splint* or advancement or advancing or protruding or protrude or protruded or protrusion or reposition* or position*)):ti,ab		
#19.	(positive airway* pressure or PAP or CPAP or aPAP or nCPAP or autoCPAP or auto- CPAP or biPAP or BPAP or NBiPAP or NBPAP or NIV):ti,ab		
#20.	(positive near/3 pressure near/1 (therapy or device* or ventilat*)):ti,ab		
#21.	(OR #14-#20)		
#22.	#7 AND #13 AND #21		

3

4

5

6

7

8

Epistemonikos search terms

1. ((title:((sleep apnea syndromes) OR (sleep* AND (apn?ea* OR hypopn?ea*)) OR (sleep* AND (apn?ea* OR hypopn?ea*)) OR (sleep* AND (disorder* OR breath*)) OR (OSAHS OR OSA OR OSAS) OR (obes* AND hypoventil*) OR pickwick*) OR abstract:((sleep apnea syndromes) OR (sleep* AND (apn?ea* OR hypopn?ea*)) OR (sleep* AND (apn?ea* OR hypopn?ea*)) OR (sleep* AND (disorder* OR breath*)) OR (OSAHS OR OSA OR OSAS) OR (obes* AND hypoventil*) OR pickwick*)))

2 **B.2** Health Economics literature search strategy

Health economic evidence was identified by conducting a broad search relating to sleep apnoea population in NHS Economic Evaluation Database (NHS EED – this ceased to be updated after March 2015) and the Health Technology Assessment database (HTA – this ceased to be updated after March 2018) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional searches were run on Medline and Embase for health economics and quality of life studies.

9 B.2.1 Health economic studies strategy

10

Table 9: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline	2014 – 6 July 2020	Exclusions Health economics studies
Embase	2014 – 6 July 2020	Exclusions Health economics studies
Centre for Research and Dissemination (CRD)	HTA - Inception – 31 March 2018 NHSEED - Inception to March 2015	None

Database		Dates searched	Search filter used
Medline (Ovi	d) search terms	. ,	
	exp Sleep Apnea Syn		
1.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.		
2.	(sleep* adj4 disorder* adj4 breath*).ti,ab.		
3.	(OSAHS or OSA or O	SAS).ti,ab.	
4.	(obes* adj3 hypoventi	l*).ti,ab.	
5.	pickwick*.ti,ab.		
6.	or/1-6		
7.	limit 7 to English lang	uage	
8.	letter/		
9.	editorial/		
10.	news/		
11.	exp historical article/		
12.	Anecdotes as Topic/		
13.	comment/		
14.	case report/		
15.	(letter or comment*).ti.		
16.	or/9-16		
17.	randomized controlled	trial/ or random*.ti,ab.	
18.	17 not 18		
19.	animals/ not humans/		
20.	exp Animals, Laborate	-	
21.	exp Animal Experimentation/		
22.	exp Models, Animal/		
23.	exp Rodentia/		
24.	(rat or rats or mouse of	or mice).ti.	
25.	or/19-25		
26.	8 not 26		
27.	Economics/		
28.	Value of life/		
29.	exp "Costs and Cost Analysis"/		
30. 31.	exp Economics, Hospital/		
31.	exp Economics, Medical/		
33.	Economics, Nursing/ Economics, Pharmaceutical/		
33.	exp "Fees and Charges"/		
35.	exp Budgets/		
36.	budget*.ti,ab.		
37.	cost*.ti.		
38.	(economic* or pharmaco?economic*).ti.		
39.	(price* or pricing*).ti,a		

40.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
41.	(financ* or fee or fees).ti,ab.
42.	(value adj2 (money or monetary)).ti,ab.
43.	or/28-43
44.	27 and 44

Embase (Ovid) search terms

1.	exp Sleep Disordered Breathing/
2.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
3.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
4.	(OSAHS or OSA or OSAS).ti,ab.
5.	(obes* adj3 hypoventil*).ti,ab.
6.	pickwick*.ti,ab.
7.	or/1-6
8.	limit 7 to English language
9.	letter.pt. or letter/
10.	note.pt.
11.	editorial.pt.
12.	case report/ or case study/
13.	(letter or comment*).ti.
13.	or/9-13
14.	randomized controlled trial/ or random*.ti,ab.
_	14 not 15
16.	
17.	animal/ not human/
18.	nonhuman/
19.	exp Animal Experiment/
20.	exp Experimental Animal/
21.	animal model/
22.	exp Rodent/
23.	(rat or rats or mouse or mice).ti.
24.	or/16-23
25.	8 not 24
26.	health economics/
27.	exp economic evaluation/
28.	exp health care cost/
29.	exp fee/
30.	budget/
31.	funding/
32.	budget*.ti,ab.
33.	cost*.ti.
34.	(economic* or pharmaco?economic*).ti.
35.	(price* or pricing*).ti,ab.

36.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
37.	(financ* or fee or fees).ti,ab.
38.	(value adj2 (money or monetary)).ti,ab.
39.	or/26-38
40.	25 and 39

3

NHS EED and HTA (CRD) search terms

#1.	MeSH DESCRIPTOR Sleep Apnea Syndromes EXPLODE ALL TREES
#2.	(sleep* adj4 (apn?ea* or hypopn?ea*))
#3.	(sleep* adj4 disorder* adj4 breath*)
#4.	(OSAHS or OSA or OSAS)
#5.	(obes* adj3 hypoventil*)
#6.	(pickwick*)
#7.	#1 OR #2 OR #3 OR #4 OR #5 OR #6
-	

2 B.2.2 Quality of life studies strategy

Table 10: Database date parameters and filters used

Database	Dates searc	ched S	Search filter used
Medline	1946 – 26 N		Exclusions Quality of life studies
Embase	1974 – 26 N		Exclusions Quality of life studies

4 Medline (Ovid) search terms

1.	exp Sleep Apnea Syndromes/
2.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
3.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
4.	(OSAHS or OSA or OSAS).ti,ab.
5.	(obes* adj3 hypoventil*).ti,ab.
6.	pickwick*.ti,ab.
7.	or/1-6
8.	limit 7 to English language
9.	letter/
10.	editorial/
11.	news/
12.	exp historical article/
13.	Anecdotes as Topic/
14.	comment/
15.	case report/
16.	(letter or comment*).ti.
17.	or/9-16
18.	randomized controlled trial/ or random*.ti,ab.

19.	17 not 18	
20.	animals/ not humans/	
21.	exp Animals, Laboratory/	
22.	exp Animal Experimentation/	
23.	exp Models, Animal/	
24.	exp Rodentia/	
25.	(rat or rats or mouse or mice).ti.	
26.	or/19-25	
27.	8 not 26	
28.	quality-adjusted life years/	
29.	sickness impact profile/	
30.	(quality adj2 (wellbeing or well being)).ti,ab.	
31.	sickness impact profile.ti,ab.	
32.	disability adjusted life.ti,ab.	
33.	(qal* or qtime* or qwb* or daly*).ti,ab.	
34.	(euroqol* or eq5d* or eq 5*).ti,ab.	
35.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.	
36.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.	
37.	(hui or hui1 or hui2 or hui3).ti,ab.	
38.	(health* year* equivalent* or hye or hyes).ti,ab.	
39.	discrete choice*.ti,ab.	
40.	rosser.ti,ab.	
41.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.	
42.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.	
43.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.	
44.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.	
45.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.	
46.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.	
47.	or/28-46	
48.	27 and 47	

Embase (Ovid) search terms


1.	exp Sleep Disordered Breathing/
2.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
3.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
4.	(OSAHS or OSA or OSAS).ti,ab.
5.	(obes* adj3 hypoventil*).ti,ab.
6.	pickwick*.ti,ab.
7.	or/1-6
8.	limit 7 to English language
9.	letter.pt. or letter/
10.	note.pt.

11.	editorial.pt.
12.	case report/ or case study/
13.	(letter or comment*).ti.
14.	or/9-13
15.	randomized controlled trial/ or random*.ti,ab.
16.	14 not 15
17.	animal/ not human/
18.	nonhuman/
19.	exp Animal Experiment/
20.	exp Experimental Animal/
20.	animal model/
21.	exp Rodent/
22.	(rat or rats or mouse or mice).ti.
24.	or/16-23
25.	8 not 24
26.	quality adjusted life year/
27.	"quality of life index"/
28.	short form 12/ or short form 20/ or short form 36/ or short form 8/
29.	sickness impact profile/
30.	(quality adj2 (wellbeing or well being)).ti,ab.
31.	sickness impact profile.ti,ab.
32.	disability adjusted life.ti,ab.
33.	(qal* or qtime* or qwb* or daly*).ti,ab.
34.	(euroqol* or eq5d* or eq 5*).ti,ab.
35.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
36.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
37.	(hui or hui1 or hui2 or hui3).ti,ab.
38.	(health* year* equivalent* or hye or hyes).ti,ab.
39.	discrete choice*.ti,ab.
40.	rosser.ti,ab.
41.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
42.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
43.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
44.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
45.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
46.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
47.	or/26-46
48.	25 and 47

1 2

Appendix C: Clinical evidence selection

Figure 1: Flow chart of clinical study selection for the review of adherence



3 4

1

2

© NICE 2021. All rights reserved. Subject to Notice of rights.

Appendix D: Clinical evidence tables

Study	Askland et al⁵
Study type	Systematic review
Number of studies (number of participants)	N= 41 studies, 8968 patients Randomised, parallel-controlled trials of any duration.
Countries and setting	Conducted in Multiple countries; Setting: Hospital, community or home based
Line of therapy	Mixed line
Duration of study	Intervention + follow up: 28 days – 2 years
Method of assessment of guideline condition	Yes
Stratum	Severe OSAHS
Subgroup analysis within study	Not applicable
Inclusion criteria	For inclusion in the review, intervention and control groups must have either 1) received the same make of CPAP machine and pressure delivery mode (i.e. fixed, auto-titrating, bi-level, etc.) or 2) receive CPAP machines in a randomly distributed manner, such that machine make remained independent of group assignment.
	Intervention group
	Any short-term or sustained behavioural intervention aimed at encouraging uptake, acclimation, improvement or maintenance of CPAP adherence among people with a diagnosis of OSA. Examples of modalities that may

Study	Askland et al⁵
	fall under 'behavioural interventions' include educational, supportive, interactive, group-based, mindfulness- based, cognitive, behavioural, motivational or approaches utilizing a combination of these strategies.
	Control group
	Participants in the control group may receive instruction that would be used by the study centre in question, provided that the equivalent 'background' level of instruction was also offered and/or delivered to the intervention group.
Exclusion criteria	Trials that explicitly recruited patients with central sleep apnoea were not eligible for inclusion.
Recruitment/selection of patients	Participants had to be randomised in trials assessing one of the following comparisons:
	1. Behavioural therapy + CPAP versus control + CPAP
	2. Educational interventions + CPAP versus usual care + CPAP
	 Increased practical support and encouragement during follow-up + CPAP versus usual care + CPAP Mixed (SUP/EDU/BEH) Intervention + CPAP versus Usual Care + CPAP
Age, gender and ethnicity	Average age of the study populations was 52.9 years. Patients were of mixed gender predominately male and of different ethnicities.
Further population details	Participants were adults of either sex with a diagnosis of obstructive sleep apnoea (OSA) diagnosed using a
	recognised sleep diagnostic tool giving an Oxygen Desaturation Index (ODI) of ≥5 per hours or an Apnoea Hypopnea Index (AHI) ≥5 per hour.
Extra comments	Most studies were conducted in the North America and Europe with smaller number of trials conducted in China and Australia.
	Study population ranged from 12 to 3100 participants.
Indirectness of population	No indirectness
Interventions	Intervention 1 : Behavioural therapy + CPAP versus control + CPAP
	(n=11 studies; 1139 participants):

	I≥ O
	OSAHS: DRAFT FOR CONSULTATION Adherence
sual care +	DNSULTATION

Study	Askland et al⁵
	Duration between 2 months and 12 months Indirectness: No indirectness
	Intervention 2: Educational interventions + CPAP versus usual care + CPAP
	(n= 11 studies; 2752 participants)
	Duration between 28 days and 12 months
	Indirectness: No indirectness
	Intervention 3: Increased practical support and encouragement during follow-up + CPAP versus usual care + CPAP
	(n= 14 studies; 1498 participants)
	Duration 2 months to 6 months.
	Indirectness: No indirectness
	Intervention 4: Mixed (SUP/EDU/BEH) Intervention + CPAP versus Usual Care + CPAP
	(n= 12 studies; 5041 participants)
	Duration 1 month to 2 years.
	Indirectness: No indirectness
Funding	The majority of the included studies were funded by industry

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: Behavioural therapy + CPAP versus control + CPAP

Study	Askland et al⁵		
Protocol outcome 1: CPAP device usage (ho	urs/night) rs/night) ; MD 1.31 hours/night higher(0.95 higher to 1.66 higher)		
Risk of bias: All domain - high, Selection - high	gh, Blinding - Low, Incomplete outcome data - high, Outcome reporting - high, Measurement - high, Crossover er 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness		
- Low, Subgroups - Low, Other T - Low, Other	1 2 - Low, Other 5 - Low, indirectness of outcome. No indirectness		
Protocol outcome 2: Number of participants v			
- Actual outcome: Number of participants who	o used CPAP therapy > 4 hours per night; RR; 1.33 [95% CI 1.10, 1.61]		
	Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - high, Measurement - Low, Crossover		
- Low, Subgroups - Low, Other 1 - Low, Othe	er 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness		
Protocol outcome 3: Withdrawal			
- Actual outcome: Withdrawals; RR; 0.70 [95	% CI 0.51,0.98]		
	gh, Blinding - Low, Incomplete outcome data - high, Outcome reporting - high, Measurement - Low, Crossover - 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness		
Low, Subgroups - Low, Other 1 - Low, Other			
Protocol outcome 4: Symptoms (Enworth Sle	peniness Scale)		

Protocol outcome 4: Symptoms (Epworth Sleepiness Scale)
- Actual outcome: Epworth sleepiness scale (Endpoint scores); MD; -2.22 (-3.68, -0.75]
Risk of bias: All domain - high, Selection – high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - high, Measurement - Low, Crossover
- Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: serious indirectness

Protocol outcome 5: AHI on treatment

- Actual outcome: AHI on treatment (endpoint scores); MD; -0.95 [95% CI -2.25, to 0.35]

Risk of bias: All domain - high, Selection - high, Blinding - high, Incomplete outcome data - high, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Askland et al⁵

Protocol outcome 6: Quality of life (Functional Outcome of Sleep Questionnaire) - Actual outcome: Quality of life (Functional Outcome of Sleep Questionnaire)Endpoint ; MD 0.01 [95% CI -0.26, 0.29]

Risk of bias: All domain - high, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - high, Measurement - high, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 7: Quality of life (SF-36 PH) - Actual outcome: Quality of life (SF-36 PH); MD -0.07 [95% CI -0.82, 0.67]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - high, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: Educational interventions + CPAP versus usual care + CPAP

Protocol outcome 1: CPAP device usage (hours/night) - Actual outcome: CPAP Device Usage (hours/night); MD 0.88 hours/night higher (0.40 higher to 1.36 higher)

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - high, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 2: Deemed Adherent (Number of participants who used CPAP therapy > 4 hours/night) - Actual outcome: Number of participants who used CPAP therapy > 4 hours per night; RR; 1.31 [95% CI 1.15, 1.48]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data – High, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 3: Withdrawals - Actual outcome: Withdrawals; RR 0.73 [0.52, 1.02]

P NICE 2012

All righte received

Cubiont

to Ninting of righte

ב ת

Study

Askland et al⁵

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - high, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 4: Symptoms (Epworth Sleepiness Scale) - Actual outcome: Symptoms (Epworth Sleepiness Scale); MD -0.08 [-0.92, 0.76]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data – high, Outcome reporting – high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: Increased practical support and encouragement during follow-up + CPAP versus usual care + CPAP

Protocol outcome 1: CPAP Machine usage (hours/night) - Actual outcome: Machine usage (hours/night); MD 0.70 [0.36, 1.05]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - high, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 2: Deemed Adherent (Number of participants who used CPAP therapy > 4 hours/night) - Actual outcome: Number of participants who used CPAP therapy > 4 hours per night; RR; 1.19 [95% CI 1.03, 1.37]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - high, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 3: Withdrawals

- Actual outcome: Withdrawals; RR 1.22 [0.97, 1.52]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - high, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 4.1 Symptoms (Epworth Sleepiness Scale) - Actual outcome: Endpoint scores (Epworth Sleepiness Scale); MD 0.03 [-0.59, 0.64]

Study Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness Protocol outcome 4.2 Symptoms (Epworth Sleepiness Scale) - Actual outcome: Change from baseline (Epworth Sleepiness Scale); MD -0.32 [-1.19, 0.56]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - high, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 5.1: Quality of life (Functional Outcome of Sleep Questionnaire) - Actual outcome: Functional Outcome of Sleep Questionnaire - Endpoint: SMD 0.15 [95% CI -0.23, 0.53]

Askland et al⁵

Risk of bias: All domain - high, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - high, Measurement - high, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 5.2: Quality of life (SAQLI) - Actual outcome: SAQLI - Endpoint; SMD 0.22 [95% CI -0.04, 0.47]

Risk of bias: All domain - high, Selection - Low, Blinding - Low, Incomplete outcome data - high, Outcome reporting - high, Measurement - low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 5.3: Quality of life (SF-36 PH) - Actual outcome: Quality of life - SF-36 PH - endpoint; SMD 0.13 [95% CI -0.09, 0.34]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - high, Outcome reporting - low, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 6.1: Quality of life (Functional Outcome of Sleep Questionnaire) - Actual outcome: Functional Outcome of Sleep Questionnaire - Change from baseline; SMD 0.24 [95% CI -0.40, 0.87]

Risk of bias: All domain - high, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - high, Measurement - high, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Study

Askland et al⁵

Protocol outcome 6.2: Quality of life (SF-36 PH)

- Actual outcome: Quality of life - SF-36 PH - change from baseline; SMD 0.04 [95% CI -0.40, 0.47]

Risk of bias: All domain - high, Selection - low, Blinding - Low, Incomplete outcome data - high, Outcome reporting - low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 6.3: Quality of life (Functional Outcome of Sleep Questionnaire - 10) - Actual outcome: Functional Outcome of Sleep Questionnaire - 10 – Change from baseline; SMD 0.24 [95% CI 0.00, 0.60]

Risk of bias: All domain - high, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - high, Measurement - high, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 7: Anxiety Symptom Rating (HADS-A)

- Actual outcome: Anxiety symptom rating (HADS-A) -comparison of values at endpoint; MD -1.10 [95% CI -2.95, 0.75]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - low, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 8: AHI on treatment

- Actual outcome: AHI on treatment -comparison of values at endpoint; MD 0.48 [95% CI -4.23, 5.18]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - high, Outcome reporting - low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 9.1: HADS - Depression

- Actual outcome: HADS Depression -comparison of values at endpoint; SMD -0.43 [95% CI -0.87, 0.01]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - low, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 9.2: CES - D

- Actual outcome: CES - D -comparison of values at endpoint; SMD 0.25 [95% CI 0.02, 0.49]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - high, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Study

Askland et al⁵

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: Mixed (SUP/EDU/BEH) Intervention + CPAP versus Usual Care + CPAP

Protocol outcome 1: CPAP device usage (hours/night)

- Actual outcome: CPAP Device Usage (hours/night); MD 0.82 hours/night higher (95% CI 0.20, 1.43)

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 2: Deemed Adherent (Number of participants who used CPAP therapy > 4 hours/night) - Actual outcome: Number of participants who used CPAP therapy > 4 hours per night; RR; 1.14 [95% CI 1.04, 1.26]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data – low, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 3: Withdrawals

- Actual outcome: Withdrawals; RR 0.64 [0.32, 1.28]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 4.1: Quality of life (Functional Outcome of Sleep Questionnaire - 10) - Actual outcome: Functional Outcome of Sleep Questionnaire - 10 – Change from baseline; SMD 0.25 [95% CI -0.05, 0.54]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - high, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 4.2: Quality of life (SF-36 MH)

- Actual outcome: Quality of life - SF-36 MH - change from baseline; SMD Not Estimable

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - low, Outcome reporting - high, Measurement - high, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 4.3: Quality of life (SF-36 PH)

- Actual outcome: Quality of life - SF-36 PH - change from baseline; SMD 0.59 [95% CI -0.52, 0.67]

Protocol outcome 6.2: DASS - Anxiety - Actual outcome: DASS - Anxiety - endpoint; SMD -0.19 [95% CI -0.47, 0.09]

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 6.3: BAI - Anxiety - Actual outcome: BAI - Anxiety - endpoint; SMD -0.15 [95% CI -0.63, 0.34]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 6.4: STAI – State - Actual outcome: STAI - state - Anxiety - endpoint; SMD -0.49 [95% CI -0.92, -0.06]

Study

Askland et al⁵

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - high, Measurement - high, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 5.1: Quality of life (FOSQ - Endpoint) - Actual outcome: QOL: FOSQ - Endpoint; SMD 0.10 [95% CI -0.19, 0.40]

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 5.2: Quality of life (SF-36 PH)

- Actual outcome: Quality of life - SF-36 PH - endpoint; SMD 0.59 [95% CI -0.01, 1.19]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - high, Measurement - high, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 6.1: Anxiety symptom rating - comparison of values at endpoint - Actual outcome: Anxiety symptom rating - endpoint; SMD -0.19 [95% CI -0.47, 0.09]

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - high, Outcome reporting - high, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

120

Study

Askland et al⁵

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - high, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 7.1: Depression Symptom rating – endpoint – NO META ANALYSIS PERFORMED - Actual outcome: Depression Symptom rating – endpoint – No totals

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 7.2: BDI - depression – endpoint – NO META ANALYSIS PERFORMED - Actual outcome: BDI – depression – endpoint – No totals

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 7.3: HADS - depression – endpoint – NO META ANALYSIS PERFORMED - Actual outcome: HADS – depression – endpoint – No totals

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - high, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 7.4: DASS - depression – endpoint – NO META ANALYSIS PERFORMED - Actual outcome: DASS – depression – endpoint – No totals

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 8.1: Epworth sleepiness scale – endpoint scores – NO META ANALYSIS PERFORMED - Actual outcome: Epworth sleepiness scale score – endpoint – No totals

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Protocol outcome 8.2: Epworth sleepiness scale – change from baseline – NO META ANALYSIS PERFORMED - Actual outcome: Epworth sleepiness scale score – change from baseline – No totals

Risk of bias: All domain - high, Selection - high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - high, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness

Study	Askland et al⁵
Protocol outcomes not reported by the study	None
Study	Berry 2020 ¹²
Study type	RCT (Patient randomised)
Number of studies (number of participants)	1 (n=250) (Standard care, n= 126, standard care + cloud-based sleep coaches (CBSC), n= 124).
Countries and setting	Conducted in USA; Setting: hospital
Line of therapy	1st line
Duration of study	Intervention + 3 months follow up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Age 21 to 75 years (men and women)
	Diagnostic apnea-hypopnea index ≥ 15 events/h (diagnostic polysomnography [PSG], diagnostic portion of split PSG, or home sleep apnea test)
	Eligible for treatment with automatically adjusting continuous positive airway pressure or bilevel positive airway pressure
	Residence in area covered by wireless network
Exclusion criteria	· Participation in another interventional research study concerned with sleep disorders within the last 30 days

Study	Berry 2020 ¹²
	\cdot Major uncontrolled medical condition that would interfere with the demands of the study, adherence to positive airway pressure (PAP), or the ability to commit
	to follow-up assessment including conditions such as poorly managed or controlled or advanced stages of pulmonary disease, cardiac disease,
	neurological disease, neuromuscular disease, cancer, and renal disease
	· Prior PAP use within the previous 12 months
	 Predominantly central apnoea's (≥ 50% central apnoea's) or Cheyne Stokes respiration (CSR) present during ≥ 20% of total sleep time
	\cdot Chronic respiratory failure or insufficiency with suspected or known neuromuscular disease, moderate chronic obstructive pulmonary disease, or any
	condition with an elevation of arterial carbon dioxide levels while awake or the requirement for continuous supplemental oxygen or mechanical ventilation
	\cdot Surgery involving the upper airway, nose, sinus, eye, teeth, or middle ear within the previous 90 days
	· PAP therapy is otherwise medically complicated or contraindicated, such as those with a difficult to size or adjust interface (mask) resulting in facial pain,
	skin irritation or trauma, or excessive air leaks
Recruitment/selection of patients	Participants recruited at PAP set-up
Age, gender and ethnicity	Age: CBSC 54.9 ± 11.5 years; control: 55.2 ± 13.4 years
	AHI: CBSC 36.6 \pm 20.6 events/h; control 36.7 \pm 21.1 events/h
	Gender male %: CBSC 88.7%; control 89.7%
Further population details	Sleepiness: ESS: CBSC 11.2 ± 6.0; control 10.8 ± 6.1
Indirectness of population	No indirectness

Study	Berry 2020 ¹²
Interventions	(n=124) Intervention 1: Cloud-based sleep coach (CBSC) Participants randomised to SC+CBSC follow-up received all elements of standard care and, in addition, interaction/communication from the CBSC service. The participants were informed that they would receive a telephone call from the CBSC system in 3 to 4 days to discuss their experience with therapy. Further contact from the CBSC could be expected if their adherence goals were not reached. All participants received calls on day 3 to 4 and on day 32 after PAP initiation. The participants were also provided with information on, and encouraged to use, the mobile application (PAPapp), allowing them to view their current adherence.
	(n=126) Intervention 2: standard care Participants attending PAP setup classes were educated about use of their PAP device, including cleaning, ramp option, and humidification. All patients were encouraged to use therapy nightly for as long as they can, preferably for the entire time they sleep. Each participant was fitted with a mask based on physician order, participant preference, and the ability to obtain a good mask seal. The type of PAP device (autoadjusting CPAP or auto-adjusting bilevel PAP) and pressure settings were determined by physician order. Participants practiced putting on their masks and turning on the PAP device. All devices contained wireless modems with information accessed via a cloud-based programme. Device data were uploaded into the database via wireless modems programmed to call in automatically. Device data were associated with the individual participant based upon the serial number of the device and modem entered by the staff. All PAP devices had the ability to deliver heated humidification. At the PAP setup class, participants received information about the PAPapp (written information also supplied with each PAP unit).
	Participants were provided with telephone numbers for PAP supply replacement and for PAP treatment issues. They were also encouraged to use the secure messaging service "My Healthy Vet" to facilitate communication with the sleep providers. Participants had a 6-week inspection of adherence and efficacy data if ordered by the physician reading the sleep study. Pressure settings could be changed remotely based on physician order. A participant could be scheduled for an individual mask fitting CPAP RT appointment if discomfort or leak issues were significant. A 3-month (90 to 120 days) sleep clinic visit with a sleep provider (physician or physician extender) was scheduled.
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CBSC versus standard care

2

Study

Berry 202012

Protocol outcome 1: adherence

- Actual outcome : Average use (all days) in hours at 3 months; Group 1: CBSC n= 124, (4.4 ± 2.6); Group 2: n= 126, (3.7 ± 2.7) Risk of bias: All domain - low, Selection - low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: no indirectness

Protocol outcome 2: adherence

- Actual outcome : % Days > 4 hours at 3 months; Group 1: CBSC n= 124, (57.9 ± 35.4); Group 2: n= 126, (48.1 ± 36.8) Risk of bias: All domain - low, Selection - low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: no indirectness

Protocol outcome 3: AHI (events/h)

- Actual outcome : AHI at 3 months; Group 1: CBSC n= 124, (4.6 ± 4.3); Group 2: n= 126, (4.4 ± 3.9) Risk of bias: All domain - low, Selection - low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: no indirectness

Protocol outcome 4: ESS

- Actual outcome: ESS at 3 months; Group 1: CBSC n= 120, (8.9 ± 5.4); Group 2: n= 120,(8.3 ± 5.5)

Risk of bias: All domain - low, Selection - low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: no indirectness

Protocol outcomes not reported by the study Quality of life at >1 month; Mortality at >1 month; CO2 control at >1 month; Driving outcomes at >1 month; Neurocognitive outcomes at >1 month; Systolic blood pressure for hypertension at >1 month; HbA1c for diabetes at >1 month

Study	Hanger 2018 ³⁴
Study type	RCT (Patient randomised)
Number of studies (number of participants)	1 (n=56) (standard care $n=23$): telemedicine ($n=33$)

Study	Hanger 2018 ³⁴
Countries and setting	Conducted in USA; Setting: hospital
Line of therapy	1st line
Duration of study	Intervention + 3 months follow up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Adults, at least 18 years of age, newly diagnosed with moderate to severe OSA on HSAT or PSG; provision of CPAP device by DME with wireless data transmission capability and English speaking
Exclusion criteria	Prior PAP use of any kind, including CPAP, APAP, bi-level or adaptive seroventilation
	Current use of prescribed supplemental oxygen
	 Significant co-morbid medical condition(s) that could prevent/interfere with the
	participant using CPAP on a daily basis
	Home location being outside of wireless capability
	• Sleep environment where the participant does not sleep in the same location on a
	frequent basis
Recruitment/selection of patients	Participants in the study were adults who had recently been diagnosed with moderate to severe obstructive sleep apnoea through a home sleep apnoea test (HSAT) or in-lab polysomnography (PSG), based on AASM criteria of an apnoea-hypopnea index (AHI) ≥15 as moderate OSA and an AHI of ≥30 as severe OSA. Participants were prescribed treatment with positive airway pressure (PAP) therapy. Participants were recruited into the study from February 21 through June 30, 2018. Data monitoring was completed on October 3, 2018

Study	Hanger 2018 ³⁴
Age, gender and ethnicity	Age (mean SD): medicine 60.0±14.2 ; control: 51.4±13.8
	AHI: telemedicine38.0±21.1; control 37.27±18.8
	Gender: female%: telemedicine 42 ; control 42.1
Further population details	Sleepiness: ESS: telemedicine 8.8±4.9 ; control 11.3±5.5
Indirectness of population	No indirectness
Interventions	(n=23) Intervention 1: Telemedicine care group (TM).
	In addition to standard care, participants randomised to the TM group received the intervention, which entailed an initial call to all participants after one week of PAP therapy. CPAP usage data was monitored weekly via a web-based database. Use of CPAP of less than 4 hours per night, on less than 70% of nights (or more than 2 days), in the preceding week of monitoring, was considered non-adherent and triggered a phone call from the research coordinator to provide support and troubleshooting as needed. Participants were seen back in clinic after 6 weeks, per standard care. Data monitoring, as outlined above, continued for the first 3 months of CPAP usage. The study period culminated with a phone call, by the author, to all participants from both study arms, at the end of 3 months, to discuss any questions or concerns and to survey satisfaction of their follow-up care. (n=23) Intervention 2: Standard care
	Participants in the standard care (SC) group received the standard follow-up regimen currently used by the Sleep Center. Following diagnosis of moderate or severe OSA and the participant was prescribed CPAP therapy. Patients obtained equipment; they were fitted with a mask and given instructions on set up, use and care of the PAP machine. Devices were equipped with wireless data transmission technology. Patients were advised to call for any equipment concerns and the Sleep Center with any other concerns or questions related to PAP use; they were seen back in clinic after 6 weeks to discuss adherence and efficacy, review device data, and to address any issues or questions they may have. If patients were doing well, they were seen back yearly for monitoring, with more frequent follow-up if needed.
Funding	Funding not stated

P NICE 2012

All righte received Cubiect to Notice of righte

128

Hanger 2018³⁴

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: Telemedicine versus standard care

Protocol outcome 1: adherence

- Actual outcome : non-adherence at 3 months; Group 1: n= 25, (2/25); Group 2: n=19, 3/19 Risk of bias: All domain - low, Selection - low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: no indirectness

Protocol outcome 2: AHI

- Actual outcome :AHI at 3 months; Group 1: n= 25, (4.1±3.0); Group 2: n=19, (3.4±3.8)

Risk of bias: All domain - low, Selection - low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: no indirectness

Protocol outcome 3: ESS

- Actual outcome :ESS at 3 months; Group 1: n= 25, (4.0±2.7); Group 2: n=19, (6.5±4.1) Risk of bias: All domain - low, Selection - low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: no indirectness

Protocol outcome 4: Number of days used >4 hours

- Actual outcome : Number of days used >4 hours at 3 months; Group 1: n= 25, (89.9±13.1); Group 2: n=19, (83.5±15.8) Risk of bias: All domain - low, Selection - low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: no indirectness

Protocol outcomes not reported by the study Quality of life at >1 month; Mortality at >1 month; CO2 control at >1 month; Driving outcomes at >1 month; Neurocognitive outcomes at >1 month; Systolic blood pressure for hypertension at >1 month; HbA1c for diabetes at >1 month

1

Kotzian 201943

Study type

Study

RCT (Patient randomised)

Adherence	OSAHS:
Û	DRAFT FO
	R CONSUL
	TATION

Study	Kotzian 2019 ⁴³
Number of studies (number of participants)	1 (n=251 recruited; n=70 therapy relevant OSA, n=33 randomised)
Countries and setting	Conducted in Austria; Setting: hospital
Line of therapy	1st line
Duration of study	Intervention + follow up 1year
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Moderate-severe
Subgroup analysis within study	Not applicable
Inclusion criteria	Subacute adult (19-70 years of age) stroke survivors (>1 months to <1 year post stroke) with a completed stroke confirmed by a neurologist based on the history of a sudden onset of a neurological deficit lasting longer than 24 h, the presence of a neurological deficit upon physical examination, and a brain lesion compatible with the neurological deficit in computerised tomography or MRI of the brain were included. For evaluation of OSA, eligible patients underwent in hospital sleep studies. Therapy relevant OSA was defined as showing an AHI >15 per hour of sleep, indicating moderate sleep apnoea.
Exclusion criteria	Patients unable to understand the protocol due to cognitive impairments ;patients with COPD; chronic kidney disease >4; co-existing causes of daytime sleepiness; experiences of major psychiatric or any other acute medical condition; previously established PAP therapy; patients with central sleep apnoea; and patients unable or unwilling to comply with the protocol.
Recruitment/selection of patients	The study was conducted in Vienna, Austria from April 18 2016 to April 18 2018. All people with stroke referred to rehabilitation were initially included in the study.
Age, gender and ethnicity	Age: telemonitoring: 62.9 (5.3 years); control: 61.8 (5.3) years
	Gender: male: telemonitoring 64.7% : control: 75%
Further population details	1. BMI: telemonitoring: 30.9 kg/m ² (4.8) : control: 29 kg/m ² (3.1)

Study	Kotzian 2019 ⁴³
Study	2. AHI: telemonitoring: 37 (14.1): control: 37 (12.8)
Indirectness of population	No indirectness
Interventions	 (N=17)Intervention 1: tele medical monitoring system to improve CPAP adherence All patients referred to PAP therapy received a 30 min introductory lesson with nasal or oro-nasal mask fitting, device handling and information about PAP therapy. Patients were provide with an AirSendse 10 Autoset CPAP including humidifier and were set to auto-tirate at pressures between 6 and 13 cm H2D. Patients were motivated to use the PAP device for at least 4h of sleep/night. The PAP training period lasted at least one week, with bedside coaching in the moming and the evening. During the night the patients were coached by trained nurses. Relatives were also trained in using the humidifier and cleaning the mask and the humidifier chamber. The AHI, oximetry and leakage information were collected every day in coaching sessions with the patient. Pressure limits could be increased or decreased to improve patient confort. If the patient had problems to tolerate high pressures while falling asleep in the first week, the fixed window was reduced to sub-therapeutic pressures (e.g. 4-8 mbar) for a few nights to enable the patient to get used to therapy. If the Autoset PAP device did not react to obstructive events, titration was too slow or did not decrease; either a fixed CPAP or a narrow Auto CPAP window was attached. Those who tolerated PAP therapy with a median PAP use of >4h/night underwent PSG with PAP. The PAP coordinator at the homecare provider reviewed the downloaded information every morning except on weekends and holidays and contacted the patients if the 90th percentile of pressure was >16 com H20 or mask leakage of the 95th percentile was >24l/min or use was <4h or the AHI was >10 events/h for three consecutive days. (n=16) Intervention 2: Standard PAP treatment. No tele medical monitoring system Both groups: Patients were asked to call their homecare provider if any problems with the device occurred or their physician in case of medical problems.

Study	Kotzian 2019 ⁴³
Funding	This research did not receive any specific grant from funding agencies in the public, commercial, or not-for- profit sectors.
RESULTS (NUMBERS ANALYSED) AND RI Protocol outcome 1: Days PAP used >4 h	SK OF BIAS FOR COMPARISON: telemonitoring system versus no telemonitoring system
- Actual outcome : Days PAP used >4 h [mea	an SD] at 12 months; Group 1: n=12; 271 (99), Group 2: ; n=11; 282 (55) h,, Blinding - Low, Incomplete outcome data - high,, Outcome reporting - Low, Measurement - Low, Crossove

Risk of bias: All domain - high, Selection - high,, Blinding - Low, Incomplete outcome data - high,, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: serious; Group 1 Number missing: 5 (lost to follow up due to medical reason=1, discontinued intervention due to discomfort device =4), Group 2 Number missing: 5 (Lost to follow up due to medical reason = 2, discontinued intervention due to discomfort with device =3)

Protocol outcome 2: AHI

- Actual outcome: AHI [mean SD] at 12 months; Group 1: n=12 : 4.2 (3.9), Group 2 (n=11): 1.6 (1.3) Risk of bias: All domain - high,, Selection - high, Blinding - Low, Incomplete outcome data - high,, Outcome reporting - Low, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: serious; Group 1 Number missing: 5 (lost to follow up due to medical reason=1, discontinued intervention due to discomfort device =4), Group 2 Number missing: 5 (Lost to follow up due to medical reason = 2, discontinued intervention due to discomfort with device =3)

Protocol outcome 3: adherence

- Actual outcome : Mean adherence all days (min per day) [mean SD] at 12 months ; Group 1: n=12, 352 (97) Group 2: n=11, 307 (62) Risk of bias: All domain - high, Selection - high,, Blinding - Low, Incomplete outcome data - high, Outcome reporting - Low, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: serious; Group 1 Number missing: 5 (lost to follow up due to medical reason=1, discontinued intervention due to discomfort device =4), Group 2 Number missing: 5 (Lost to follow up due to medical reason = 2, discontinued intervention due to discomfort with device =3)

Protocol outcomes not reported by the study Protocol outcomes not reported by the study Driving outcomes at >1 month; Mortality at >1 month; Sleepiness score at >1 month;; CO2 control at >1 month; Driving outcomes at >1 month; self-reported adherence (continuous), mood or anxiety, withdrawals, treatment related withdrawals, oxygen desaturation index, minor adverse effects of treatment Neurocognitive outcomes at >1 month; Systolic blood pressure for hypertension at >1 month; HbA1c for diabetes at >1 month

OSAHS: DRAFT FOR CONSULTATION Adherence

Study	Murase 2020 ⁵⁷
Study type	RCT (Patient randomised)
Number of studies (number of participants)	1 (n=508)
Countries and setting	Conducted in Japan; Setting: hospital
Line of therapy	1st line
Duration of study	Intervention + follow up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	The criteria for patient inclusion were >18 years old; fulfilled the requirements for CPAP treatment under Japanese governmental health insurance (AHI>20/h by PSG or respiratory event index >40/h by portable monitoring device at OSA diagnosis; CPAP implemented more than 3 months previously; residual AHI under CPAP use<20/h; having clinic visits every month or every 2 months for follow-up of CPAP therapy; recent CPAP adherence data available.
Exclusion criteria	Not stated
Recruitment/selection of patients	Participants were consecutively recruited from patients who were regularly visiting hospitals or clinics for CPAP management.
Age, gender and ethnicity	Age: telemedicine group: 60 (11); control: 60 (13) years
	AHI: telemedicine: 40.6; control 40.6
	Gender: male%: telemedicine 87%; control 86.1%
Further population details	1. BMI: telemedicine: 27.4 kg/m ² (3.8); control: 27kg/m ² (5.4)

D		
2	Study	Murase 2020 ⁵⁷
		2. Sleepiness: ESS: telemedicine 5.7 (4.0); 4.9 (2.3)
0001	Indirectness of population	No indirectness
	Interventions	(n=161) Intervention 1: telemedicine group
hte.		Physician checked adherence data utilising the telemonitoring system.
roconia		Follow-every 3 months.
2		(3 months n= 166; 1 month, n=156) Intervention 2: No telemedicine
2		Follow-up 1 month and 3 months
1.3.3	Funding	Funding not stated
Notice of r	RESULTS (NUMBERS ANALYSED) AND RE	SK OF BIAS FOR COMPARISON: telemonitoring system versus no telemonitoring

Protocol outcome 1: adherence

- Actual outcome : CPAP use min/night ; Group 1: n= 161, 327(91); Group 2: n=166, 307 (107) Risk of bias: All domain - low, Selection - low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: no indirectness

Protocol outcomes not reported by the study Quality of life at >1 month; Mortality at >1 month; Sleepiness score at >1 month; AHI/RDI at >1 month; CO2 control at >1 month; Driving outcomes at >1 month; Neurocognitive outcomes at >1 month; Systolic blood pressure for hypertension at >1 month; HbA1c for diabetes at >1 month

Study	Nilius 2019 ⁶¹
Study type	RCT (Patient randomised)

Study	Nilius 2019 ⁶¹
Number of studies (number of participants)	1 (n=80)
Countries and setting	Conducted in Germany ; Setting: hospital
Line of therapy	1st line
Duration of study	Intervention + follow up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Moderate severe OSA
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients who had suffered an ischaemic stroke within last 3 months; a moderate to severe baseline OSA with an AHI>15, that had been confirmed in the sleep laboratory; physical capability to operate a PAP device and mask; age<75;CPAP naïve; no COPD; and regular PAP usage (<3h/night) during the inpatient phase.
Exclusion criteria	Not stated
Recruitment/selection of patients	Patients were informed about the study during the first anamnesis upon being admitted to hospital. In case of a positive diagnosis of moderate to severe sleep apnoea (AHI>15/h), the patients received a positive pressure device.
Age, gender and ethnicity	Age: telemedicine 55.4 (10.4) years; control: 58.6 (9.3) years
	Gender: all females
	ethnicity: not stated
Further population details	1. BMI: telemedicine 31.7 kg/m ² (5.4); control 30.1kg/m ² (6.6) ; Sleepiness ESS: telemedicine 2.4 (3.7); 3.9 (4.9); AHI: 41.2 (19); control: 37.6 (18.4)
Indirectness of population	No indirectness

Study	Nilius 2019 ⁶¹
Interventions	(n=37) Intervention 1: telemedicine
	Therapy was uniformly initiated in all eligible patients that is after a positive PSG., patients were visited by sleep lab staff, and a training session and mask adjustment followed before the initial therapy PSG. The device used was usually an APAP device set to a pressure 4-18 cm H20.
	The online data of the telemedicine group was anonymously transferred to the password protected web server each morning. The data was evaluated for relevant therapy details each week starting 7 days after the individual discharge date of each patient.
	(n=38) Intervention 2: No intervention – Standard care
	All patients went home with a PAP device and the sleep lab informed the homecare provider about the therapy settings and equipment. The patients were advised to visit their primary care physician or lung specialist if they experienced any problem.
	Follow-up 6 months
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: versus

Protocol outcome 1: Usage hours/night

- Actual outcome : ; Group 1: n=37, 4.4 (2.5); Group 2: ; n=38, 2.1 (2.2)

Risk of bias: All domain - low, Selection - low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: no indirectness .

Protocol outcome 2: ESS

- Actual outcome:; Group 1: n=36, 3.7 (3.2) Group 2: ; n=37, 6.1 (4.1)

Risk of bias: All domain - low, Selection - low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: no indirectness .

Protocol outcome 3: Systolic blood pressure-

Study

Nilius 2019⁶¹

- Actual outcome:; Group 1: n=26, 129.5 (15.2);Group 2: ; n=29, 138.8 (16.1)

Risk of bias: All domain - low, Selection - low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: no indirectness.

Protocol outcome 4: diastolic blood pressure-

- Actual outcome:; Group 1: n=26, G 78.4 (11.1); group 2: ; n=29, 82.8 (9.2) Risk of bias: All domain - low, Selection - low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover -Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: no indirectness.

Protocol outcomes not reported by the study Quality of life at >1 month; Mortality at >1 month; Driving outcomes at >1 month; Neurocognitive outcomes at >1 month; HbA1c for diabetes at >1 month

Appendix E: Forest plots

2 E.1 Adherence for CPAP

3 E.1.1 Behavioural therapy + CPAP versus control + CPAP – severe OSAHS

Figure 2: CPAP Device Usage (hours/night) (higher is better)

	Behavi	oural+C	PAP	cont	rol+CP	AP		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Aloia 2001	7.76	1.86	6	4.65	3.38	6	1.3%	3.11 [0.02, 6.20]	
Aloia 2013	4.34	2.35	62	3.65	2.36	55	17.1%	0.69 [-0.17, 1.55]	+ - -
Bakker 2016	4.4	2.9	41	3.3	2.7	42	8.6%	1.10 [-0.11, 2.31]	
Dantas 2015	6.2	1.3	20	5.1	1.4	20	17.8%	1.10 [0.26, 1.94]	_
Diaferia 2017	5.1	2.3	22	3.6	1.8	27	9.0%	1.50 [0.32, 2.68]	— • — ·
Lai 2014	4.4	1.8	49	2.4	2.3	51	19.2%	2.00 [1.19, 2.81]	
Olsen 2012	4.63	2.69	50	3.16	2.69	50	11.2%	1.47 [0.42, 2.52]	_
Sparrow 2010	2.4	2.5	110	1.48	2.5	112		Not estimable	
Wang 2012	3.7	2.3	38	2.6	1.6	38	15.8%	1.10 [0.21, 1.99]	
Total (95% CI)			288			289	100.0%	1.31 [0.95, 1.66]	•
	Heterogeneity: Chi ² = 6.89, df = 7 (P = 0.44); I ² = 0%								
Test for overall effect: Z = 7.24 (P < 0.00001)							Favours control+CPAP Favours behavioural+CPAP		

4

Figure 3: N deemed adherent (≥ four hours/night)

	behavioural	+CPAP	Control+	CPAP		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Aloia 2001	5	6	4	6	3.9%	1.25 [0.64, 2.44]		
Diaferia 2017	11	22	8	27	7.0%	1.69 [0.82, 3.45]		
Lai 2014	20	49	10	51	9.5%	2.08 [1.09, 3.99]		
Smith 2009	30	55	24	42	26.4%	0.95 [0.67, 1.36]		
Sparrow 2010	46	104	38	111	35.7%	1.29 [0.92, 1.81]		+=-
Wang 2012	26	38	18	38	17.5%	1.44 [0.97, 2.15]		+
Total (95% CI)		274		275	100.0%	1.33 [1.10, 1.61]		◆
Total events	138		102					
Heterogeneity: Chi ² =	5.81, df = 5 (P	= 0.32);	l²=14%				-	
Test for overall effect	Z = 2.97 (P = 1	0.003)					0.01	0.1 1 10 100 Favours Control+CPAP Favours behavioural+CPAP

5

Figure 4: Withdrawal

	behavioural	+CPAP	Control+	CPAP		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Aloia 2001	0	6	0	6		Not estimable	
Aloia 2013	11	73	19	74	27.0%	0.59 [0.30, 1.15]	_
Bakker 2016	3	41	2	42	2.8%	1.54 [0.27, 8.73]	
Dantas 2015	0	20	1	20	2.1%	0.33 [0.01, 7.72]	
Lai 2014	1	49	1	51	1.4%	1.04 [0.07, 16.18]	
Olsen 2012	5	53	7	53	10.0%	0.71 [0.24, 2.11]	
Scala 2012	0	13	0	15		Not estimable	
Smith 2009	11	55	13	42	21.1%	0.65 [0.32, 1.30]	
Sparrow 2010	14	124	14	126	19.9%	1.02 [0.51, 2.04]	+
Wang 2012	5	38	11	38	15.7%	0.45 [0.17, 1.18]	
Total (95% CI)		472		467	100.0%	0.70 [0.51, 0.98]	•
Total events	50		68				
Heterogeneity: Chi² = Test for overall effect			²=0%				0.01 0.1 1 10 100 Favours behavioural+CPAP Favours Control+CPAP

Figure 5: Epworth Sleepiness Scale (Endpoint scores) (0-24; higher is worse)


	behavio	oural+Cl	PAP	Cont	rol+CP	AP		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Scala 2012	5.3	4.5	13	12.5	4.6	15	11.1%	-7.20 [-10.58, -3.82]	·
Dantas 2015	3.7	4.1	20	7.1	3.2	20	16.4%	-3.40 [-5.68, -1.12]	
Lai 2017	7.3	4.8	49	8.9	4.7	51	18.9%	-1.60 [-3.46, 0.26]	
Olsen 2012	6	3.16	48	7.47	3.83	46	21.7%	-1.47 [-2.89, -0.05]	
Wang 2012	9.4	3.7	33	10.8	4.2	27	17.9%	-1.40 [-3.43, 0.63]	
Diaferia 2017	7.3	5.7	22	7.2	3.6	27	13.9%	0.10 [-2.64, 2.84]	
Total (95% CI)			185			186	100.0%	-2.22 [-3.68, -0.75]	◆
Heterogeneity: Tau ² =	2.04; Chi	² = 13.84	4, df = 5	(P = 0.0)	02); I 2 =	64%			
Test for overall effect:	Z = 2.97 (P = 0.00	3)						Favours behavioural+CPAP Favours control+CPAP

2

Figure 6: AHI on treatment – Endpoint (lower is better)

	behavio	ural+Cl	PAP	Contro	ol+CP	AP		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Dantas 2015	2.7	2.7	20	3.7	3.1	20	52.2%	-1.00 [-2.80, 0.80]	•
Diaferia 2017	3.4	2.7	22	4.3	4	27	47.8%	-0.90 [-2.78, 0.98]	•
Total (95% CI)			42			47	100.0%	-0.95 [-2.25, 0.35]	•
Heterogeneity: Chi ² = Test for overall effect:	•			= 0%					-100 -50 0 50 100 Favours behavioural+CPAP Favours control+CPAP

Figure 7: Quality of Life - Comparison of Values at Endpoint (FOSQ 5-20, higher is better) (SF- 36, 0-100, higher is better)



4 E.1.2 Educational interventions + CPAP versus usual care + CPAP- severe OSAHS

Figure 8: CPAP Device Usage (hours/night) (higher is better)

	Educa	ational+C	PAP	usual	care+C	PAP		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Aloia 2013	4.48	2.5	66	3.65	2.36	55	11.0%	0.83 [-0.04, 1.70]	
Basoglu 2011	5.5	1.2	66	5.1	1.6	67	14.7%	0.40 [-0.08, 0.88]	
Chervin 1997	7.1	1.8	14	4.4	3.4	7	2.7%	2.70 [0.01, 5.39]	
Falcone 2014	5.25	2.5	90	4.12	2.5	71	11.9%	1.13 [0.35, 1.91]	
Hwang 2017	4	2.4	163	3.8	2.5	129	13.9%	0.20 [-0.37, 0.77]	
Pengo 2018	3.065	2.4919	60	3.1	2.7	25	8.1%	-0.04 [-1.27, 1.20]	
Richards 2007	5.38	2.55	48	2.51	2.7	48	9.5%	2.87 [1.82, 3.92]	
Roecklein 2010	2.35	2.23	13	1.97	2.24	15	5.7%	0.38 [-1.28, 2.04]	
Sarac 2017	5.2	2.1	52	4.2	2.5	63	11.3%	1.00 [0.16, 1.84]	_
Wang 2012	3.4	2.1	38	2.6	1.6	38	11.3%	0.80 [-0.04, 1.64]	
Total (95% CI)			610			518	100.0%	0.88 [0.40, 1.36]	◆
Heterogeneity: Tau ² =	= 0.35; Cł	ni ≈ = 26.30), df = 9	(P = 0.00	12); I 2 = 6	66%		-	
Test for overall effect:	Z = 3.58	(P = 0.00	03)						-4 -2 U 2 4 Favours usual care+CPAP Favours educational+CPAP
									Favours usual cale+CFAF Favours educational+CFAF

5 6


Figure 9: N deemed adherent (≥ four hours/night)

_	Educational	+CPAP	usual care+	+CPAP		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl
Basoglu 2011	47	66	38	67	14.0%	1.26 [0.97, 1.63]		
Falcone 2014	87	90	50	71	22.7%	1.37 [1.17, 1.60]		+
Hwang 2017	100	163	69	129	18.3%	1.15 [0.94, 1.40]		
Richards 2007	37	48	15	48	6.4%	2.47 [1.58, 3.86]		
Sarac 2017	45	52	43	63	18.5%	1.27 [1.04, 1.55]		
Soares-Pires 2013	45	71	41	75	13.2%	1.16 [0.88, 1.52]		+
Wang 2012	23	38	18	38	7.0%	1.28 [0.84, 1.95]		+
Total (95% CI)		528		491	100.0%	1.31 [1.15, 1.48]		•
Total events	384		274					
Heterogeneity: Tau ² :	= 0.01; Chi ² = 1	0.66, df=	6 (P = 0.10);	I ² = 44%				
Test for overall effect	: Z= 4.18 (P < 0	0.0001)					0.01	0.1 1 10 100 Favours control+CPAP Favours educational+CPAP

Figure 10: Withdrawals

	Educational	CPAP	usual care+	CPAP		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
Aloia 2013	14	80	19	74	17.3%	0.68 [0.37, 1.26]	
Basoglu 2011	0	66	0	67		Not estimable	
Falcone 2014	13	103	32	103	18.3%	0.41 [0.23, 0.73]	
Hwang 2017	51	375	53	354	27.9%	0.91 [0.64, 1.30]	_ _
Richards 2007	2	50	2	50	2.9%	1.00 [0.15, 6.82]	
Roecklein 2010	1	14	1	16	1.5%	1.14 [0.08, 16.63]	
Sarac 2017	0	52	0	63		Not estimable	
Soares-Pires 2013	29	100	27	102	23.8%	1.10 [0.70, 1.71]	
Wang 2012	4	38	11	38	8.2%	0.36 [0.13, 1.04]	
Total (95% CI)		878		867	100.0%	0.73 [0.52, 1.02]	◆
Total events	114		145				
Heterogeneity: Tau ² =	= 0.07; Chi ² = 10	0.12, df=	6 (P = 0.12);	I ² = 41%			
Test for overall effect:	Z = 1.84 (P = 0	.07)					0.1 0.2 0.5 1 2 5 10 Favours educational+CPAP Favours usual care+CPAP

Figure 11: ESS – comparison of values at end point (0 to 24, higher is worse)



3


4 E.1.3 Increased practical support and encouragement during follow-up + CPAP 5 versus usual care + CPAP- severe OSAHS

Figure 12: CPAP Device Usage (hours/night) (higher is better)

	Increase	d support+	CPAP	usua	I care+CF	PAP		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Chervin 1997	5.7	2.3	12	4.4	3.4	7	1.6%	1.30 [-1.54, 4.14]	
DeMolles 2004	4.4	3	15	2.9	2.4	15	3.1%	1.50 [-0.44, 3.44]	
Fox 2012	3.18	2.45	28	1.75	1.97	26	6.2%	1.43 [0.25, 2.61]	
Hoet 2017	5.7	1.6	20	4.2	1.9	17	6.4%	1.50 [0.36, 2.64]	
Hoy 1999	5.4	1.8974	40	3.8	2.5298	40	7.5%	1.60 [0.62, 2.58]	
Hwang 2017	4.4	2.2	125	3.8	2.5	129	11.0%	0.60 [0.02, 1.18]	
Mendelson 2014	3.12	2.97	54	4.17	2.77	53	6.8%	-1.05 [-2.14, 0.04]	
Munafo 2016	5.1	1.9	58	4.7	2.1	64	9.8%	0.40 [-0.31, 1.11]	
Nilius 2019	4.4	2.5	37	2.1	2.2	38	6.9%	2.30 [1.23, 3.37]	
Parthasarathy 2012	4.35	2.6	22	3.4	2.6	15	3.8%	0.95 [-0.76, 2.66]	
Pepin 2019	5.28	2.23	157	4.75	2.5	149	11.5%	0.53 [-0.00, 1.06]	
Stepnowsky 2007	4.1	1.8	20	2.8	2.2	20	5.8%	1.30 [0.05, 2.55]	
Stepnowsky 2013	3.9	2.3	126	3.2	2.4	114	10.9%	0.70 [0.10, 1.30]	
Turino 2017	5.1	2.1	52	4.9	2.2	48	8.6%	0.20 [-0.64, 1.04]	
Total (95% CI)			766			735	100.0%	0.83 [0.45, 1.22]	•
Heterogeneity: Tau ² =	0.26; Chi ² =	29.44. df=	13 (P = 0).006); P	= 56%				
Test for overall effect: .			· · ·	-71 -					-2 -1 U 1 2
									Favours usual care+CPAP Favours increased support+CPAP

© NICE 2021. All rights reserved. Subject to Notice of rights.

Figure 13: Days PAP used >4 h at 12 months



2

1

Figure 14: Days PAP used >4 h at 3 months

	increased	support+	cpap	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Berry 2020	57.9	35.4	124	48.1	36.8	126	49.0%	9.80 [0.85, 18.75]	-8-
Hanger 2018	89.9	13.1	25	83.5	15.8	19	51.0%	6.40 [-2.37, 15.17]	+ - -
Total (95% CI)			149			145	100.0%	8.06 [1.80, 14.33]	◆
Heterogeneity: Chi ² = Test for overall effect:			I ² = 0%						-100 -50 0 50 100 Favours control Favours increased support+cpap

3

Figure 15: Mean adherence all days (min per day)

	Increased s	upport+C	PAP	usual c	are+Cl	PAP		Mean Difference		Mean D	ifference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixe	d, 95% Cl		
Kotzian 2019	352	97	12	307	62	11	100.0%	45.00 [-20.99, 110.99]					
Total (95% CI)			12			11	100.0%	45.00 [-20.99, 110.99]					
Heterogeneity: Not ap Test for overall effect:).18)							-100	-50 Favours usual care+CPAP	0 Favours increa	50 sed support+	100 CPAP

Figure 16: CPAP use min/night

	Increased s	upport+C	PAP	usual	care+Cl	PAP		Mean Difference		Mean D	ifference)	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixe	d, 95% Cl		
Murase 2019	327	91	161	307	107	166	100.0%	20.00 [-1.51, 41.51]					
Total (95% CI)			161			166	100.0%	20.00 [-1.51, 41.51]					
Heterogeneity: Not ap Test for overall effect:).07)							-100	 1 50 usual care+CPAP	0 Favour:	50 s increased su	100 pport+CPAP

Figure 17: N deemed adherent (≥ four hours/night)

	Increased suppor	t+CPAP	usual care+	ЮРАР		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
Hwang 2017	82	125	69	129	60.3%	1.23 [1.00, 1.51]	
Munafo 2016	48	58	47	64	39.7%	1.13 [0.93, 1.36]	+
Total (95% CI)		183		193	100.0%	1.19 [1.03, 1.37]	◆
Total events	130		116				
Heterogeneity: Chi² = Test for overall effect		3); I² = 0%					0.01 0.1 10 100 Favours usual care+CPAP Favours increased support+CPAP

4

Figure 18: Withdrawals

	Increased support	t+CPAP	usual care-	+CPAP		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
DeMolles 2004	0	15	0	15		Not estimable	
Fox 2012	11	39	10	36	8.9%	1.02 [0.49, 2.10]	
Hoet 2017	6	23	3	23	2.6%	2.00 [0.57, 7.05]	
Hoy 1999	0	40	0	40		Not estimable	
Hwang 2017	58	380	53	354	47.0%	1.02 [0.72, 1.44]	+
Mendelson 2014	14	54	11	53	9.5%	1.25 [0.62, 2.50]	+
vlunafo 2016	12	70	6	70	5.1%	2.00 [0.80, 5.03]	
Parthasarathy 2012	0	22	2	17	2.4%	0.16 [0.01, 3.06]	· · · · · · · · · · · · · · · · · · ·
Pepin 2019	40	157	27	149	23.7%	1.41 [0.91, 2.17]	+ - -
Stepnowsky 2007	4	21	1	24	0.8%	4.57 [0.55, 37.77]	
Turino 2017	0	52	0	48		Not estimable	
Total (95% CI)		873		829	100.0%	1.22 [0.97, 1.52]	◆
Total events	145		113				
Heterogeneity: Chi ² =	6.74, df = 7 (P = 0.46); l ² = 0%					
Test for overall effect:							0.01 0.1 1 10 100 Favours increased support+CPAP Favours usual care+CPAP

Figure 19: ESS score – end point and change from baseline (0-24; higher is worse)

	Increase	d support+	CPAP		Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
3.4.1 ESS: Endpoint §	Scores								
Berry 2020	8.9	5.4	120	8.3	5.5	120	10.4%	0.60 [-0.78, 1.98]	- -
DeMolles 2004	0	0	0	0	0	0		Not estimable	
Hanger 2018	4	2.7	25	6.5	4.1	19	4.4%	-2.50 [-4.63, -0.37]	
Hoy 1999	5.5	3.7947	40	6.3	5.0596	40	5.1%	-0.80 [-2.76, 1.16]	
Mendelson 2014	6.4	4.4	40	5.1	3.3	42	6.9%	1.30 [-0.39, 2.99]	+
Nilius 2019	3.7	3.2	36	6.1	4.1	37	7.0%	-2.40 [-4.08, -0.72]	
Parthasarathy 2012	7.1	4.7	22	8.1	4.3	17	2.5%	-1.00 [-3.83, 1.83]	
Pepin 2019	4.58	3.88	108	6.05	4.07	111	17.8%	-1.47 [-2.52, -0.42]	
Stepnowsky 2007	9.2	6.6	20	9.9	5.2	20	1.5%	-0.70 [-4.38, 2.98]	
Stepnowsky 2013	7.1	4.5	126	5.7	3.6	114	18.7%	1.40 [0.37, 2.43]	
Subtotal (95% CI)			537			520	74.3%	-0.27 [-0.78, 0.25]	•
3.4.2 ESS: Change fr									
Fox 2012	-1.6	5.1	28	-0.7	5.2	26	2.6%	-0.90 [-3.65, 1.85]	
Hwang 2017	-3.7	5.2	90	-3.7	4.7	83	9.1%	0.00 [-1.48, 1.48]	
Mendelson 2014	-2.3	4	40	-2.1	4.1	42	6.4%	-0.20 [-1.95, 1.55]	
Munafo 2016	-5.8	5.5	58	-5.1	5.9	64	4.8%	-0.70 [-2.72, 1.32]	
		5	22	-3	3.5	17	2.8%	-0.40 [-3.07, 2.27]	
	-3.4	5	238	Ŭ		232	25.7%	-0.32 [-1.19, 0.56]	◆
Parthasarathy 2012 Subtotal (95% CI) Heterogeneity: Chi ^z =		-	238	Ŭ		232	25.7%	-0.32 [-1.19, 0.56]	•
Subtotal (95% CI) Heterogeneity: Chi ² =	0.51, df = 4	(P = 0.97); I	238	Ū	0.0	232	25.7%	-0.32 [-1.19, 0.56]	•
Subtotal (95% CI)	0.51, df = 4	(P = 0.97); I	238	Ū				-0.32 [-1.19, 0.56] -0.28 [-0.73, 0.16]	
Subtotal (95% CI) Heterogeneity: Chi ² = Test for overall effect:	0.51, df = 4 Z = 0.71 (P =	(P = 0.97); I = 0.48)	238 ² = 0% 775	-					
Subtotal (95% Cl) Heterogeneity: Chi² = Test for overall effect: Total (95% Cl)	0.51, df = 4 Z = 0.71 (P = 31.47, df = 1	(P = 0.97); I = 0.48) 3 (P = 0.00	238 ² = 0% 775	-				-0.28 [-0.73, 0.16]	-10 -5 0 5 10 avours Increased support+CPAP Favours control

Figure 20: Quality of Life: Comparison of Values at Endpoint (FOSQ 5-20; higher is better, SF-36 0-100; higher is better)

3.5.1 QoL: FOSQ - Endpoint DeMolles 2004 18.1 2 Parthasarathy 2012 17.1 3 Stepnowsky 2007 15.2 Subtotal (95% CI) Heterogeneity: Chi ^p = 0.52, df = 2 (P = 0.7 Test for overall effect: Z = 0.79 (P = 0.43) 3.5.2 QoL: SAQLI - Endpoint Stepnowsky 2013 5.1 Subtotal (95% CI) Heterogeneity: Not applicable Test for overall effect: Z = 1.66 (P = 0.10) 3.5.3 QoL: SF-36 (PH) - Endpoint Hoy 1999 49 12.64/ Mendelson 2014 44.6 S	ort+CPAP	usua	I care+CP	AP		Mean Difference	Mean Difference
DeMolles 2004 18.1 2 Parthasarathy 2012 17.1 3 Stepnowsky 2007 15.2 3 Subtotal (95% CI) Heterogeneity: Chi² = 0.52, df = 2 (P = 0.7 1 Test for overall effect: Z = 0.79 (P = 0.43) 3.5.2 QoL: SAQLI - Endpoint 3 Subtotal (95% CI) Heterogeneity: Not applicable 5.1 3 Test for overall effect: Z = 1.66 (P = 0.10) 3.5.3 QoL: SF-36 (PH) - Endpoint 12.642 Mendelson 2014 44.6 9 9 12.642 Mendelson 2014 45.6 5 5 5 Subtotal (95% CI) Heterogeneity: Chi² = 1.71, df = 2 (P = 0.43) 5	SD Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Parthasarathy 2012 17.1 3 Stepnowsky 2007 15.2 Subtotal (95% CI) 15.2 Heterogeneity: Chi² = 0.52, df = 2 (P = 0.1 Test for overall effect: Z = 0.79 (P = 0.43) 3.5.2 QoL: SAQLI - Endpoint Stepnowsky 2013 Subtotal (95% CI) Heterogeneity: Not applicable Test for overall effect: Z = 1.66 (P = 0.10) 3.5.3 QoL: SF-36 (PH) - Endpoint Hoy 1999 49 12.642 Mendelson 2014 44.6 9 Pepin 2019 45.6 5 Subtotal (95% CI) Heterogeneity: Chi² = 1.71, df = 2 (P = 0.40)							
Stepnowsky 2007 15.2 Subtotal (95% CI) Heterogeneity: Chi ^P = 0.52, df = 2 (P = 0.79) Test for overall effect: Z = 0.79 (P = 0.43) 3.5.2 QoL: SAQLI - Endpoint Stepnowsky 2013 5.1 Subtotal (95% CI) Heterogeneity: Not applicable Test for overall effect: Z = 1.66 (P = 0.10) 3.5.3 QoL: SF-36 (PH) - Endpoint Hoy 1999 49 12.642 Mendelson 2014 44.6 9 Pepin 2019 45.6 5 Subtotal (95% CI) Heterogeneity: Chi ^P = 1.71, df = 2 (P = 0.40)	.8 15	17	3.7	15	33.4%	1.10 [-1.25, 3.45]	
Subtotal (95% CI) Heterogeneity: Chi ² = 0.52, df = 2 (P = 0.7 Test for overall effect: Z = 0.79 (P = 0.43) 3.5.2 QoL: SAQLI - Endpoint Stepnowsky 2013 5.1 Subtotal (95% CI) Heterogeneity: Not applicable Test for overall effect: Z = 1.66 (P = 0.10) 3.5.3 QoL: SF-36 (PH) - Endpoint Hoy 1999 49 12.64% Mendelson 2014 44.6 Subtotal (95% CI) Heterogeneity: Chi ² = 1.71, df = 2 (P = 0.4)	.5 22	17.1	3	17	44.1%	0.00 [-2.04, 2.04]	•
Heterogeneity: Chi ^P = 0.52, df = 2 (P = 0.7 Test for overall effect: Z = 0.79 (P = 0.43) 3.5.2 QoL: SAQLI - Endpoint Stepnowsky 2013 5.1 Subtotal (95% CI) Heterogeneity: Not applicable Test for overall effect: Z = 1.66 (P = 0.10) 3.5.3 QoL: SF-36 (PH) - Endpoint Hoy 1999 49 12.644 Mendelson 2014 44.6 Subtotal (95% CI) Heterogeneity: Chi ^P = 1.71, df = 2 (P = 0.45)	5 20	14.4	4.2	20	22.5%	0.80 [-2.06, 3.66]	
Test for overall effect: Z = 0.79 (P = 0.43) 3.5.2 QoL: SAQLI - Endpoint Stepnowsky 2013 5.1 Subtotal (95% CI) Heterogeneity: Not applicable Test for overall effect: Z = 1.66 (P = 0.10) 3.5.3 QoL: SF-36 (PH) - Endpoint Hoy 1999 49 Mendelson 2014 44.6 Pepin 2019 45.6 Subtotal (95% CI) Heterogeneity: ChiP = 1.71, df = 2 (P = 0.4)	57			52	100.0%	0.55 [-0.81, 1.90]	
3.5.2 QoL: SAQLI - Endpoint Stepnowsky 2013 5.1 Subtotal (95% Cl) Heterogeneity: Not applicable Test for overall effect: Z = 1.66 (P = 0.10) 3.5.3 QoL: SF-36 (PH) - Endpoint Hoy 1999 49 Mendelson 2014 44.6 Pepin 2019 45.6 Subtotal (95% Cl) Heterogeneity: Chi ^P = 1.71, df = 2 (P = 0.4)							
Stepnowsky 2013 5.1 Subtotal (95% CI) Heterogeneity: Not applicable Test for overall effect: Z = 1.66 (P = 0.10) 3.5.3 QoL: SF-36 (PH) - Endpoint Hoy 1999 49 Mendelson 2014 44.6 Pepin 2019 45.6 Subtotal (95% CI) Heterogeneity: Chi ^P = 1.71, df = 2 (P = 0.4)							
Subtotal (95% CI) Heterogeneity: Not applicable Test for overall effect: Z = 1.66 (P = 0.10) 3.5.3 QoL: SF-36 (PH) - Endpoint Hoy 1999 49 Hoy 1999 49 Pepin 2014 44.6 Pepin 2019 45.6 Subtotal (95% CI) Heterogeneity: Chi² = 1.71, df = 2 (P = 0.4)							
Heterogeneity: Not applicable Test for overall effect: Z = 1.66 (P = 0.10) 3.5.3 QoL: SF-36 (PH) - Endpoint Hoy 1999 49 Mendelson 2014 44.6 Pepin 2019 45.6 Subtotal (95% CI) Heterogeneity: Chi² = 1.71, df = 2 (P = 0.4)	2 126		2.6	114	100.0%	0.50 [-0.09, 1.09]	+
Test for overall effect: Z = 1.66 (P = 0.10) 3.5.3 QoL: SF-36 (PH) - Endpoint Hoy 1999 49 Hoy 1999 49 Pendelson 2014 44.6 Pepin 2019 45.6 Subtotal (95% CI) Heterogeneity: Chi² = 1.71, df = 2 (P = 0.4)	126			114	100.0%	0.50 [-0.09, 1.09]	
3.5.3 QoL: SF-36 (PH) - Endpoint Hoy 1999 49 12.64 Mendelson 2014 44.6 9 Pepin 2019 45.6 5 Subtotal (95% CI) Heterogeneity: Chi ² = 1.71, df = 2 (P = 0.4)							
Hoy 1999 49 12.64// Mendelson 2014 44.6 9 Pepin 2019 45.6 5 Subtotal (95% CI) Heterogeneity: Chi² = 1.71, df = 2 (P = 0.4)							
Mendelson 2014 44.6 9 Pepin 2019 45.6 5 Subtotal (95% CI) Heterogeneity: Chi² = 1.71, df = 2 (P = 0.4)							
Pepin 2019 45.6 5 Subtotal (95% CI) Heterogeneity: Chi ² = 1.71, df = 2 (P = 0.4	31 40	48	12.6491	40	6.7%	1.00 [-4.54, 6.54]	• •
Subtotal (95% CI) Heterogeneity: Chi ² = 1.71, df = 2 (P = 0.4	.4 40	45.9	8.5	42	13.6%	-1.30 [-5.19, 2.59]	• • • • • • • • • • • • • • • • • • •
Heterogeneity: Chi ² = 1.71, df = 2 (P = 0.4	.3 80	44.1	5.4	92	79.8%	1.50 [-0.10, 3.10]	_
	160			174	100.0%	1.09 [-0.34, 2.52]	
Test for overall effect: Z = 1.49 (P = 0.14)	I3); I² = 0%						
							-2 -1 0 1 2
Test for subgroup differences: Chi² = 0.5	5 df= 0 /D =	0.763 18	- 00				Favours [control] Favours [experimental]

Figure 21: Quality of Life: Comparison of Change from Baseline Values(FOSQ, 5-20; higher is better, SF-36 0-100; higher is better)

	Increased	support+C	PAP	usual	care+C	PAP		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
3.6.1 QoL: FOSQ - Ch	ange from Ba	seline							
Parthasarathy 2012 Subtotal (95% CI)	1.9	3.4	22 22	1.1	3.1	17 17		0.80 [-1.25, 2.85] 0.80 [-1.25, 2.85]	
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 0.77 (P = 1	0.44)							
3.6.2 QoL: SF-36 (PH)	- Change froi	m Baseline	e						
Mendelson 2014 Subtotal (95% CI)	3.2	8.6	40 40	2.9	7	42 42		0.30 [-3.10, 3.70] 0.30 [-3.10, 3.70]	
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 0.17 (P = 0	D.86)							
3.6.3 QoL: FOSQ-10 -	Change from	Baseline							
Hwang 2017 Subtotal (95% CI)	-10.9	11.2	90 90	-14.2	10.3	83 83		3.30 [0.10, 6.50] 3.30 [0.10, 6.50]	
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 2.02 (P = 0	0.04)							
									-50 -25 0 25 5
									Favours usual care+CPAP Favours increased support+CPAP

Test for subgroup differences: $Chi^2 = 2.06$, df = 2 (P = 0.36), $i^2 = 2.8\%$

Figure 22: diastolic blood pressure

	Increased	support+(CPAP	usual	care+Cl	PAP		Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI	
Nilius 2019	78.4	11.1	26	82.8	9.2	29	100.0%	-4.40 [-9.82, 1.02]	· ·	
Total (95% CI)			26			29	100.0%	-4.40 [-9.82, 1.02]	•	
Heterogeneity: Not ap Test for overall effect:		0.11)							-100 -50 0 50 Favours increased support+CPAP Favours usual care+CPAP	100

3


4

© NICE 2021. All rights reserved. Subject to Notice of rights.

Figure 23: systolic blood pressure

	Increased	support+0	PAP	usual	care+C	PAP		Mean Difference		Mear	Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fi	xed, 95% Cl		
Nilius 2019	129.5	15.2	26	138.8	16.1	29	100.0%	-9.30 [-17.57, -1.03]		-			
Total (95% CI)			26			29	100.0%	-9.30 [-17.57, -1.03]					
Heterogeneity: Not ap Test for overall effect:		0.03)							-100 Favours incr	-50 eased support+CP/	0 NP Favours u	50 sual care+CPAP	100

Figure 24: AHI on treatment- comparison of values at end point (lower is better)



3

4 E.1.4 Mixed (SUP/EDU/BEH) Intervention + CPAP versus Usual Care + CPAP- severe 5 OSAHS

Figure 25: CPAP Device Usage (hours/night) (higher is better)

	Mix	ed+CPA	0	usua	care+CF	PAP		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Bartlett 2013	3.5	2.57	109	4.1	2.74	97	10.1%	-0.60 [-1.33, 0.13]	
Bouloukaki 2014	6.9	1.8	1550	5.2	2.2	1550	11.6%	1.70 [1.56, 1.84]	+
Chen 2015	6.41	1.3	40	4.2	1.2	40	10.7%	2.21 [1.66, 2.76]	
Hui 2000	5.3	1.4697	54	5.3	2.2045	54	10.1%	0.00 [-0.71, 0.71]	
Hwang 2017	4.8	2.3	138	3.8	2.5	129	10.6%	1.00 [0.42, 1.58]	
Lewis 2006	4.9	0	32	4.5	0	26		Not estimable	
Meurice 2007	5.1176	2.3664	85	4.7	2.4	27	8.8%	0.42 [-0.62, 1.45]	
Sawyer 2017	4.8	2.27	30	4.7	1.85	30	8.7%	0.10 [-0.95, 1.15]	
Sedkaoui 2015	4.57	2.28	188	4.13	2.42	189	10.9%	0.44 [-0.03, 0.91]	
Shapiro 2017	5.4	1.8	32	5.5	2.5	33	8.7%	-0.10 [-1.16, 0.96]	
Wang 2012	5.2	2	38	2.6	1.6	38	9.7%	2.60 [1.79, 3.41]	
Total (95% CI)			2264			2187	100.0%	0.82 [0.20, 1.43]	-
Heterogeneity: Tau ² =	= 0.84; Ch	i ² = 111.8	3. df =	9 (P < 0	.00001); I	² = 92%		-	
Test for overall effect:	Z = 2.61	(P = 0.00	9)						-2 -1 U 1 2 Favours usual care+CPAP Favours mixed+CPAP

6

Figure 26:

N deemed adherent (≥ four hours/night)

	Mixed+(CPAP	usual care+	+CPAP		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Bartlett 2013	55	109	54	97	9.3%	0.91 [0.70, 1.17]	
Bouloukaki 2014	1389	1497	1069	1339	28.4%	1.16 [1.13, 1.20]	•
Hui 2000	40	54	38	54	10.5%	1.05 [0.83, 1.33]	+
Hwang 2017	101	138	69	129	13.5%	1.37 [1.13, 1.65]	-
Sawyer 2017	19	30	20	30	5.3%	0.95 [0.66, 1.38]	
Sedkaoui 2015	141	188	124	189	18.7%	1.14 [1.00, 1.30]	-
Shapiro 2017	23	33	25	33	7.6%	0.92 [0.68, 1.24]	
Smith 2006	9	10	4	9	1.5%	2.02 [0.95, 4.33]	
Wang 2012	30	38	18	38	5.3%	1.67 [1.15, 2.42]	
Total (95% CI)		2097		1918	100.0%	1.14 [1.04, 1.26]	•
Total events	1807		1421				
Heterogeneity: Tau ² :	= 0.01; Chi ^a	² = 16.3	1, df = 8 (P = (0.04); I ² =	: 51%		
Test for overall effect							0.01 0.1 1 10 100 Favours usual care+CPAP Favours mixed+CPAP

Figure 27: Withdrawal

	Mixed+(CPAP	usual care+	CPAP		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Bartlett 2013	10	109	19	97	14.4%	0.47 [0.23, 0.96]	
Bouloukaki 2014	53	1550	211	1550	16.5%	0.25 [0.19, 0.34]	
Hui 2000	9	54	2	54	9.5%	4.50 [1.02, 19.87]	
Hwang 2017	57	346	53	354	16.4%	1.10 [0.78, 1.55]	
Lewis 2006	4	36	10	36	12.1%	0.40 [0.14, 1.16]	
Meurice 2007	0	85	0	27		Not estimable	
Sawyer 2017	7	61	8	57	12.9%	0.82 [0.32, 2.11]	
Sedkaoui 2015	1	189	1	190	4.6%	1.01 [0.06, 15.95]	
Shapiro 2017	1	33	0	33	3.7%	3.00 [0.13, 71.07]	
Smith 2006	0	10	0	9		Not estimable	
Wang 2012	2	38	11	38	9.8%	0.18 [0.04, 0.77]	
Total (95% CI)		2511		2445	100.0%	0.64 [0.32, 1.28]	-
Total events	144		315				
Heterogeneity: Tau ² =	= 0.73; Chi ^a	² = 55.1	0, df = 8 (P < I	0.00001)	; I ^z = 85%		
Test for overall effect							0.01 0.1 1 10 100 Favours mixed+CPAP Favours usual care+CPAP
							Favours mixed+GFAF Favours usual care+GFAF

Figure 28: Quality of Life: Comparison of Change from Baseline Values (FOSQ, 5-20; higher is better, SF-36 0-100; higher is better)




Figure 29: Quality of Life: Comparison of Values at Endpoint (FOSQ, 5-20; higher is better, SF-36 0-100; higher is better)

	Mixe	ed+CPAP)	usual	care+Cl	PAP		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
4.5.1 QoL: FOSQ - En	dpoint								
Bartlett 2013	17	2.9	99	16.7	2.9	78	100.0%	0.30 [-0.56, 1.16]	
Subtotal (95% CI)			99			78	100.0%	0.30 [-0.56, 1.16]	*
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 0.68 (F	^o = 0.49)							
4.5.2 QoL: SF-36 (PH)	- Endpoin	t							
Bouloukaki 2014	86.3	6.2	1497	81.7	18.2	1339	47.2%	4.60 [3.58, 5.62]	
Chen 2015	50	5	40	43	5	40	35.8%	7.00 [4.81, 9.19]	
Meurice 2007	47.0351	7.9229	74	46	10.8	24	17.0%	1.04 [-3.65, 5.72]	
Subtotal (95% CI)			1611			1403	100.0%	4.85 [2.49, 7.21]	
Heterogeneity: Tau ² =	2.79; Chi ^z	= 6.47, c	if = 2 (P	= 0.04);	l [≈] = 699	6			
Test for overall effect:	Z = 4.03 (F	P < 0.000	1)						
									-10 -5 0 5 1
									Favours usual care+CPAP Favours mixed+CPAP

Test for subgroup differences: Chi² = 12.63, df = 1 (P = 0.0004), l² = 92.1%

© NICE 2021. All rights reserved. Subject to Notice of rights.

1

Figure 30: ESS score (0-24; higher is worse)

	Mix	ed+CPAF		usual (care+C	DΔD		Mean Difference	Mean Difference
Study or Subgroup	Mean		Total		SD		Weight	IV, Random, 95% CI	IV, Random, 95% Cl
4.8.1 ESS: Endpoint !		30	Total	mean	30	Total	Teight	rv, rundom, 55% cr	14, Mandolli, 557/Cl
Bartlett 2013	7.77	4.7	99	7.6	4.5	78	11.8%	0.17 [-1.19, 1.53]	
Bouloukaki 2014	4.2	4.7	1497	7.0	4.3	1339	14.1%	-3.00 [-3.24, -2.76]	-
Chen 2015	10.3	1.35	40	11.2	1.65	40	13.5%	-0.90 [-1.56, -0.24]	
Meurice 2007	6.2188		40 85	5.2	4.1	40	10.3%	1.02 [-0.87, 2.91]	
	7.3	3.2		5.2 10.8	4.1	27	10.3%	• • •	
Wang 2012 Subtotal (95% CI)	1.3	3.2	1757	10.8	4.2	1511	60.0%	-3.50 [-5.40, -1.60] - 1.29 [-2.86, 0.28]	
	- 2 75. OK	3 - 66 50		/D = 0.00	0043-8			-1.20 [-2.00, 0.20]	
Heterogeneity: Tau ² =				(P < 0.00	JUU1); P	-= 94%			
Test for overall effect:	2 = 1.61 ((P = 0.11))						
4.8.2 ESS: Change fr	om Basel	ine							
Bouloukaki 2014	-8.1	6	1497	-4.3	6.1	1339	13.9%	-3.80 [-4.25, -3.35]	_ _
Hui 2000	-8.1	0.8	54	-7.4	0.8	54	14.0%	-0.70 [-1.00, -0.40]	
Hwang 2017	-3	3.7	93	-3.7	4.7	83	12.1%	0.70 [-0.56, 1.96]	
Subtotal (95% CI)	-		1644			1476		-1.31 [-3.78, 1.15]	
Heterogeneity: Tau ² =	= 4 59° Chi	i ² = 140.3	2 df=	2 (P < 0 (100011	I ² = 999	6		
Test for overall effect:				- (* ***					
restion overall check	. 2 - 1.04 ((1 = 0.00)	, 						
Total (95% CI)			3401			2987	100.0%	-1.32 [-2.48, -0.16]	
Heterogeneity: Tau ² =	= 2.48° Chi	i ² = 245 1	= th O	7 (P < 0 (100011				
Test for overall effect:				r (r - 0.)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1 - 373			-4 -2 0 2 4
Test for subgroup dif		• •		1 /0 - 0	00\ 12-	006			Favours mixed+CPAP Favours usual care+CPAP
rescior subgroup di	ierences.	Cni== 0.0	50, ai =	1 (P = 0.	99), IT =	0.70			

4

Appendix F: GRADE tables

Table 11: Clinical evidence profile: Behavioural therapy + CPAP versus control + CPAP - severe OSAHS

			Quality as	sessment			No of patients			Effect		
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Behavioural therapy + CPAP versus control + CPAP	Control	Relative (95% Cl)	Absolute	Quality	Importance
CPAP Dev	vice Usage (h	ours/nig	ht) (Better indicat	ted by higher v	alues)	1						
-	randomised trials		no serious inconsistency	serious indirectness ⁴	serious ²	None	288	289 Median: 3.65	-	MD 1.31 higher (0.95 to 1.66 higher)	⊕OOO VERY LOW	CRITICAL
N deemec	l adherent (≥	four hou	rs/night)									
	randomised trials		no serious inconsistency	serious indirectness ⁴	serious ²	None	138/274 (50.4%)	40.8%	RR 1.33 (1.1 to 1.61)	135 more per 1000 (from 41 more to 249 more)	⊕000 VERY LOW	CRITICAL
Withdraw	al	Į	1	1	1	1						
-	randomised trials		no serious inconsistency	serious indirectness ⁴	serious ²	None	50/472 (10.6%)	8.1%	RR 0.7 (0.51 to 0.98)	24 fewer per 1000 (from 2 fewer to 40 fewer)	⊕000 VERY LOW	IMPORTAN

6	randomised trials	serious ¹	serious ³	serious indirectness ⁴	serious ²	None	185	186	-	MD 2.22 lower (3.68 to 0.75 lower)	⊕OOO VERY LOW	IMPORTANT
AHI on tr	eatment - Enc	lpoint (Be	etter indicated by	lower values)								
2	randomised trials		no serious inconsistency	serious indirectness ⁴	very serious ²	None	42	47	-	MD 0.95 lower (2.25 lower to 0.35 higher)	⊕000 VERY LOW	IMPORTANT
Quality o	f Life - Compa	arison of	Values at Endpo	int FOSQ (PH) (Better indicate	d by higher value	s)					
2	randomised trials		no serious inconsistency	serious ⁴	no serious imprecision	None	99	101	-	MD 0 higher (0.15 lower to 0.16 higher)	⊕⊕OO LOW	CRITICAL
Quality o	f Life - Compa	arison of	Values at Endpo	int SF-36 (PH) (Better indicate	d by higher value	s)	I	1			1
1	randomised trials		no serious inconsistency	serious ⁴	no serious imprecision	None	13	15	-	MD 1.1 lower (11.46 lower to 9.26 higher)	⊕⊕OO LOW	CRITICAL
Mortality												
Not reported												CRITICAL

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias 2 Downgraded by one increment if the confidence interval crossed one MID and downgraded by two increments if the confidence interval crossed both MIDs. MID for machine usage (adherence)- 1 hour ; Established MIDs for SF-36 physical/mental- 2/3 ; FOSQ- 2 ; ESS -2.5;SAQLI – 2. GRADE default MID (0.5XSD)used for all other continuous outcomes. 3 Downgraded by 1 or 2 increments for heterogeneity, unexplained by subgroup analysis . Random effect analysis used.

4 Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively

Table 12: Clinical evidence profile: Educational interventions + CPAP versus usual care + CPAP - severe OSAHS

			Quality as:	sessment			No of patients			Effect		
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Educational interventions + CPAP versus usual care + CPAP	Control	Relative (95% Cl)	Absolute	Quality	Importance
CPAP De	vice Usage (I	hours/nig	ht) (Better indica	ted by higher v	values)							
10	randomised trials	serious ¹	serious ²	serious indirectness ⁴	serious ³	None	610	518	-	MD 0.88 higher (0.4 to 1.36 higher)	⊕OOO VERY LOW	CRITICAL
N deeme	d adherent (≥	four hou	rs/night)									
7	randomised trials	serious ¹	no serious inconsistency	serious indirectness ⁴	serious ³	None	384/528 (72.7%)	54.7%	RR 1.31 (1.15 to 1.48)	170 more per 1000 (from 82 more to 263 more)	⊕000 VERY LOW	CRITICAL
Withdraw	val	I	I	I	I	I					I	L
9	randomised trials	serious ¹	no serious inconsistency	serious indirectness ⁴	no serious imprecision	None	114/878 (13%)	15%	RR 0.73 (0.52 to 1.02)	41 fewer per 1000 (from 72 fewer to 3 more)	⊕⊕OO LOW	IMPORTAN
Epworth	Sleepiness S	cale - Co	mparison of Valu	es at Endpoint	- (Better indica	ted by lower valu	es)	<u> </u>		I	<u> </u>	<u> </u>
3	randomised trials		no serious inconsistency	serious indirectness ⁴	no serious imprecision	None	190	165	-	MD 0.08 lower (0.92 lower to 0.76 higher)		IMPORTAN
Mortality	I			1	1	L		ı			1	

Not reported												CRITICAL	
-----------------	--	--	--	--	--	--	--	--	--	--	--	----------	--

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias ² Downgraded by 1 or 2 increments for heterogeneity, unexplained by subgroup analysis. Random effect analysis used.

³ Downgraded by one increment if the confidence interval crossed one MID and downgraded by two increments if the confidence interval crossed both MIDs. MID for machine usage (adherence)- 1 hour ; Established MIDs for SF-36 physical/mental- 2/3 ; FOSQ- 2 ; ESS -2.5;SAQLI – 2. GRADE default MID (0.5XSD)used for all other continuous outcomes.

4 Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively

Table 13: Clinical evidence profile: Increased practical support and encouragement during follow-up + CPAP versus usual care + CPAP - severe OSAHS

			Quality ass	essment			No of patients		1	Effect		
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Othor	Increased practical support and encouragement during follow-up + CPAP versus usual care + CPAP		Relative (95% Cl)	Absolute	Quality	Importance
CPAP D	evice Usage	(hours/ni	ght) (Better indica	ated by lower v	values)					·		
4	randomised trials	serious ¹	serious ³	no serious indirectness	serious ²	None	766	735	-	MD 0.83 higher (0.45 to 1.22 higher)	⊕000 VERY LOW	CRITICAL
Days PA	P used >4 h	ours at 12	months (Better i	ndicated by hi	gher values)				ł			
		no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ²	None	12	11	-	MD 11 lower (75.76 lower to 53.76 higher)	⊕⊕OO LOW	CRITICAL

2		no serious risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	None	149	145	-	MD 8.06 higher (1.80 to 14.33 higher)	⊕⊕⊕⊕ HIGH	CRITICAL
Mean a	dherence all o	days (min	per day) at 12 m	onths (Better i	ndicated by hig	jher values)						
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ²	None	12	11	-	MD 45 higher (20.99 lower to 110.99 higher)	⊕⊕⊕O MODERA TE	CRITICAL
CPAP	use min/night	(Better in	dicated by highe	r values)								
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	None	161	166	-	MD 20 higher (1.51 lower to 41.51 higher)	⊕⊕⊕⊕ HIGH	CRITICAL
N deen	ned adherent ((≥ four ho	urs/night)			l						
2	randomised trials	serious ¹	no serious inconsistency	serious indirectness ⁴	serious ²	None	130/183 (71%)	63.5%	RR 1.19 (1.03 to 1.37)	121 more per 1000 (from 19 more to 235 more)	⊕000 VERY LOW	CRITICAL
Withdr	awals	<u></u>	1	1	1	1	L	<u> </u>				<u> </u>
11	randomised trials	serious ¹	no serious inconsistency	serious indirectness ⁴	serious ²	None	145/873 (16.6%)	11.8%	RR 1.22 (0.97 to 1.52)	26 more per 1000 (from 4 fewer to 61 more)	⊕OOO VERY LOW	IMPORTAN

	1		1						-		
randomised trials	serious ¹	serious ³	no serious indirectness	no serious imprecision	None	775	752	-	MD 0.28 lower (0.73 lower to 0.16 higher)	⊕⊕OO LOW	IMPORTANT
of Life: Com	parison of	Values at Endpo	int - QoL: FOS	Q - Endpoint (I	Better indicated I	by higher values)	•		•		
randomised trials	serious ¹	no serious inconsistency	serious ⁴	no serious imprecision	None	57	52	-	MD 0.55 higher (0.81 lower to 1.9 higher)	⊕⊕OO LOW	CRITICAL
of Life: Com	parison of	Values at Endpo	int - QoL: SAQ	LI - Endpoint (Better indicated	by higher values)					
randomised trials	serious ¹	no serious inconsistency	serious ⁴	no serious imprecision	None	126	114	-	MD 0.5 higher (0.09 lower to 1.09 higher)	⊕⊕OO LOW	CRITICAL
of Life: Com	parison of	Values at Endpo	int - QoL: SF-3	6 (PH) - Endpo	oint (Better indica	ited by higher values)			· /		
randomised trials	serious ¹	no serious inconsistency	serious ⁴	serious ²	None	160	174	-	MD 1.09 higher (0.34 lower to 2.52 higher)	⊕OOO VERY LOW	CRITICAL
of Life: Com	parison of	Change from Ba	seline Values -	QoL: FOSQ -	Change from Bas	seline (Better indicated by hig	her valu	es)	II		
randomised trials	serious ¹	no serious inconsistency	serious ⁴	serious ²	None	22	17	-	MD 0.8 higher (1.25 lower to 2.85 higher)	⊕OOO VERY LOW	CRITICAL
of Life: Com	parison of	Change from Ba	seline Values -	- QoL: SF-36 (F	PH) - Change fron	n Baseline (Better indicated b	y higher	values)	II		
randomised trials	serious ¹	no serious inconsistency	serious ⁴	very serious ²	None	40	42	-	MD 0.3 higher (3.1 lower to 3.7 higher)	⊕000 VERY LOW	CRITICAL
	trials of Life: Comp randomised trials of Life: Comp randomised trials of Life: Comp randomised trials of Life: Comp randomised trials	of Life: Comparison of randomised serious ¹ of Life: Comparison of randomised serious ¹ randomised serious ¹ randomised serious ¹ of Life: Comparison of randomised serious ¹ of Life: Comparison of randomised serious ¹ randomised serious ¹	trialsof Life: Comparison of Values at Endporandomised trialsserious1no serious inconsistencyof Life: Comparison of Change from Baserandomised trialsserious1no serious inconsistency	trialsindirectnessof Life: Comparison of Values at Endpoint - QoL: FOSrandomised trialsserious1no serious inconsistencyserious4of Life: Comparison of Values at Endpoint - QoL: SAQrandomised trialsserious1no serious inconsistencyserious4of Life: Comparison of Values at Endpoint - QoL: SF-3randomised trialsserious1no serious inconsistencyserious4of Life: Comparison of Values at Endpoint - QoL: SF-3randomised trialsserious1no serious inconsistencyserious4of Life: Comparison of Change from Baseline Values - inconsistencyserious4randomised trialsserious1no serious inconsistencyserious4of Life: Comparison of Change from Baseline Values - inconsistencyserious4randomised trialsserious1no serious inconsistencyserious4of Life: Comparison of Change from Baseline Values - inconsistencyserious4of Life: Comparison of Change from Baseline Values - inconsistencyserious4	trialsindirectnessimprecisionof Life: Comparison of Values at Endpoint - QoL: FOSQ - Endpoint (randomisedserious1no seriousinconsistencyserious4no seriousof Life: Comparison of Values at Endpoint - QoL: SAQLI - Endpoint (randomisedserious1no serioustrialsserious1no seriousinconsistencyserious4no seriousinconsistencyserious4no seriousof Life: Comparison of Values at Endpoint - QoL: SF-36 (PH) - Endpointof Life: Comparison of Values at Endpoint - QoL: SF-36 (PH) - Endpointrandomisedserious1no seriousserious4serious2of Life: Comparison of Change from Baseline Values - QoL: FOSQ -randomisedserious1no seriousrandomisedserious1no seriousserious4serious2of Life: Comparison of Change from Baseline Values - QoL: FOSQ -randomisedserious1no seriousserious4trialsserious1no seriousserious4serious2of Life: Comparison of Change from Baseline Values - QoL: SF-36 (Frandomisedserious1no seriousserious4trialsserious1no seriousserious4serious2of Life: Comparison of Change from Baseline Values - QoL: SF-36 (Frandomisedserious1no seriousserious4trialsserious1no seriousserious4	trialsindirectnessimprecisionof Life: Comparison of Values at Endpoint - QoL: FOSQ - Endpoint (Better indicated I randomised serious1 no serious inconsistencyno serious2 imprecisionNoneof Life: Comparison of Values at Endpoint - QoL: SAQLI - Endpoint (Better indicated randomised serious1 no serious inconsistencyno serious2 imprecisionNoneof Life: Comparison of Values at Endpoint - QoL: SAQLI - Endpoint (Better indicated trialsno serious3 inconsistencyserious4 imprecisionNoneof Life: Comparison of Values at Endpoint - QoL: SF-36 (PH) - Endpoint (Better indicated inconsistencyno serious4 imprecisionNoneof Life: Comparison of Values at Endpoint - QoL: SF-36 (PH) - Endpoint (Better indicated trialsno serious1 inconsistencyserious4 serious2 Noneof Life: Comparison of Values at Endpoint - QoL: SF-36 (PH) - Endpoint (Better indicated inconsistencyserious4 serious2 NoneNoneof Life: Comparison of Change from Baseline Values - QoL: FOSQ - Change from Baseline trialsserious2 NoneNoneof Life: Comparison of Change from Baseline Values - QoL: SF-36 (PH) - Change from inconsistencyserious4 serious2 Noneof Life: Comparison of Change from Baseline Values - QoL: SF-36 (PH) - Change from inconsistencyserious4 serious2 None	trialsImage: Image:	trials Image: Image	trials Image: Image	ItrialsIndIndirectnessImprecisionImprecisionImprecisionImprecisionImprecisionImprecisionImprecisionImprecisionImprecisionImprecisionImprecisionImprecisionImprecisionImprecisionImprecisionImprecisionImprecisionImprecisionImprecisionIm	ItilaisIndirectnessImprecision </td

1	randomised trials	serious¹	no serious inconsistency	Serious⁴	serious ²	None	90	83	-	MD 3.3 higher (0.1 to 6.5 higher)	⊕OOO VERY LOW	CRITICAL
diastolio	c blood pres	sure (Bette	er indicated by Ic	ower values)								
1	randomised trials	No	no serious inconsistency	no serious indirectness	serious ²	None	26	29	-	MD 4.4 lower (9.82 lower to 1.02 higher)	⊕⊕⊕O MODERA TE	IMPORTAN
systolic	blood press	ure (Bette	r indicated by lo	wer values)				- I				
1	randomised trials	No	no serious inconsistency	no serious indirectness	serious ²	None	26	29	-	MD 9.3 lower (17.57 to 1.03 lower)	⊕⊕⊕O MODERA TE	IMPORTAN
AHI on t	treatment - C	ompariso	n of Values at En	dpoint (Better	indicated by I	ower values)			<u> </u>	<u> </u>		
5	randomised trials	serious ¹	very serious ³	no serious indirectness	serious ²	None	209	202	-	MD 0.80 higher (0.66 lower to 2.25 higher)	⊕OOO VERY LOW	IMPORTAN
Mortality	1					<u> </u>						
												CRITICA

(adherence)- 1 hour ; Established MIDs for SF-36 physical/mental- 2/3 ; FOSQ- 2 ; ESS -2.5;SAQLI – 2. GRADE default MID (0.5XSD)used for all other continuous outcomes. ³ Downgraded by 1 or 2 increments for heterogeneity, unexplained by subgroup analysis. Random effect analysis used.

⁴Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively

○ NIICE 2001 All rights received Cubicot to Notion of rights


Quality assessment No of patients Effect							Effect						
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Mixed (SUP/EDU/BEH) Intervention + CPAP versus Usual Care + CPAP	Control	Relative (95% Cl)	Absolute	Quality	Importance	
CPAP De	PAP Device Usage (hours/night) (Better indicated by higher values)												
10	randomised trials	serious ¹	,	serious indirectness ⁴	serious ³	None	2264	2187	-	MD 0.82 higher (0.2 to 1.43 higher)	⊕OOO VERY LOW	CRITICAL	
N deeme	I deemed adherent (≥ four hours/night)												
9	randomised trials	serious ¹	Serious ²	serious indirectness ⁴	serious ³	None	1807/2097 (86.2%)	65.6%	RR 1.14 (1.04 to 1.26)	92 more per 1000 (from 26 more to 171 more)	⊕OOO VERY LOW	CRITICAL	
Withdraw	val												
11	randomised trials	serious ¹	very serious ²	serious indirectness ⁴	very serious ³	None	144/2511 (5.7%)	13.6%	RR 0.64 (0.32 to 1.28)	49 fewer per 1000 (from 92 fewer to 38 more)	⊕OOO VERY LOW	IMPORTANT	
Quality of life: Comparison of Change from Baseline Values - QoL: FOSQ-10 - Change from Baseline (Better indicated by higher values)													
1	randomised trials		no serious inconsistency	Serious ⁴	serious ³	None	93	83	-	MD 2.9 higher (0.52 lower to 6.32 higher)	⊕OOO VERY LOW	CRITICAL	

1	randomised trials	serious ¹	no serious inconsistency	Serious ⁴	no serious imprecision	none	1497	1339	-	MD 5.7 higher (4.98 to 6.42 higher)	⊕⊕OO LOW	CRITICAL
Qualit	y of Life: Comp	arison of	Values at Endpo	oint - QoL: FOS	Q - Endpoint (Better indicated b	by higher values)					•
1	randomised trials	serious ¹	no serious inconsistency	Serious⁴	no serious imprecision	none	99	78	-	MD 0.3 higher (0.56 lower to 1.16 higher)	⊕⊕OO LOW	CRITICAL
Qualit	y of Life: Comp	arison of	Values at Endpo	oint - QoL: SF-3	36 (PH) - Endpo	oint (Better indica	ted by higher values)					•
3	randomised trials	serious ¹	no serious inconsistency	Serious ⁴	no serious imprecision	none	1611	1403	-	MD 4.85 higher (2.49 to 7.21 higher)	⊕⊕OO LOW	CRITICAI
		1						1	<u> </u>	I	1	1
Epwor	th Sleepiness S	cale Sco	re (Better indica	ated by lower v	alues)							
Epwor 8			re (Better indica no serious inconsistency	serious indirectness ⁴	serious ³	None	3401	2987	-	MD 1.32 lower (2.48 to 0.16 lower)	⊕000 VERY LOW	IMPORTAI
	randomised trials		no serious	serious		None	3401	2987	-	(2.48 to 0.16	VERY	IMPORTA

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias ² Downgraded by 1 or 2 increments for heterogeneity, unexplained by subgroup analysis. Random effect analysis used. ³ Downgraded by one increment if the confidence interval crossed one MID and downgraded by two increments if the confidence interval crossed both MIDs. MID for machine usage (adherence)- 1 hour ; Established MIDs for SF-36 physical/mental- 2/3 ; FOSQ- 2 ; ESS -2.5; SAQLI – 2. GRADE default MID (0.5XSD) used for all other continuous outcomes.

4 Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively

Appendix G: Health economic evidence selection



- * Non-relevant population, intervention, comparison, design or setting; non-English language
- ** Two studies (in three papers) were included for two different questions
- *** One study was considered for two different questions

4 5

1

2

Appendix H: Excluded studies

2 H.1 Excluded clinical studies

3

1

Table 15: Studies excluded from the clinical review for CPAP

Reference	Reason for exclusion
Aardoom 2020 ¹	Meta-analysis- screened for relevant references.
Aloia 2013 ²	No Author Response; unable to determine if CPAP make or pressure delivery mode was consistent between groups.
Bague 2015 ⁷	No Author Response; unable to verify certain review inclusion criteria. No full publication available.
Bague-Cruz 2014 ⁶	No Author Response; unable to verify certain review inclusion criteria. No full publication available.
Cartwright 2017 ¹⁴	No Author Response; unable to verify certain review inclusion criteria. No full publication available.
Chen 2020 ¹⁵	Meta-analysis- screened for relevant references.
Cotton 2012 ¹⁸	No Author Response; unable to verify certain review inclusion criteria due to lack of valid contact information.
Dawson 2015 ²¹	No Author Response; unable to verify certain review inclusion criteria.
Deng 2013 ²⁵	Inconsistent CPAP make across groups.
Epstein 2000 ²⁷	No Published Report/Data Found.
Escourrou 2012 ²⁸	No Author Response; unable to verify certain review inclusion criteria.
Guralnick 2017 ³³	Inclusion criteria not met.
Harris 2014 ³⁵	No Author Response; unable to verify certain review inclusion criteria due to lack of valid contact information.
Hwang 2018 ³⁹	Study already included in the review
Isetta 2014 ⁴⁰	Inclusion criteria not met.
Isetta 2015 ⁴¹	Inclusion criteria not met.
Kataria 2017 ⁴²	No Author Response; unable to verify certain review inclusion criteria.
Lai 2014 ⁴⁵	NCT represents duplicate of a published study.
Lopez-Martin 2005 ⁴⁸	Wrong comparator. No Author Response; unable to verify certain review inclusion criteria.
Lugo 2019 ⁴⁹	Study compares hospital routine (HR) with out-of-hospital Virtual Sleep Unit VSU. Study to be considered for inclusion in monitoring review.
Luyster 2018 ⁵⁰	No Author Response; unable to verify certain review inclusion criteria.
Marques 2017 ⁵¹	No Author Response; unable to verify certain review inclusion criteria.
Marshall 2003 ⁵²	No randomization, randomization not verifiable due to lack of valid author contact information.
Moore 2012 ⁵⁵	No Author Response; unable to verify certain review inclusion criteria.
Nadeem 2013 ⁵⁹	Inclusion criteria not met.
Ong 2020 ⁶³	Inappropriate comparison- cognitive behavioural therapy versus positive airway pressure (PAP)

Reference	Reason for exclusion
Rodgers 2015 ⁷⁰	No Author Response; unable to verify certain review inclusion criteria.
Schiefelbein 200575	Inclusion criteria not met; review outcomes of interest not examined in study
Schoch 2019 ⁷⁶	Full text paper not available
Singhal 2016 ⁸⁰	No randomisation, randomisation not verifiable due to lack of valid author contact information.
Shapiro, 2019 ⁷⁸	Study already included in the review
Sweetman 2019 ⁸⁸	Participants not on CPAP during CBT intervention.
Suarez 2017 ⁸⁷	No Published Report/Data Found
Tatousek 2015 ⁸⁹	No Author Response; unable to verify certain review inclusion criteria.
Taylor 2006 ⁹⁰	Inclusion criteria not met
Tolson 2016 ⁹¹	No Published Report/Data Found.
Wiese 2005 ⁹⁶	No Author Response; unable to determine procedures for OSA diagnosis.

3

Table 16: Studies excluded from the clinical review for oral devices and positional modifiers

Reference	Reason for exclusion
Berger 2018 ¹¹	Incorrect study design - conference abstract
Cunali 2011 ¹⁹	Incorrect stratum and Incorrect population - only included patients with TMD
De Vries 2017 ²³	Incorrect study design - conference abstract
De Vries 2018 ²²	Incorrect study design - conference abstract
Garbuio 2008 ³¹	Incorrect study design - conference abstract
Gauthier 2010 ³²	Incorrect study design - conference abstract
Murphie 2016 ⁵⁸	Incorrect study design - conference abstract
Pepin 2018 ⁶⁷	Incorrect stratum and incorrect population - CPAP users
Quintela 2009 ⁶⁸	Inappropriate comparison and incorrect study design - conference abstract
Sheets 2019 ⁷⁹	Incorrect stratum and incorrect study design - conference abstract
Vanderveken 2011 ⁹³	Incorrect stratum and incorrect study design - conference abstract
Vanderveken 2013 ⁹⁴	Incorrect stratum and incorrect intervention - no behavioural/supportive/educational intervention included
Yoshioka 2017 ⁹⁷	Incorrect stratum and incorrect study design- conference abstract

1 H.2 Excluded health economic studies

Published health economic studies that met the inclusion criteria (relevant population,
 comparators, economic study design, published 2003 or later and not from non-OECD
 country or USA) but that were excluded following appraisal of applicability and
 methodological quality are listed below:

- 6 None.
- 7
- 8

Appendix I: Research recommendations

I.1 Interventions to improve CPAP adherence

Research question: Which interventions including behavioural interventions are clinically and cost-effective to improve adherence of CPAP in people with OSAHS, OHS and COPD-OSAHS overlap syndrome who have difficulty using CPAP?

6 Why this is important

1

2

3

4

5

19

When CPAP is used to overcome upper airway obstruction in people with OSAHS, OHS or
COPD-OSAHS overlap syndrome, regular nightly use is essential in order for it to be
effective. For patients to adapt to using this physical therapy each time they sleep, they
require education from trained sleep professionals, access to support in the early adaptation
period and clinical review to optimise aspects such as machine pressure, mask fit and
humidification.

- For people who continue to find CPAP difficult to use despite this input, there have been no
 randomised controlled trials to determine an effective universal approach to improve ongoing
 CPAP use. Current research is limited to all people commencing CPAP and not just those
 who experience difficulties.
- 17 If people stop using CPAP, they are no longer having the optimal therapy for their airway18 obstruction and this has health and economic impacts.

Criteria for selecting high-priority research recommendations:

Sinterna for selecting in	ign-phoney research recommendations.
PICO question	Population: Adults with OSAHS (any severity), OHS or COPD-OSAHS overlap syndrome who have been initiated on CPAP therapy but having difficulty with use of CPAP regularly (such as less than 3 hours/night on 5 nights or more in preceding month) Intervention(s): Psychological and/or behavioural intervention Comparison: Usual care Outcome(s): CPAP adherence (hours/night), ESS, quality of life, cost
Importance to patients or the population	This research would establish whether those people who find CPAP difficult to use regularly who are given appropriate support can increase CPAP use and therefore improve their sleep and quality of life. Potentially the numbers of patients giving up CPAP in the short term would decrease, the numbers of people using CPAP long term would increase. The numbers of people seeking alternative treatments for OSAHS, OHS and COPD-OSAHS overlap syndrome instead of CPAP would decrease. Long term health benefits from CPAP would potentially increase.
Relevance to NICE guidance	Future NICE guidance can give specific recommendations regarding which interventions to use to optimise CPAP use and reduce existing uncertainty.
Relevance to the NHS	A clear recommendation for a behavioural or psychological intervention will offer clinicians clear guidance on best care for optimising CPAP adherence. This is likely to be provided by training existing sleep teams in best practice and will therefore not have impact in terms of more equipment being required or more staffing. Service delivery will be affected as it is likely a new intervention would take more time for existing staff.
National priorities	None
Current evidence base	The current evidence is reviewed in Evidence report N the full guideline. Current research is limited to all people with moderate and severe OSAHS commencing CPAP and not just those who experience difficulties and

	there is no research in people with OHS or COPD-OSAHS overlap syndrome commencing CPAP.
Equality	The recommendation is unlikely to impact on equality issues.
Study design	Randomised controlled trial with economic analysis. There should be randomisation with minimisation to allow separate subgroups of people with: OSAHS, OHS, COPD-OSAHS overlap syndrome to be allocated equally across the intervention and control arms and power calculations will determine size of these subgroups to allow comparisons.
Feasibility	The trial is feasible and should be straightforward to carry out. The control group will reflect usual clinical care which is currently given at sleep centres.
Other comments	The trial may attract commercial funding from companies who provide CPAP.
Importance	Medium: the research is relevant to the recommendations in the guideline, but the research recommendations are not key to future updates.